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Abstract 
This thesis consists of 4 components: 
Part One is a comprehensive log of the first 500 cases seen as an oncology resident at 
Perth Veterinary Oncology and an assessment of the proportion of different tumour 
cases presented during this time. Lymphoma was the most common disease seen, 
comprising 122/500 (24.4%) of cases. There were 88.4% canine cases and 11.6% feline 
cases. The majority of dogs were crossbreeds; however, the three most common pure 
breeds seen were the Labrador, golden retriever and Staffordshire bull terrier.  
 
Part Two provides a description of the cases classified as ‘Tumours of the Skeletal 
System’. Dogs with a confirmed diagnosis of osteosarcoma are then described. The 
patient signalment and disease presentation are compared and contrasted to previous 
studies to determine whether osteosarcoma in our cohort of dogs is a similar entity.  
 
Part Three is a description of reported risk factors for the development of osteosarcoma. 
It includes a literature review demonstrating the evidence supporting or refuting these 
risks.  
 
Part Four is a retrospective analysis of 33 canine patients diagnosed with appendicular 
osteosarcoma treated with amputation and an adjuvant chemotherapy protocol 
consisting of two doses of doxorubicin given two weeks apart, followed by four doses 
of carboplatin given at three weekly intervals. This chemotherapy protocol has not been 
previously described. The most effective adjuvant chemotherapy protocol for the 
treatment of canine appendicular osteosarcoma post limb amputation has not yet been 
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Lymphosarcoma Jack Francis  
6yo Mn Poodle cross 
Generalized lymphadenopathy with 
histopathologic diagnosis of lymphoma; bilateral 
uveitis and hyphaema 





UW-19. Recurrence 17/04/08; last recorded 





Lymphosarcoma Devon Fildes  
9yo Mn Welsh Springer 
spaniel 
Generalized lymphadenopathy; fine needle aspirate 
diagnosis of lymphoma 
Node biopsy for histopathology and 
IHC, bone marrow aspirate  
T cell pleomorphic 
lymphoma 
Stage IIIa 
HDC-BMT. Recurrence 03/2008; rescue 
protocol using Lomustine 70mg/m2 every 3 





Lymphosarcoma Mia Massey  
3yo F Dogue de Bordeaux 
Mild, Generalized lymphadenopathy; resolving 
hypercalcaemia; FNA suggestive of lymphoma 
Node biopsy for histopathology and 
IHC 
T cell pleomorphic 
lymphoma; Stage IIIb 
UW-19. Initial response to treatment but 





Tumours of the skin 
and subcutaneous 
tissues 
Bear Palermo  
4yo Mn Rottweiler 
Swollen, ulcerated mass on toe 5 right hind foot; 
dog started licking it 5 weeks prior; incisional 
biopsy diagnosed melanoma 
CBC, Biochemistry, U/A; FNA 




Surgery (toe amputation); carboplatin every 
3 weeks x 6. Suspected boney metastasis of 







Alex Cunningham  
8yo Mn Golden Retriever 
Lethargy and inappetance for 2-3 weeks; CBC 
suggestive of leukaemia 
CBC, bone marrow aspirate ALL; Stage Vb Palliation with prednisolone and 
enrofloxacin. Euthanased 20/9/07 
19/09/07 
6 
Tumours of the 
skeletal system 
Tango Matthews  
11yo Fn Whippet 
Firm swelling on 8th rib right side noted one month 
prior; radiographs showed lytic lesion 





Haemangiosarcoma Major Bailey  
8yo Mn Rottweiler 
One month history of rapidly growing mass over 
left thoracic inlet; histopathologic diagnosis of 
haemangiosarcoma 
CBC, Biochemistry, U/A; thoracic 




Doxorubicin and cyclophosphamide every 3 






Lymphosarcoma Isah Nguyen  
6yo Fn Kelpie cross 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
CBC, Biochemistry; thoracic 
radiographs; abdominal ultrasound; 
node biopsy for histopathology and 
IHC; bone marrow aspirate 
Lymphoma (IHC 
inconclusive); Stage IVa 
UW-19. Recurrence 18/3/08; Killed by 




Mast Cell Tumours Jack Lavell  
7yo Mn Staffordshire bull 
terrier 
Small mass noted 8 weeks prior; excisional biopsy 
diagnosed mast cell tumour, grade 2, clean but 
close margins 
CBC, Biochemistry, U/A; abdominal 
ultrasound; FNA nodex2; bone 
marrow aspirate 
MCT grade 2; T1N0M0; 
Stage 0a 




Haemangiosarcomas Beefcake Gibbons 
8yo Mn Rottweiler cross 
Presented to referring vet collapsed with 
haemabdomen; presented to PVO 3 weeks post 
splenectomy 




T2N0M0, Stage II 





Cancer of the Nasal 
Planum 
Kiwi Eyles 
15yo Fn DSH cat 
12 month history of early crusts on nasal planum; 
seen 2 weeks post nasal biopsy 
None Squamous Cell Carcinoma; 
T1N0M0 
Cryosurgery. Disease recurrence; referred 





Lymphosarcoma Zoe Lisle 
4yo Fn German 
Shorthaired Pointer 
Chronic diarrhea and weight loss; exploratory 
laparotomy and biopsy diagnosed lymphoma 
Bone marrow aspirate; Vitamin B12 
and Folic acid measurement 
Gastrointestinal (duodenal) 
LSA; Stage Ib 
UW-19. Owner stopped treatment mid 
protocol due to side effects; lost to follow up 
02/10/07 
13 
Tumours of the 
Skeletal System 
Clancy Gow 
7yo Mn Rottweiler cross 




Lymphosarcoma Loki Nesic 
5yo Mn Pit bull terrier 
cross 
Multiple dermal nodules; excisional biopsy 
diagnosed lymphoma 
IHC on previous biopsy (CD3, 
CD79a) 
Cutaneous T cell 
lymphosarcoma; Stage Ia 
None. Owner declined further diagnostics 




Lymphosarcoma Frasier Smith 
4yo Mn Rottweiler cross 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
None Lymphosarcoma; Stage 
IIIa or higher 
None. Owner declined further diagnostics 





Lymphosarcoma Manson Foley 
11yo Mn German shepherd 
cross 
Generalized lymphadenopathy; pyrexia; 
inappetance; FNA node diagnosed lymphoma 
CBC, Biochemistry Lymphosarcoma; Stage 
IIIb or higher 
Doxorubicin every 3 weeks x 6. Recurrence 





Cancer of the Nasal 
Planum 
Milo Orchard 
11yo Fn DSH 
Nasal, pinnal and possible facial SCC lesions for 
12 months 
CBC, Biochemistry, U/A; FNA 
submandibular lymph nodes 
Squamous cell carcinoma; 
T1N0M0 
Cryotherapy. Aggressive recurrence; repeat 
cryotherapy plus intralesional 





Lymphosarcoma Foggy House 
10yo Fn Blue Heeler 
Mild lymphadenopathy; receiving prednisolone None  Lymphosarcoma; Stage 
IIIa or higher 
Doxorubicin every 3 weeks x 6. Euthanased 
after 3 treatments due to gastrointestinal 




Mast Cell Tumours Cabernet Boulton 
5yo Fn Staffordshire 
Terrier cross 
Mass slowly growing over the last 3 months. Seen 
2 weeks post surgery; clean but close margins 
None MCT grade 2; T1NxMx; 
Stage 0a or higher 
None. Owner declined further diagnostics 
and treatment. Seen by referring vet 24/9/08 




Tumours of the 
skeletal system 
Hero Lee 
7yo M Akita 
4/5 lame left foreleg for one month; radiographs 
showed large lytic-proliferative lesion of proximal 
humerus 
None Open; T2Mx Palliation with codeine and carprofen. 





Hepatic Tumours Max McCarthy 
8yo Mn Bichon Friese 
 
Presented to referring vet unwell; abdominal 
ultrasound found solitary hepatic mass; examined 2 
weeks post liver mass resection 




Monitoring only; repeat CT scan and bloods 




Soft Tissue Sarcomas Ben Adams 
9yo Mn Kelpie cross 
Completely resected mass from inner right lip 
which had been present for 2 months 
CT scan jaw and chest; CBC, 
Biochemistry 
Undifferentiated sarcoma, 
Grade 3; T1aN0M0, Stage 
II 
Nothing further. Seen by referring vet March 




Soft Tissue Sarcomas Alpal Hodgson 
14yo Mn Border Collie 
Rapid growth of mass on proximal right 
antebrachium; FNA inconclusive 
Needle core biopsy; FNA right 
prescapular node; thoracic 
radiographs; CBC, Biochemistry, U/A 
Fibrosarcoma, Grade 2; 
T1aN0M0, Stage I 
Referred for surgical resection. Clean but 
narrow margins achieved; post-operative 





Histiocytic Sarcomas Holly Grant  
5yo Fn Bernese Mountain 
dog 
4/5 lame right hind leg; otherwise well; lytic lesion 
seen in distal right femur 
IHC on previous biopsy sample; 
thoracic radiographs; abdominal 
ultrasound; CBC, Biochemistry 
Histiocytic sarcoma – 
disseminated 
Lomustine every 3 weeks x 8; pamidronate 
every 3-8 weeks; codeine, carprofen. 





Soft Tissue Sarcomas Zac Mihalj 
7yo Mn  
Chow Chow 
10 days post biopsy; otherwise well CBC, Biochemistry, U/A; CT thorax, 
abdomen, pelvis 
Fibrosarcoma, Grade 2-3; 
T2bN0M0, Stage III 
Referred for surgical resection – owners 




Lymphosarcoma Thor Date 
4yo Mn Bull Terrier cross 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
None Lymphosarcoma; Stage 
IIIa or higher 
None. Owner declined further diagnostics 




Lymphosarcoma Sebastian Goddard 
7yo Mn Labrador 
Generalized lymphadenopathy; unwell and 
anorexic 
Node biopsy for histopathology and 
IHC; bone marrow aspirate; CBC, 
Biochemistry, U/A 
Diffuse, mixed, low grade 
T cell lymphoma; Stage 
IVb or higher  
UW-19:  not completed. Lost to follow up 
25/10/07 
28 
Lymphosarcoma George Mascall 
14yo Mn Golden retriever 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
None Lymphosarcoma; Stage 
IIIa or higher 
None. Owner declined further diagnostics 




Histiocytic Sarcomas Zena O’Shea 
10yo Fn Rottweiler 
Post splenectomy IHC on spleen; thoracic radiographs; 
abdominal ultrasound; CBC, 
Biochemistry, U/A 
Histiocytic sarcoma – 
localized 




Tumours of the 
skeletal system 
Rolly Oliver 
7yo M Rottweiler 
One week acute onset lameness; seen post hind 
limb amputation 
Thoracic radiographs; abdominal 
ultrasound; CBC, Biochemistry, U/A  
Osteoblastic osteosarcoma; 
T2M0 
Doxorubicin x2, carboplatin x4. Euthanased 








17yo Fn Tonkinese 
Mass over left eye present 2 months; excisional 
biopsy diagnosed melanoma, close margins 
None Cutaneous malignant 
melanoma; T1NxMx 
None. Owner declined further diagnostics 





Tumours of the 
skeletal system 
Shingalana Turnbull 
7yo Fn Bull Mastiff 
3/5 lame left foreleg with pain on palpation of 
proximal humerus 
Shoulder radiographs; thoracic 
radiographs; FNA left prescapular 
node; CBC, Biochemistry, U/A 
Poorly differentiated 
sarcoma; T2M0 
Limb amputation; doxorubicin x 2, 
carboplatin x 4. Owner ceased treatment 
after 3 doses for financial reasons ; still alive 





Lung cancer Shandy De Meo 
10yo Fn German Shepherd 
3 days of anorexia and suspected abdominal pain; 
radiographs showed solitary pulmonary mass; 
referring vet ultrasound guided FNA of mass 
suggestive of carcinoma 
CT Thorax Likely carcinoma based on 
FNA results, unable to give 
cell of origin; T1N0M0 
Surgery declined; carboplatin every 3 weeks 
x 6. Side effects after first dose so owner 





Tumours of the 
skeletal system 
Eddie Mulcahy 
5yo Mn English mastiff 
2/5 lame left foreleg; firm swelling proximal to left 
carpus 
Carpal radiographs; thoracic 
radiographs; Jamshidi bone biopsy; 
FNA left prescapular node 
Poorly differentiated 
sarcoma; T2M0 
Doxorubicin x 2, carboplatin x 4, 
Carprofen, codeine. Euthanased 30/01/08 




Lymphosarcoma Keisha Hearne 
8yo Fn Border collie cross 
Generalized lymphadenopathy for 3 weeks; 
otherwise well 
Node biopsy for histopathology and 
IHC; bone marrow aspirate; CBC, 
Biochemistry, U/A  
Centroblastic B cell 
lymphoma 
Stage III-IVa 





(Lymphosarcoma) Toby Eyres 
7yo Mn Rhodesian 
ridgeback cross 
Weight loss despite good appetite Thoracic radiographs; abdominal 
ultrasound; FNA spleen; CBC, 
Biochemistry, U/A 
No abnormalities detected. None. Dietary change allowed weight gain; 
no neoplastic disease diagnosed  
31/10/07 
37 
Lymphosarcoma Chelsea Hills 
8yo Fn Rottweiler cross 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
None Lymphosarcoma;  
Stage IIIa or higher 




Lymphosarcoma Odin Cover 
13yo Mn Border Collie 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
None Lymphosarcoma 
Stage IIIa or higher 
None. Owner declined further diagnostics 




Haemangiosarcoma Trudi Churn 
9yo Fn Dachshund 
Cavitatory mass on spleen, recovered from small 




Splenic haematoma Referral to surgery for splenectomy. Good 
recovery; seen October 2008 for vaccination 
and doing well 
02/11/07 
40 
Lymphosarcoma Milo Hopkins 
8yo Mn Shih Tsu 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
None Lymphosarcoma 
Stage IIIa or higher 






Lymphosarcoma LittleJack Francis 
8yo Mn JRT 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma; also anorexic for 2 weeks, marked 
weight loss and now icteric; neutropenic and large 
lymphocytes in circulation 
None Lymphosarcoma – Stage 
IVb or higher 
 
HDC -BMT; intensive care on admission. 
Lymphoma recurred in CNS – confirmed 









7yo Mn Blue Heeler cross 
Post skin biopsy; still multiple squamous cell 
carcinoma lesions at various stages of development 
 
Abdominal ultrasound; CBC, 
Biochemistry, U/A 
Squamous Cell Carcinoma; 
T1(2)N0M0 
Cryosurgery. Marginal excision of 2 small 
masses; repeat cryosurgery on smaller crusts 
– 20/02/08; local recurrence so referred from 




Lymphosarcoma Penny Charles 
10yo Fn Fox terrier 
Generalized lymphadenopathy – mild; already 
receiving prednisolone 
CBC, Biochemistry, U/A; UPCR, 
urine M/C/S; abdominal ultrasound; 
renal biopsy 
Lymphoma; Stage IIIa or 
higher; chronic renal 
failure 
UW-19. Had an acute on chronic renal 
episode from which she could not be 




Soft Tissue Sarcomas Genie Czerkasow 
11yo Fn Jack Russell 
terrier 
Incompletely resected mass from right foreleg Thoracic radiographs; FNA right 
prescapular node 
Poorly differentiated soft 
tissue sarcoma, Grade 2; 
T1aN0M0, Stage I 
VAC protocol – mid protocol dropped to 
doxorubicin only every 3 weeks. No 





Haemangiosarcoma Tess Munday 
8yo Fn Border Collie 




T0N0M0; Stage I 
Referral for excision of third eyelid. 
Ophthalmologist couldn’t locate any 






Tumours of the 
Endocrine System 
Layla Gibson 
9yo Fn Beagle 
In remission with lymphosarcoma; follicular 
thyroid carcinoma diagnosed on incisional biopsy 




T2aN0M0, Stage II 
Referral for surgical resection. Owner 
declined adjuvant chemotherapy. Dog alive 
and well with no recurrence of lymphoma or 








5yo Mn Boxer 
Completely resected mass from left lower lip None Malignant Melanoma; 
T0NxMx 






Soft Tissue Sarcomas Charlie Phillips 
17yo Mn Cocker spaniel 
 
Excisional biopsy of mass over right antebrachium; 
incomplete excision 
Thoracic radiographs; FNA right 
prescapular nodes 
Haemangiopericytoma, 
Grade 2; T1aN0M0, Stage 
I 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 






Soft Tissue Sarcomas Owen Zeeman 
6yo Mn Ridgeback cross 
Incompletely resected grade 1 
haemangiopericytoma from cranial right elbow 
Thoracic radiographs; FNA right 
prescapular node 
Haemangiopericytoma, 
Grade 1; T1aN0M0, Stage 
I 
Referral for aggressive surgical resection. 
Complete excision achieved; no further 









7yo Mn Labrador 
Massive subcutaneous growth on right lateral thigh 
over 2 years 




Referral for surgical resection. 3.3kg mass 





Lymphosarcoma Major Brain 
11yo Mn Bull terrier cross 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma; inappetance for a week  
CBC, Biochemistry Lymphosarcoma 
Stage IIIb or higher 
Doxorubicin q3wks x 6. Suffered side effects 







Soft Tissue Sarcomas Rommel Gosbell 
6yo Mn Miniature Pinscher 
Mass on left side of lumbar musculature CBC, Biochemistry, U/A; CT thorax 
and mass  
Poorly differentiated 
sarcoma, possible 
liposarcoma, Grade 3; 
T2bN0M0, Stage II 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 
daily for life. Progressive disease; 
medication stopped 7/3/08; euthanased due 
to disease progression June 2008 
23/11/07 
53 
(Lymphosarcoma) Sheba Craigie 
13yo Tonkinese 
Mediastinal mass U/S guided FNA of mass, CT mass 
and chest 
Keratinizing branchial cleft 
cyst 
Referral for surgical excision. Died post-
operatively due to hypotension 
23/11/07 
54 
Mast Cell Tumours Tammy Fairley 
5yo Fn Golden Retriever 
Close margin resection of low grade tumour CBC, Biochemistry; abdominal 
ultrasound; bone marrow aspirate 
MCT grade 1; T1N0M0; 
Stage 0a 
Vinblastine and prednisolone protocol. Lost 











10yo Fn Kelpie cross 
Close excision low grade malignant fibrous 
histiocytoma from left hind foot 
CBC, Biochemistry, U/A; FNA left 
popliteal node; abdominal ultrasound 
Malignant fibrous 
histiocytoma; T0N0M0 
None until/if recurrence. Represented 
18/4/08 for masses on the neck and right 
hind foot which were biopsied and 
diagnosed as undifferentiated sarcomas. 
Thoracic radiographs demonstrated multiple 
large pulmonary nodules 
27/11/07 
56 
Tumours of the 
Skeletal System 
Nellie Junk 
11yo Fn Rottweiler 
Osteolytic mass attached to buccal side of left 
mandible 
CBC, Biochemistry, U/A; CT jaw and 
thorax; biopsy mass 




Haemangiosarcoma Kahlua Puntigam 
10yo Fn German Shepherd 
Post splenectomy; hepatic nodules sighted at 
surgery 
None further Splenic 
haemangiosarcoma; 
T2N0M1, Stage III 







Lymphosarcoma Ben Watts 
12yo Mn Pitt Bull terrier 
cross 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma; hepatosplenomegaly palpable 
CBC, Biochemistry, U/A Lymphosarcoma 
Stage IVa or higher 
Doxorubicin every 3 weeks x 6. Became 
resistant to doxorubicin after 2 doses. 
Changed protocol to UW-19 but no response 




Lymphosarcoma Zor Blazey 
10yo Mn Bull Terrier cross 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
CBC, Biochemistry, U/A; bone 
marrow aspirate 
Lymphosarcoma 
Stage IIIa  







Mast cell Tumours Carrie Taylor 
11yo Fn Golden retriever 
Multiple dermal masses Incisional biopsy all masses, FNA 
regional nodes; abdominal ultrasound; 
bone marrow aspirate. 
Multiple MCTs; 
T1(4)N0M0; Stage IIIa 
Neoadjuvant chemotherapy. No reduction in 
size with neoadjuvant chemotherapy. 
Referred to surgery for excision of masses; 









14yo Mn Staffordshire bull 
terrier 
Very large, ulcerated perineal mass FNA mass; CBC, Biochemistry, U/A Undifferentiated  round 
cell tumour; T3NxMx 
Palliative – prednisolone. Lost to follow up 
07/12/07 
62 
Haemangiosarcoma Bella Harding 
8yo Fn Golden retriever 
Post splenectomy; no evidence of hepatic nodules 
or enlarged nodes at exploratory laparotomy 
None further Splenic 
haemangiosarcoma; 
T2N0M0, Stage II 









Nasal Tumours Leo Jarvis 
10yo Mn DLH cat 
6 week history of progressive increased snuffling 
then mucoid nasal discharge from right nostril; 
seen post nasal flush biopsy 
Chest radiographs, FNA right 
submandibular lymph node 
Nasal adenocarcinoma; 
T1N0M0 
Alternating Carboplatin, Doxorubicin; 
piroxicam. Developed snuffling, nasal 
discharge then neurological signs after 5 
treatments. CT scan showed no gross 
intracranial lesions nor breach of cribriform 
plate; large soft tissue density still present in 





Lymphosarcoma Herman Gilbert 
11yo Mn domestic 
shorthaired cat 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
Node biopsy; thoracic radiographs; 
abdominal U/S, echocardiogram; bone 
marrow aspirate; TT4 
Diffuse, large cell, high 
grade lymphoma 
Stage III 
Palliative – prednisolone. Euthanased 









Mast Cell Tumours Jock Gillingham 
8yo M Staffordshire bull 
terrier 
Incompletely resected mass from scrotum CBC, Biochemistry, U/A, abdominal 
ultrasound; FNA medial iliac nodes; 
bone marrow aspirate 
MCT grade 3; T1N0M0; 
Stage 0a 
Vinblastine, prednisolone. Recurrence 5 
weeks after initial presentation – referred for 
radical excision; recommenced Vinblastine, 
Lomustine, prednisolone protocol but dog 
developed repeated neutropenic sepsis 





Soft Tissue Sarcomas Harry Grygorcewicz 
14yo Mn Labrador cross 
Incompletely resected soft tissue sarcoma from left 
foreleg 
FNA left prescapular node; thoracic 
radiographs 
Soft tissue sarcoma, Grade 
2; T1aN0M0, Stage I 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 




Lung Cancer  Charlotte Graham  
8yo Fn bull mastiff cross 
Very large intrathoracic mass; biopsy inconclusive None Open  Trialled one cycle of VAC protocol. Repeat 
CT scan showed disease progression and no 
further treatment given; lost to follow up 
14/12/07 
68 
Cancer of the oral 
cavity 
Sophia Olden 
1yo Fn DSH cat 
Lesion proximal to left upper canine tooth CT scan head and thorax Ameloblastic fibroma; 
T1bN0M0, Stage I 
Referred for surgical resection. Complete 









Mast Cell Tumours Angel Schelfhout 
6yo Fn Boxer 
 
Ulcerated mass removed from caudal left 
mammary chain; histopathologic diagnosis of mast 
cell tumour, grade 3; Recurrence of primary 
tumour within 3 weeks; nodal metastasis palpable 
at this time 
FNA recurrent mass, FNA enlarged 
inguinal node; abdominal ultrasound; 
bone marrow aspirate; CBC, 
Biochemistry, U/A. 
MCT grade 3; T1N1M0; 
Stage IVb 
Referred for surgical excision of recurrent 
mass and inguinal node; adjuvant 
chemotherapy using Vinblastine, Lomustine, 
prednisolone protocol. Recurrence 2 weeks 
post surgery; continued adjuvant 
chemotherapy using Vinblastine, Lomustine, 
prednisolone protocol but developed 




Cancer of the Nasal 
Planum 
Missy Puss Chaplin 
10yo Fn DLH cat 
Advanced nasal planum squamous cell carcinoma; 
already treated with 2 surgeries and 4 cryotherapy 
treatments in the last year 
FNA submandibular nodes; thoracic 
radiographs  
Squamous Cell Carcinoma; 
T4N0M0 
Carboplatin and Gemcitabine, every 3 weeks 
x 6. Euthanased three weeks after first dose 







Lymphosarcoma Chiffon Ross 
9yo Fn Beagle 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma; palpable hepatosplenomegaly  
Node biopsy for histopathology and 
IHC; abdominal ultrasound; bone 
marrow aspirate 
Diffuse, large cell, 
Lymphosarcoma B cell 
lymphoma; Stage Iva 
UW-19. Didn’t achieve complete remission; 
received 10/16 treatments of induction 
protocol then swapped to rescue protocol of 
Lomustine given every 3 weeks. Two doses 




Mast Cell Tumours Abbi Scott 
9yo Bernese mountain dog 
Grade 2 mast cell tumour removed with 2mm from 
adjacent anus 
None  MCT grade 2; T1NxMx; 
stage 0a or higher 







Lymphosarcoma Rosie Carling 
12yo F Shih Tsu cross 
Generalized lymphadenopathy; left caudal 
mammary mass 
Node biopsy for histopathology and 
IHC; excisional biopsy mammary 
mass; abdominal ultrasound; bone 
marrow aspirate; CBC, Biochemistry, 
U/A 
Diffuse, large cell 
lymphoma, T-cell; 
Stage IIIa; 
Benign mixed mammary 
tumour 





Soft Tissue Sarcomas Baillie McCartney 
11yo Fn Golden retriever 
8x8cm fixed mass on left thorax post incisional 
biopsy 
None  Spindle cell sarcoma, 
Grade 2; T2bNxMx, Stage 
III or higher 
None. Owner declined further diagnostics 








Lymphosarcoma Brandy Kittle 
11yo Fn Heeler cross 
Generalized lymphadenopathy; ecchymoses on 
ventrum 
Node biopsy for histopathology and 
IHC; bone marrow aspirate; CBC, 
Biochemistry 
Diffuse, large cell, 
immunoblastic, B cell 
lymphoma; Stage IVb  
UW-19; prednisolone at 2mg/kg for 3 weeks, 
then weaned off once platelet count stable. 
Disease recurrence 3 months post 
chemotherapy; started rescue protocol of 
Lomustine every 3 weeks; 2 doses given 




Tumours of the 
Skeletal System 
Zharia Richter 
7yo Fn Rottweiler 
2/5 lame left hindleg; pain localized to distal femur Jamshidi bone biopsy Chondroblastic 
osteosarcoma; T2Mx 
Palliation: carprofen and codeine. Owner 




Hepatic Tumours Maggie Momber 
10yo Fn Border Collie 
Urinary incontinence; abdominal enlargement CBC, Biochemistry, PT/PTT, 








Ocular Tumours Winston Parasiliti 
12yo Mn Poodle cross 
1.5x2cm sessile mass near dorsolateral margin of 
left eye; lumbar pain 










Mast Cell Tumours Krassimir Santos 
12yo Mn Labrador cross 
 
Rapidly growing mass on right antebrachium; FNA 
suggestive of MCT 
Biopsy of mass for histopathology; 
FNA right prescapular node; 
abdominal ultrasound; bone marrow 
aspirate 
MCT grade 2 (high grade); 
T2N0M0; Stage 1a 
Palliative: prednisolone, omega 3 fish oil; 
antihistamines as needed. Euthanased 
26/6/08; the primary tumour had developed a 
draining fistula; the right prescapular lymph 








13yo Fn Cairn terrier 
Urinary incontinence; hyperglobulinaemia Bone marrow aspirate; survey skeletal 
radiographs; serum plasmaphoresis 
 
Multiple Myeloma Melphalan 0.1mg/ kg sid for 10d, then eod 
for life; prednisolone 0.5 mg/kg sid for 10d, 
eod for 60d. Still alive and well January 




Mast Cell Tumours Angus Stuart-Smith 
6yo Mn Pug 
Incompletely resected grade 2 MCT left shoulder; 
second new mass under tail base noted at initial 
consult 
FNA left prescapular node; abdominal 
ultrasound; biopsy mass under tail 
Multiple MCT, Grade 2 
and 1; T1(2)N0M0; Stage 
3a 





Tumours of the 
Intestinal Tract 
Max Moir 
3yo Mn Blue Heeler 
Diarrhoea and weight loss; hypercalcaemia; 
thickened descending colon and enlarged 
mesenteric nodes 
CBC, Biochemistry, U/A; Parathyroid 
hormone assay; upper and lower 
gastrointestinal endoscopy 
Large cell lymphoma of T 
cell origin with low to 
intermediate grade 




Tumours of the 
Endocrine System 
Seth Richerdson 
11yo Mn Alaskan 
malamute 
7x6cm firm, fixed mass ventral right neck Needle core biopsy Thyroid carcinoma; 
T3bNxMx, Stage III or 
higher 
Piroxicam 0.3mg/kg sid. Euthanased 
11/10/08 due to gradual inappetance, 




Mast Cell Tumours Chota Besson 
10yo Mn Jack Russell 
terrier 
Completely excised grade 2 mast cell tumour left 
thorax 
 
CBC, Biochemistry, U/A; abdominal 
ultrasound; bone marrow aspirate 
MCT Grade 2; T1N0M0; 
Stage 0a or less 
Vinblastine x 8; prednisolone. No recurrence 




Mast Cell Tumours Zed Coll 
8yo Mn Bull terrier cross 
Incompletely excised grade 2 mast cell tumour left 
foreleg 
 
CBC, Biochemistry; FNA left 
prescapular node; abdominal 
ultrasound 
MCT Grade 2; T1N0M0; 
Stage 0a 
Vinblastine x 8; prednisolone. No recurrence 




Mast Cell Tumours Brains Thornett 
5yo Mn miniature 
Schnauzer 
Two completely excised grade 1 mast cell tumours: 
one right rump and one right shoulder 
FNA right prescapular node; 
abdominal ultrasound; bone marrow 
aspirate 
MCT Grade 1; 
T1(2)N0M0; Stage IIIa  
No further treatment required. No recurrence 




Tumours of the 
Intestinal Tract 
Mac Boland 
12yo Fn West Highland 
White terrier 
3 month history of tenesmus and mucoid diarrhea; 
endoscopic biopsy diagnosed colonic carcinoma 
None Colonic carcinoma; 
T1NxMx 






Lymphosarcoma Bronson Spargo 
13yo Mn Burmese cat 
Weight loss, enlarged kidneys, FNA of kidney 
suggestive of lymphoma; also has diabetes mellitus 
and grade II/VI parasternal heart murmur 
Thoracic radiographs; CBC, 
Biochemistry, U/A 
Renal Lymphosarcoma; 
Stage II or higher 
Intravenous fluids for 24 hours before 
commencing UW-25. Recurrence of disease 





Soft Tissue Sarcoma Lucy Ross 
8yo Fn Dalmatian 
Rapidly growing mass on left cranial thoracic wall; 
biopsy = undifferentiated sarcoma  
CBC, Biochemistry, U/A Undifferentiated sarcoma, 
Grade 3; T2bNxM0, Stage 
III 
VAC protocol. Disease progression and 





Tumours of the 
Skeletal System 
Chase Fewster 
10yo Fn Ridgeback cross 
Lytic bone lesion right distal femur; 5cm firm mass 
adjacent right side of rectum 
 
Thoracic radiographs, abdominal 
ultrasound 
Open; T2Mx Doxorubicin x 2, carboplatin x 4. No 
response after first Doxorubicin; owners 
ceased treatment for financial reasons; 








8yo Fn Staffordshire bull 
terrier 
Excisional biopsy of 2 masses on ventrum Thoracic radiographs; abdominal 
ultrasound 
Squamous Cell Carcinoma; 
T0NxM0 
Referred for more aggressive surgical 







Tumours of the 
Skeletal System 
Bob Hale 
13yo Mn Kelpie 
Horner’s syndrome left side; coughing and 
dyspnoea; cranial mediastinal mass on plain 
radiographs 
 
CT scan head, thorax, abdomen 
 
 
Extensive, right sided 
thoracic mass, with an 
associated aggressive 
monostotic bone lesion of 
the right 5th rib; T1Mx 
Owner declined biopsy; palliated with 
prednisolone, etamiphylline, codeine. Died 






Mast Cell Tumours Simba Slattery 
7yo M Bull mastiff cross 
Incompletely resected Grade 3 mast cell tumour 
lateral right thigh; abdominal ultrasound and 
regional node aspirate negative for metastatic 
disease 
 
None further MCT Grade 3; T2N0M0; 
Stage 1a 
Vinblastine, Lomustine, prednisolone. 
Neutropenic sepsis post first Lomustine; 
required dose reduction; completed protocol 
with no further concerns; no evidence of 





Lymphosarcoma Tank Beven 
10yo M Bull terrier cross 
Generalized lymphadenopathy; bilateral uveitis and 
chemosis; ulcerated anus 
 
CBC, Biochemistry, U/A; node 
biopsy for histopathology and IHC; 
abdominal ultrasound; bone marrow 
aspirate 
Diffuse, high grade, large 
cell, B cell 
lymphosarcoma; Stage IVa 
UW-19; chloramphenicol ophthalmic 
ointment. Didn’t achieve complete 
remission; received 8/16 doses then 





Hepatic Tumours Sally Smith 
11yoFn Cocker spaniel 
cross 
Lethargy and inappetance; multiple hepatic masses 
detected on abdominal ultrasound; moderate, 
poorly regenerative anaemia; moderate 
neutrophilia 
None further Open; T1(m)NxMx Palliation: ranitidine, ‘liver diet’. Last seen 
March 2008 and was deteriorating at that 





Lymphosarcoma Weatos Mills 
7yo F Mastiff cross 
Generalized lymphadenopathy for 3 months CBC, Biochemistry, U/A; node 
biopsy for histopathology and IHC; 
abdominal ultrasound; bone marrow 
aspirate 
Diffuse, low grade, small 
cell, T cell 
lymphosarcoma; Stage IIIa  
UW-19. Received 5/16 treatments but didn’t 
receive complete remission. Owner stopped 





Hepatic Tumours Belle Cornish-Smith 
11yo Fn Golden retriever 
Lethargy and inappetance; multiple hepatic masses 
detected on ultrasound; mild anaemia and 
neutropenia on recent CBC; proteinuria with no 
active sediment 
CBC, Biochemistry, U/A; ultrasound-
guided liver biopsy. 
Hepatocellular adenoma, 
T1N0M0;  
None. Owner elected euthanasia due to rapid 
clinical deterioration suspected unrelated to 
the hepatic mass 
22/02/08 
98 
Tumours of the Male 
Reproductive System 
George Vicary 
7yo Mn Golden retriever 
Resected Sertoli cell tumour, detected at routine 
vaccination 
CBC, abdominal ultrasound, thoracic 
radiographs 
Sertoli cell tumour; 
T2N0M0 
No further treatment required. Last seen 








Lymphosarcoma Tex Edwards 
9yo Mn Kelpie cross 
Single enlarged right inguinal node removed for 
histopathology and IHC 
CBC, abdominal ultrasound Diffuse, low grade 
lymphocytic lymphoma; 
negative CD3, weakly 
positive CD79a, strongly 
positive CD20 – possible 
marginal zone lymphoma; 
Stage IIa 








Lymphosarcoma Coco Harmsworth 
17yo DSH cat 
Intracranial disease signs – circling to right side, 
hypersalivation, bilaterally enlarged pupils, absent 
PLR; enlarged right cervical lymph node, 
suggestive of lymphoma on FNA; negative for 
cryptococcosis, toxoplasma; T4 and blood pressure 
normal; uncompensated chronic renal failure 
FeLV, FIV ELISA – both negative Suspected CNS lymphoma; 
Stage Vb 
UW-25. Initial clinical improvement; 






Tumours of the 
Skeletal System 
Jupiter Verrall 
8yo Mn Mastiff cross 
Lame left foreleg; lytic bone lesion proximal left 
humerus 
Jamshidi biopsy; radiographs left 
humerus; thoracic radiographs; FNA 
left prescapular node; CBC, 
Biochemistry.  
Osteosarcoma; T2M0 Palliation: carprofen and codeine. 




Ocular Tumours William Wallace Attwood 
12yo Mn Cairn terrier 
Resected third eyelid; histopathology diagnosis of 
lacrimal gland tumour 
CT scan head and thorax Lacrimal gland carcinoma; 
T1NxM0 
No further treatment. No evidence of 







Mast Cell Tumours Dusty Walker 
8yo M Mastiff 
Previously resected MCT right lateral thigh (grade 
unknown); now mass on scrotum, large right 
inguinal node, mass toe 2 left hind foot 
CBC, Biochemistry, U/A; plain 
radiographs left hind foot; thoracic 
radiographs; abdominal ultrasound; 
FNA right medial iliac node; biopsy 
scrotal mass 
MCT Grade 2; T1N1M1; 
Stage IV; Mass on left hind 
foot causing bone lysis – 
separate disease? Owner 
declined toe amputation for 
biopsy 
Palliation: ranitidine and tramadol. 








Hepatic Tumours Rusty Salleo 
13yo Fn Kelpie cross 
PU/PD, marked increased ALT and ALP, solitary 
hepatic mass visualized on abdominal ultrasound 
Ultrasound guided FNA; CBC, 
Biochemistry, U/A; UPCR; CT scan 
thorax and abdomen 
Hepatocellular adenoma; 
T1(m)N0M0 
Referred for surgical excision of mass. 
Complete excision of mass; repeat CT scan 3 
months later diagnosed a small mass 
adjacent lower oesophageal sphincter; 
endoscopic biopsy non-diagnostic; later 




Haemangiosarcoma Eva Fischer 
13yo Fn German Shepherd 
Post splenectomy after ruptured mass; 2 red 
nodules also visualized on liver but not biopsied 
during surgery 
CBC, Biochemistry, U/A Splenic 
Haemangiosarcoma; 
T2N0M1, Stage III 
Doxorubicin every 3 weeks x 6. 
Haemabdomen developed again 2 weeks 





Lymphosarcoma Millie Matthews 
4yo Fn Miniature 
schnauzer 
Generalized lymphadenopathy, 
hepatosplenomegaly; FNA diagnosis of lymphoma 
CBC, Biochemistry, U/A; node 
biopsy for histopathology and IHC; 
abdominal ultrasound; bone marrow 
aspirate 
Centroblastic, B cell 
lymphoma; Stage IVa 
HDC-BMT. Disease recurrence September 
2008; commenced rescue chemotherapy 
following UW-19 protocol; entered 





Lymphosarcoma Cleveland Di Giovanni 
11yo Mn Blue Heeler 
Generalized lymphadenopathy, 
hepatosplenomegaly; marked lymphocytosis 
CBC, bone marrow aspirate, node 
biopsy for histopathology and IHC 
Lymphoblastic, T cell 
lymphoma; Stage Va 
UW-19. Only achieved partial remission; 
developed progressive disease and 






Tumours of the 
Skeletal System 
Ky Radford 
8yo Mn Akita 
Lame left foreleg for 2 months and swollen left 
carpus; mixed lytic and proliferative lesion distal 
radius seen on plain radiographs 
None Open; T2M0 Owner declined further diagnostics and 
elected palliation with  Previcox; 2 doses of 
pamidronate also given 6 weeks apart. Lost 




Mast Cell Tumours Danny Lebreton 
10yo Mn Kelpie 
1cm diameter grade 2 (low grade) MCT on penis 
diagnosed with incisional biopsy for 
histopathology and toluidine blue staining 
Abdominal ultrasound MCT Grade 2 (low grade); 
T1N0M0; Stage 1a 
None. Owner declined further diagnostics 











Endocrine Tumours Buster Huntley 
7yo M Heeler cross 
PU/PD, diagnosed with hyperadrenocorticism via 
ACTH stimulation test; abdominal ultrasound 
detected large mass within mesentery  
CT scan brain, thorax and abdomen Fat with diffuse interstitial 
haemorrhage. 
Started trilostane for hyperadrenocorticism; 
Once hyperadrenocorticism controlled, was 
referred for exploratory laparotomy and 
mass excision. Biopsy comment: the process 
is chronic and ongoing. Suggestive of 
haemorrhagic diathesis, i.e. congenital or 
acquired coagulopathy. 
Owner declined further workup. Last seen 
November 2008 for ACTH stimulation test 








14yo Mn DSH cat 
Bilateral ocular squamous cell carcinoma with 
main lesion right medial canthus; nose unaffected  
 
None Squamous cell carcinoma Referred for surgical excision. Complete 





Cancer of the Nasal 
Planum 
Benson Visse 
12yo Mn DSH cat 
5 month history of non healing wound over the 
nasal planum; biopsy confirmed squamous cell 
carcinoma 
CBC, Biochemistry, U/A; thoracic 
radiographs; FNA left submandibular 
lymph node 
Squamous cell carcinoma Complete nasal plane excision. Last seen 
June 2008 and there was no clinical evidence 





Renal Cancer Chloe Cunliffe 
10yo F Maltese cross 
Haematuria and stranguria; cavitatory mass around 
right kidney visualized on ultrasound, as were large 
haematomas within bladder 
None Open; T3N0Mx None. Verbal report from owner 2 months 
after presentation was that dog clinically 
well and haematuria had reduced; then lost 






Soft Tissue Sarcoma Sally Lobban 
12yo FN Samoyed 
8cm diameter raised mass over left hock; 
cytological diagnosis of soft tissue sarcoma 
CBC, biochemistry, U/A; thoracic 
radiographs 
Soft tissue sarcoma, Grade 
2; T2aNxM0, Stage II 
Referred for marginal excision; then 
metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 
daily for life. No recurrence of disease when 





Tumours of the 
Skeletal System 
Gary Poric 
8yo M Rottweiler 
2 week history of right foreleg lameness; 
proliferative lesion seen on radiographs of right 
humerus 
Repeat radiographs of right humerus; 
Jamshidi biopsy of bone lesion  
Osteosarcoma; T1Mx Palliation: carprofen 2mg/kg daily and 
codeine 1mg/kg bid. Owner declined more 
intensified analgesia and elected euthanasia 
4 weeks after initial presentation 
25/03/08 
116 
Tumours of the 
Skeletal System 
Gorm Dickenson 
8yo F Irish Setter 
6 week history of lameness left hindleg; painful, 
firm swelling distal left femur 
Radiographs left femur and thorax Open Owner declined further diagnostics and 




Histiocytic Sarcoma Sasha Peterson 
9yo Fn Pittbull terrier cross 
Rottweiler 
Episodes of acute pain not localized; solitary lung 
mass seen on radiographs; palpable abdominal 
mass on examination 
CT scan thorax and abdomen; CBC, 
biochemistry; PT/PTT; FNA hepatic 
mass 
Histiocytic Sarcoma - 
disseminated 
Lomustine every 3 weeks x 8; codeine and 
carprofen for analgesia. Euthanased 5/6/08 














11yo Fn Welsh Springer 
spaniel 
Weight loss and vomiting for 1 month; 
lymphocytosis detected on CBC 
Bone marrow aspirate and repeat CBC Chronic Lymphocytic 
Leukaemia; Stage Vb  
Chlorambucil at 0.2mg/kg sid for 14 days, 
then 0.1mg/kg sid until stable, then 
0.1mg/kg eod; 
Prednisolone 1mg/kg sid for 14 days, then 
0.5mg/kg sid then 0.5mg/kg eod. Developed 
progressive, non-regenerative anaemia, then 
Generalized lymphadenopathy and 




Lymphosarcoma Cindy Jensen 
13yo Fn Tonkinese 
Weight loss and vomiting for 3 months; thickened 
small intestine detected on ultrasound  
None Open – suspected 
lymphoma 




Mast Cell Tumour Nuno Basic 
7yo M Boxer 
Mass on ventrum, just cranial to prepuce; FNA 
suggests MCT 
Mass biopsy for grading; abdominal 
ultrasound, bone marrow aspirate; 
CBC, Biochemistry, U/A 
MCT Grade 2; T2N0M0; 
stage 1a 








Lymphosarcoma Jessica Jane Holland 
12yo Fn Bull terrier cross 
Multiple subcutaneous masses; histopathology 
suggested lymphosarcoma 
IHC on submitted mass; 
histopathology and IHC on another 3 
masses; thoracic radiographs; 
abdominal ultrasound; FNA hepatic 
mass 
Lymphosarcoma, CD3 and 
CD79a negative; Stage Ia; 
hepatocellular carcinoma 
UW-19. Entered clinical remission within 
first cycle but developed disease recurrence 
during 4th cycle; owner stopped further 
treatment. Dog deteriorated clinically 2 
months later and owner elected euthanasia 
03/04/08 
122 
Lymphosarcoma Daisy Perrin 
9yo Fn golden retriever 
Generalized lymphadenopathy noticed overnight CBC, Biochemistry Lymphosarcoma; Stage 
IIIa or higher 
UW-19. Complete protocol with no 







Cancer of the Nasal 
Planum 
Tom Tomkins 
11yo Mn DSH cat 
Ulcerated nasal planum for 8 months FNA right submandibular lymph 
node; thoracic radiographs; CBC, 
Biochemistry, U/A 
Squamous cell carcinoma Electrochemotherapy. Marked reduction in 
nasal planum ulceration 5 weeks post 
procedure; small area ventrally not fully 





Haemangiosarcoma Honey Gimondo 
12yo Fn Norwegian 
Elkhound 
Post splenectomy after ruptured splenic mass; 
solitary hepatic mass also excised 
None Haemangiosarcoma; 
T2N0M1; Stage III 





Haemangiosarcoma Abby Melbardis 
9yo Fn Rhodesian 
ridgeback 
Post splenectomy after ruptured splenic mass Chest radiographs, cardiac troponin I; 
CBC 
Haemangiosarcoma; 
T2N0M0; Stage II 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 





Lymphosarcoma Elmo Fitzpatrick 
12yo Mn Staffordshire bull 
terrier 
Generalized lymphadenopathy; occasional 
circulating abnormal lymphoblasts 
None  Lymphosarcoma; Stage 
IIIa or higher 
Lomustine every 3 weeks x 6; prednisolone 




Mast Cell Tumours Jake Williams 
10yo Mn Golden retriever 
Primary mass on LFL resected 7 months prior; now 
recurrence at site, satellite masses and regional 
node involvement 
CBC, Biochemistry, U/A; FNA 
satellite masses and node; abdominal 
ultrasound; bone marrow aspirate 
Mast cell tumour; 
rT2N1bM0; Stage IIIa 
Palliation: prednisolone, omega 3 fish oils, 
antihistamines and gastric mucosal 




Soft Tissue Sarcomas Chloe Jennings-White 
10yo Fn Schipperke 
Mass over left rump; incisional biopsy diagnosis of 
grade 3 haemangiopericytoma 
Thoracic radiographs; abdominal 
ultrasound 
Haemangiopericytoma, 
Grade 3; T2bN0M0, Stage 
III 
Metronomic chemotherapy: 10mg/m2 CTX, 




Tumours of the 
Mammary Gland 
Mia Layton 
7yo Fn Kelpie cross 
Post excision of left mammary glands 3-5; chest 
radiographs NSF 




incomplete excision  




Lymphosarcoma Sasha Tucker 
10yo Fn Golden retriever 
Generalized lymphadenopathy; marked 
thrombocytopenia, lymphocytosis 
None Stage V lymphosarcoma 
vs. acute lymphoblastic 
leukaemia 
Owner declined further diagnostics and 
treatment; prednisolone commenced as 
palliation (2mg/kg then tapered) 
15/04/08 
131 
Tumours of the 
Skeletal System 
Max Connolly 
10yo Mn Rottweiler 
Post amputation of left hindleg; 3 small pulmonary 
nodules on thoracic CT scan  
None  Osteosarcoma; TxM1 Doxorubicin x 2 a fortnight apart, then 






Lymphosarcoma Maddi Young 
11yo Fn Golden retriever 
Generalized lymphadenopathy; 
hepatosplenomegaly; weight loss 
CBC, Biochemistry, U/A; node 
biopsy for histopathology and IHC; 
abdominal ultrasound; bone marrow 
aspirate 
Diffuse, large cell, low 
grade B cell lymphoma; 
Stage IVb 
UW-19. Completed one cycle of treatment 
and nodes reduced to normal range; 
hepatosplenomegaly was still palpable and 
clinically dog was unwell. Owner declined 
repeat imaging and elected euthanasia 
16/04/08 
133 
Lymphosarcoma Storm Barnard 
10yo M Doberman cross 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
None Lymphosarcoma 2 x doxorubicin given then owner declined 




Tumours of the 
Skeletal System 
Buundi Crawford 
11yo Mn Ridgeback cross 
Amputated left hindlimb with diagnosis of 
osteosarcoma; chest radiographs clear of metastatic 
disease 
None Osteoblastic osteosarcoma; 
T0M0 





Tumours of the 
Skeletal System 
Jake Buckingham 
6yo Mn Rottweiler 
Lytic proliferative lesion of distal left femur on 
radiographs 
Jamshidi biopsy of lesion; chest 
radiographs; abdominal ultrasound; 
CBC, Biochemistry, U/A 
Open – biopsy sample 
unlikely representative of 
the lesion, reactive bone 
only 
Referred for amputation of limb; routine 
pelvic radiographs prior to procedure found 




Tumours of the 
Endocrine System 
Shadow Graystone 
15yo Mn miniature Fox 
terrier 
Polyuria, polydipsia, polyphagia. Adrenal mass 
noted on abdominal ultrasound 






Cancer of the Oral 
Cavity 
Roxy Langdon 
3yo Fn Collie cross 
Solitary mass adjacent lingual side of left lower 
canine tooth 
CT scan Acanthomatous epulis Referred for surgical excision. Unilateral 
rostral mandibulectomy performed achieving 
complete excision; good recovery and no 
further treatment required 
28/04/08 
138 
Lymphosarcoma Bonnie Braithwaite 
14yo Fn Blue Heeler cross 
Generalized lymphadenopathy; FNA diagnosis of 
lymphoma 
None Lymphosarcoma; Stage 
IIIa or higher 




Lymphosarcoma Henry Willoughby 
7yo Mn Cocker spaniel 
Generalized lymphadenopathy; FNA diagnosis of 
lymphoma 
None Lymphosarcoma; Stage 
IIIa or higher 




Cancer of the Oral 
Cavity 
Whitnee Mohen 
11yo Fn Bearded collie 
Recurrent mass left mandible, adjacent PM 3 CT scan Acanthomatous epulis Referred for surgical excision. Complete 
resection of mass and excellent recovery; no 




Lymphosarcoma Austin Kirkland 
9yo Mn Border collie 
One week history of lethargy and inappetance. 
Ascites developed and CT scan showed abnormal 
liver and spleen. Splenectomy = infarcted. Liver 
biopsy = B-cell lymphoma 
CBC, Biochemistry, U/A; marrow 
aspirate 






Mast Cell Tumours Gracie Butcher 
10yo Fn Staffordshire bull 
terrier 
Mass on head present 2 years with minimal 
change; mass on right flank present 2 months but 
recent growth; FNAs of both suggestive of mast 
cell tumours 
Excisional biopsy of both masses; 
CBC, biochemistry, U/A 
MCT x 2, Grade 1-2; 
T1NxMx; Stage IIIa 





Tumours of the 
Mammary Gland 
Lily Chew 
9yo F golden retriever 
cross 
Resected mammary adenocarcinoma; complete 
excision but carcinoma cells within lymphatics 
CT scan thorax and abdomen  Mammary Ductular 
Adenocarcinoma; 
T0N0M0, Stage 1 




Mast Cell Tumours Thor Honti 
6yo M Staffordshire bull 
terrier 
Clean, but close, resection of 3 low/intermediate 
grade MCTs; new lesion on scrotum 
Fine needle aspirate of scrotal lesion MCT Grade 1-2; T1NxMx; 
Stage IIIa 
Owner declined further treatment. 
05/05/08 
145 
Tumours of the 
Endocrine System 
Peppy Knox 
13yo Fn DSH 












9yo Mn Cocker spaniel 
Single episode of haematuria and stranguria; 
abdominal ultrasound found mass in bladder 
trigone 
Cystoscopy and biopsy; chest 
radiographs; lateral lumbar spinal 
radiograph; CBC, Biochemistry 
Carcinoma; TNM Mitoxantrone every 3 weeks x 6; piroxicam 
0.3mg/kg. Repeat ultrasound after 2 cycles 
showed stable disease; protocol changed to 
carboplatin q3wks x 6; repeat ultrasound 
after 2 cycles showed mild disease 





Soft Tissue Sarcomas Ettie Murray 
12yo Fn Labrador cross 
Incompletely resected soft tissue sarcoma 
(intermediate grade) from lateral right carpus 
None Soft tissue sarcoma, Grade 
2; T1aNxMx, Stage I or 
higher 





Lymphosarcoma Bess Buscumb 
16yo Fn Border collie cross 
Left eye uveitis and hypopyon; mild enlargement 
of submandibular and prescapular nodes; 7 days 
prednisolone prior  
CBC, Biochemistry; FNA 
submandibular and prescapular nodes 




Mast Cell Tumours Rolly Armstrong 
10yo Mn Shar Pei 
 
Incompletely resected grade 2 (low grade) mast 
cell tumour between toes 3 and 4 left fore foot 
CBC, Biochemistry, U/A; FNA left 
prescapular node; abdominal 
ultrasound 
MCT, Grade 2 (low grade); 
T1N0M0; Stage Ia 








9yo Fn DSH cat 
Recurrent left pinnal ulcerated lesion None Squamous cell carcinoma, 
intermediate 
differentiation; 
Referred for complete excision of pinna and 






Lymphosarcoma Rusty Edwards 
5yo M Cattle dog 
Generalized lymphadenopathy; FNA diagnosis of 
lymphoma 
CBC, Biochemistry, U/A; biopsy right 
prescapular node for HP and IHC; 
abdominal ultrasound; marrow 
aspirate 
Lymphoma, Diffuse, large 
cell, intermediate grade, T-
cell rich B cell 
HDC-BMT; recurrence treated with 
alternating doxorubicin and Lomustine. 
Euthanased December 2009. 
12/05/08 
152 
Cancer of the Salivary 
Glands 
Saldums Bernsteins 
14yo Fn Poodle cross 
Mass over right side of neck noted 3 weeks ago 
and now having difficulty swallowing. 









11yo Fn Jack Russell 
terrier 
Grade 2 fibrosarcoma incompletely resected from 
right antebrachium 







Cancer of the Oral 
Cavity 
Jack Britton 
14yo Mn Fox terrier 
Presented to referring vet 2 weeks prior for dental 
prophylaxis; abnormal bone over upper left canine 
tooth noted and radiographs revealed lytic bone 
lesion  
CBC, biochemistry, U/A; CT scan 
head and thorax; incisional biopsy of 
jaw lesion 
Squamous Cell Carcinoma Palliation – pamidronate, codeine, carprofen; 
initial good response so administered 
Carboplatin and Gemcitabine; achieved 
partial remission but dog deteriorated 








6yo Mn Rottweiler 
Completely resected mass from right mid 
antebrachium 
CBC, Biochemistry, U/A; FNA R 
prescapular and axillary nodes; chest 
radiographs x 3 
Cutaneous malignant 
melanoma 
Carboplatin x 6 
16/05/08 
156 
Lymphosarcoma Jasmine Lee 
12yo Fn Golden retriever 










Mast Cell Tumours Buster Buckland 
5yo M Boxer 
18 months prior had low/intermediate grade mast 
cell tumour excised with close margins from left 
hindleg; one month ago had intermediate/high 
grade mast cell tumour incompletely excised from 
ventrum 
Abdominal ultrasound MCT, Grade 2 (high 







Tumours of the 
Endocrine System 
Poppy Thrasyvoulou 
12yo Fn Maltese cross 
Resected mass from right ventral neck; 
histopathologic diagnosis of thyroid carcinoma 
Ventral cervical ultrasound; 
abdominal ultrasound; chest 
radiographs; Fine needle aspirate of 
mass in right ventral neck seen on 
ultrasound  
Thyroid carcinoma Referred for surgical excision of right 
thyroid mass, followed by adjuvant 
doxorubicin q3wks x 6 
21/05/08 
159 
Lymphosarcoma Buddy Lawrence 
14yo Mn crossbreed 
Generalized lymphadenopathy; FNA suggests 
lymphoma 






Lymphosarcoma Jess Broom 
6yo Fn Border collie 
Generalized lymphadenopathy; FNA suggests 
lymphoma 
Node biopsy for histopathology and 






Mast Cell Tumours Tammy Stiglmayer 
9yo Fn silky terrier cross 
Recurrence of mass on ventral chest with satellite 
nodule; initial lump then sent for histopathology = 
high grade mast cell tumour 
None MCT, high grade; 
T2N1Mx; Stage IIa 
Palliation: prednisolone, chlorpheniramine, 




Lung Cancer Tess West 
13yo Fn Sheltie 
Increased coughing in last 5 weeks; chest 
radiographs suggest solitary mass in caudal left 
lung lobe 





Lymphosarcoma Jessica Mallett 
11yo Fn Blue Heeler 
Generalized lymphadenopathy; FNA suggests 
lymphoma 
None Lymphoma; Stage IVa or 
higher 
Owner declined further diagnostics; oral 





Soft Tissue Sarcomas Thomas Rees 
13yo Mn Poodle cross 
Incompletely resected low grade soft tissue 
sarcoma on right carpus 
CBC, Biochemistry, U/A; chest 
radiographs; regional node FNA 
Haemangiopericytoma, 
Grade 1; T1aN0M0, Stage 
I 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 








(Lymphosarcoma) Sasha Clarke 
6yo Fn German shepherd 
Lethargy, pyrexia and weight loss; subsequent 
lymphadenopathy 
Node biopsy for histopathology and 
IHC 
Subacute to chronic, 
moderate pyogranulomatous 
inflammation; IHC shows 
mixed T and B cell 
population; stains negative 
for fungi and mycobacteria 
 






Mast Cell Tumours Fletcher Henry 
2yo Mn golden retriever 
Fine needle aspirate diagnosis of mass in left 
inguinal skin fold 
Abdominal ultrasound Mast cell tumour Referred for aggressive surgical resection as 
diagnostic and therapeutic procedure. 






Tumours of the 
Skeletal System 
Pig Humphries 
6yo M Greyhound cross 
Very proliferative bone lesion of distal left radius Chest radiographs x 3; pelvic 
radiographs; fine needle aspirate of 
lesion; fine needle aspirate of left 
prescapular node 
Sarcoma  Amputation of left foreleg, including left 
prescapular node. Recurrence of disease 





Mast Cell Tumours Jimmy French 
3yo Mn golden retriever 
Incompletely resected intermediate grade MCT 
over left shoulder 
Fine needle aspirate regional node; 
CBC, biochemistry, U/A 
Mast cell tumour, grade 2 
(low grade); T2N0Mx; 
Stage Ia 





Soft Tissue Sarcomas Mollee Andrews 
12yo Fn Staffordshire bull 
terrier 
 
Incompletely resected intermediate grade soft 
tissue sarcoma on the ventrum; incompletely 
resected low grade haemangiopericytoma on the 
right antebrachium 
Thoracic radiographs; FNA right 
prescapular lymph node; CBC, 
biochemistry, U/A 
Haemangiopericytoma, 
Grade 1; T1a(2)N0M0, 
Stage I 
 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 








13yo Mn Blue heeler 
Incomplete resection of recurrent mass on dorsal 
neck; histopathologic diagnosis of squamous cell 
carcinoma 
CBC, Biochemistry, U/A Squamous cell carcinoma Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 





Tumours of the 
Skeletal System 
Alco Ho 
7yo M Rottweiler 
 
Amputated left foreleg for proliferative distal 
radius lesion; histopathologic diagnosis of 
osteosarcoma  
Fine needle aspirate of left 
prescapular lymph node; pelvic 
radiographs; left stifle radiographs; 
CBC, Biochemistry, U/A 





Hepatic Tumours Tess Willes 
12yo Fn Labrador cross 
Increased respiratory effort at night for 2 weeks; 1 
week inappetance and lethargy; liver mass detected 
on abdominal ultrasound 
CBC; PT/PTT; ultrasound guided 
FNA of hepatic mass; CT scan thorax 
and abdomen 
Hepatocellular carcinoma Palliation: codeine, metoclopramide, 









Tumours of the 
Mammary Gland 
Alice Rawlings 
13yo Tenterfield terrier  
Incompletely resected mammary adenocarcinoma 
of left gland 4 
Chest radiographs; Fine needle 
aspirate of left inguinal node  
Mammary adenocarcinoma, 
tubulopapillary, grade 2 
Gemcitabine weekly x 6; starting dose 
800mg/m2 but reduced to 720mg/m2 due to 
grade 2-3 vomiting; metronomic 
chemotherapy after systemic course: 
10mg/m2 cyclophosphamide, 0.3mg/kg 
piroxicam daily for life. Last seen Feb 2009, 









Tumours of the 
Skeletal System 
Cassie Wiburd 
9yo Fn Rottweiler 
6 week history of lame left foreleg; radiographs 
show lesion in proximal left humerus; also 
diagnosed with degenerative myelopathy 12 
months ago 
CBC, Biochemistry, U/A; radiographs 
of left humerus; 3 view thoracic 
radiographs; frog leg pelvic 
radiograph; FNA left prescapular 
node; Jamshidi bone biopsy of lesion 
Osteosarcoma; T2M0 Owner sought alternative therapies 
elsewhere. Represented 22/8/08 due to 
progressive lameness. Prescribed carprofen 
and tramadol. Added amantadine after 3 
weeks. Started pamidronate infusions every 
3 weeks. Added gabapentin in November 





Mast Cell Tumours Jake Harmer 
14yo Mn Pitt bull terrier 
cross 
Severe lethargy and inappetance; markedly 
increased liver enzymes; FNA of liver suggested 
mast cell tumour disease 
CBC, biochemistry, U/A; bone 
marrow aspirate 
Hepatic mast cell tumour 
disease 
Single Vinblastine then oral CTX 7 days 
later; clinical deterioration so palliation with 
prednisolone, ranitidine, chlorpheniramine, 
omega-3 fatty acids 
17/06/08 
176 
Perianal Tumours Jedda Mottram 
11yo Fn CKCS 
Mass present ventrolateral to anus for 3 weeks; 
FNA suggestive of perianal adenoma 
None Presumed perianal 
adenoma 





Cancer of the Oral 
Cavity 
Juma Thomson 
12yo M Labrador 
Small mass noticed at right commisure of jaw 
during dental prophylaxis; incisional biopsy taken 
suggested oral melanocytoma 
Thoracic radiographs; fine needle 
aspirate of right submandibular lymph 
node 
Oral Melanocytoma Referred for marginal resection of the mass; 








Haemangiosarcoma Connor Watchorn 
8yo Mn German shepherd 
Splenic mass and abdominal effusion at referring 
vet; splenectomy provided histopathologic 
diagnosis of HSA; thoracic radiographs 
unremarkable 
CBC, Biochemistry, U/A Splenic 
Haemangiosarcoma; 
T2N0M0, Stage II 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 
daily for life. Recurrence of haemabdomen 
23/7/08; abdominal ultrasound confirmed 







Lymphosarcoma Jack Eccles 
9yo Mn Blue heeler cross 
Generalized lymphadenopathy; progressive 
hindlimb and forelimb paresis/paralysis; brain CT 
scan NSF, CSF analysis showed mild mixed 
inflammatory cells; toxoplasma and neospora titres 
negative 
CBC, biochemistry, U/A; bone 
marrow aspirate 
Lymphoma, diffuse, large B 
cell (Kiel centroblastic); stage 
IIIb 
UW-19. Partial remission of nodes but 
deterioration of the inflammatory CNS 




Lymphosarcoma Rico Mitton 
6yo Mn Kelpie cross 
Generalized lymphadenopathy; node 
histopathology diagnosis of lymphoma 
CBC, Biochemistry, U/A; IHC on 
node biopsy 
B cell lymphoma, diffuse 





Cancer of the oral 
cavity 
Bentleigh Trevail 
11yo M Maltese terrier  
Pedunculated mass attached to right upper gum 
adjacent canine tooth; enlarged right testicle 






Perianal Tumours Brutus Bohdan 
10yo Mn Staffordshire 
terrier cross 
10cm mass right side of anus with enlarged medial 
iliac lymph nodes; FNA diagnosis of metastatic 
apocrine gland adenocarcinoma 
Thoracic radiographs Presumed apocrine gland 
adenocarcinoma 
Neoadjuvant Carboplatin and Gemcitabine 
followed by surgical excision of primary 
mass and both medial iliac nodes. Died 




Cancer of the Oral 
Cavity 
Ayesha Chappell 
13yo Fn Staffordshire bull 
terrier 
Oral malignant melanoma completely resected 
from left commissure of the lips 
CBC, biochemistry, U/A; CT scan 
head and thorax; FNA left 
submandibular lymph node 
Malignant melanoma; 
T1N1M0 
Left mandibular lymph node excision 
followed by adjuvant chemotherapy: 








12yo Fn Staffordshire bull 
terrier cross 
Cutaneous malignant melanoma resected from left 
ear, adjacent external auditory meatus 
CBC, biochemistry; Thoracic 




Lost to follow up 
07/07/08 
185 
Lymphosarcoma Duke Brinkworth 
5yo Mn DSH cat 
Caudal abdominal mass; FNA suggests discrete 
cell neoplasia 




Tumours of the 
Skeletal System 
Holly Miles 
9yo Fn Cocker spaniel 
Firm mass between eyes, biopsy diagnosis of 
osteosarcoma; mildly enlarged left submandibular 
lymph node 
CBC, biochemistry; CT scan head and 
thorax; FNA left submandibular 
lymph node 




Cancer of the Salivary 
Glands 
Bolta Geletic 
3yo Mn Bull mastiff cross 
8cm diameter firm but mobile mass adjacent to the 
caudolateral right mandible; incisional biopsy diagnosis 
of salivary gland adenocarcinoma 
None Salivary gland 
adenocarcinoma 
Marginal excision of mass; adjuvant 





Mast Cell Tumours Gus Wood 
10yo Mn Staffordshire bull 
terrier  
Multiple previous low grade mast cell tumours; 
currently mass on caudal left stifle with FNA 
diagnosis of MCT, and enlarged left inguinal node 
Excisional biopsy of popliteal and 
inguinal masses; CBC, biochemistry, 
U/A 
MCT, Grade 3; T2NxMx; 
Stage Ia; 
Inguinal mass – adipose 
tissue 
Lomustine every 3 weeks x 6; prednisolone 
2mg/kg daily, tapering. Disease progression 





Soft Tissue Sarcomas Coola Pahi 
8yo Mn Shih Tsu cross 
Incompletely excised soft tissue sarcoma from 
right hind foot 
Thoracic radiographs; FNA right 
popliteal node; CBC, Biochemistry, 
U/A 
Peripheral sarcoma of soft 
tissue, Grade 1; T1aN0M0, 
Stage I 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 
daily for life. No disease recurrence noted as 





Lymphosarcoma Mozzie Martin 
6yo Fn red heeler cross 
Generalized lymphadenopathy of 2 weeks duration Node biopsy for histopathology and 
IHC; abdominal ultrasound; bone 
marrow aspirate; CBC, Biochemistry, 
U/A 
Centroblastic B-Cell 
Lymphoma; Stage IIIa 
HDC-BMT. Disease recurrence January 





Tumours of the 
Skeletal System 
Chevy Chute 
9yo Fn Rhodesian 
ridgeback cross 
4/5 lame left hindleg with firm swelling distal to 
stifle; radiographs showed marked lysis of 
proximal tibia 
None Open None. Owner declined further diagnostics 






Tumours of the 
Skeletal System 
Seppie Bond 
12yo Fn Labrador 
Large, firm, painful swelling encircling left hock; 
histopathologic diagnosis of osteosarcoma 
None Osteoblastic osteosarcoma; 
T1Mx 
Pamidronate; carprofen; codeine; no 
noticeable improvement so analgesia 
provided with buprenorphine then fentanyl 






Soft Tissue Sarcoma Toby Bejhanovic 
6yo Mn Doberman cross 
6 month history of enlarging masses in inguinum Needle core biopsy of smallest mass Malignant neoplasia, 
poorly differentiated, likely 
sarcoma; T2bN1Mx, Stage 
IV 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 
daily for life. Disease progression after one 





Histiocytic sarcoma Buddy Mitchell 
1yo M Mastiff 
Rapidly growing mass on right side of face, 
histopathology diagnosis of malignant round cell 
tumour, CD3 and CD79a negative 
CT scan head, thorax and abdomen; 
ultrasound guided FNA of hepatic 
mass; CBC, biochemistry, U/A. 
Disseminated histiocytic 
sarcoma 
Lomustine every 3 weeks x 8. Partial 
remission achieved for 2 cycles then disease 
progression; euthanased 10/09/08 due to 




Tumours of the Skin 
and Subcutaneous 
Tissues 
Sassy B Macnab 
15yo Fn DSH cat 
1.5cm ulcerated lesion over external left pinna; 
several small crusts along right pinnal edge 
Thoracic radiographs; CBC, 
Biochemistry, U/A 
 Referred for aggressive surgical resection of 






Mast Cell Tumours Molly Everley 
5yo Fn Boxer 
Intermediate grade MCT removed from left dorsal 
head; FNA showed metastasis to the left 
submandibular lymph node 
CBC, biochemistry, U/A; abdominal 
ultrasound; bone marrow aspirate; 
FNA left prescapular node 
MCT Grade 2; T1N1M0; 
Stage IIa 
Excisional biopsy of both the submandibular 






Tumours of the 
Endocrine System 
Max Jones 
12yo Mn Kelpie cross 
2 month history of lethargy, inappetance and 
weight loss; abdominal ultrasound showed nodular 
pancreatomegaly and right adrenomegaly 








Nasal Tumours Coco Lee 
13yo Fn Old English 
Sheepdog 
Acute severe epistaxis from right nostril; CT scan 
suggestive of tumour in right nasal sinuses 
None Open  Carboplatin every 3 weeks x 6; piroxicam 
0.3mg/kg daily. Repeat CT scan of nose 
showed stable disease after one treatment; 
completed carboplatin protocol (every 3 
weeks x 6); then started doxorubicin 




Soft Tissue Sarcomas Sabian Freeman 
12yo Mn Staffordshire bull 
terrier  
Rapidly growing mass on right side of thorax; FNA 
suggestive of mesenchymal neoplasia 
Incisional biopsy of mass Soft tissue sarcoma, Grade 
1-2; T2bNxMx, Stage III 
or higher 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 




Haemangiosarcoma Basil Panegyres 
11yo Mn DSH cat 
Splenectomy performed for collapse and 














Mast Cell Tumours Roly Marriott 
8yo Mn Labrador 
High grade mast cell tumour completely excised 
from left side of ventrum 
CBC, biochemistry, U/A; abdominal 
ultrasound; bone marrow aspirate 
MCT, Grade 3; T2N0M0; 
Stage Ia 
Vinblastine/Lomustine/prednisolone 
protocol. Developed septicemia after first 
vinblastine dose and owner declined further 
chemotherapy. Developed new grade 1 MCT 
on right hindleg. No evidence of recurrence 




Mast Cell Tumours Roxy Gribble 
4yo Fn Fox terrier 
Rapid growth of inguinal mass – high grade mast 
cell tumour; another mass removed from lateral 
right hindleg 6 weeks prior (untested) 
CBC, Biochemistry; abdominal 
ultrasound; bone marrow aspirate 
MCT, Grade 3; T2N1M1; 
Stage IVa  






Mast Cell Tumours Cadbury Carpenter 
10yo Fn Labrador 
Marginal resection of high grade mast cell tumour 
over right thorax 
CBC, biochemistry, U/A; abdominal 
ultrasound; bone marrow aspirate 
MCT; grade 3; T2N0M0; 
Stage Ia 
Referred for further excision of primary; 






Tumours of the 
Skeletal System 
Zack Loos 
11yo M Rottweiler cross 
Rapidly growing mass near right axillary region; 
FNA suggestive of malignancy 
CBC, biochemistry, U/A; CT scan 










Mast Cell Tumours Stella Finnigan 
7yo Fn Labrador 
3 year history of mass on left thorax; 4 week 
history of diffuse swelling of distal right hindleg 
and enlarged right popliteal node; FNA of this 
node suggestive of metastatic mast cell tumour 
CBC, biochemistry, U/A;  
FNA mass on left thorax and swelling 
over dorsal right metatarsals; 
abdominal ultrasound; bone marrow 
aspirate 
MCT, Grade 3; T2N1M0; 
Stage IIb 







Mast Cell Tumours Stacey McCormick 
6yo Fn Labrador 
2 week history of mass on lateral left stifle; FNA 
suggested MCT so wide excision and 
histopathology performed: grade 2 MCT close 
margins 
FNA left popliteal lymph node MCT Grade 2; T2N0Mx; 
Stage Ia 








Lymphosarcoma Syd Goldstone 
12yo M Kelpie 
One week history of lymphadenopathy; node 
biopsy confirmed lymphoma; routine blood tests 
unremarkable but scattered reactive/atypical 
lymphocytes seen on smear 
None Lymphoma, diffuse 
intermediate grade 
immunoblastic; Stage IIIa 
or higher 
Doxorubicin every 3 weeks x 6. No response 
after 2 treatments so switched to Lomustine; 
No response after 2 doses so switched to oral 
CTX; developed sterile haemorrhagic 




Mast Cell Tumours Lillie Henderson 
11yo Fn Jack Russell 
terrier 
Incompletely resected intermediate grade mast cell 
tumour over right shoulder 
FNA right prescapular node MCT, Grade 2; T1N0Mx; 
Stage Ia 





Mast Cell Tumours Mattel Baskerville 
13yo Mn DSH cat 
3 weeks history of vomiting and inappetance; 
solitary mass in abdomen aspirated as likely mast 
cell neoplasia 
Abdominal ultrasound; guided FNA 
of mass and liver; CBC; bone marrow 
aspirate 
Mast cell tumour attached 
to mesentery, with hepatic 
involvement 
Referred for surgical excision. Non-
resectable mass therefore biopsies taken; 











12yo Fn German 
shorthaired pointer 
3 month history of urinary incontinence then 
developed stranguria and haematuria; abdominal 
ultrasound diagnosed mass in trigone region of 
bladder 
CBC, biochemistry, U/A (no culture 
as on ABs); thoracic and lumbar spine 
radiographs; cystoscopy and guided 
biopsies 
Carcinoma, locally 
invasive (likely transitional 
cell carcinoma); solitary 
consolidated pulmonary 
mass in left cranial lung 
lobe 
Mitoxantrone every 3 weeks x 6; piroxicam. 
Repeat ultrasound after 2 cycles showed 
stable disease; switched to Carboplatin and 
Gemcitabine every 3 weeks; minimal clinical 
improvement after 2 cycles and dog 
developed neurological disease and was 





Lymphosarcoma Koko Newman 
6yo Fn Boxer 
Generalized lymphadenopathy; fine needle aspirate 
cytology suggestive of lymphoma 
Node biopsy for histopathology and 
IHC; bone marrow aspirate; CBC, 
biochemistry, U/A 
Lymphoma, diffuse, large, 
T-cell phenotype; stage Va 
UW-19 with 5 day cytosine arabinoside CRI 
during the first week. Disease recurrence 






Perianal Tumours Bonnie Jones 
14yo Fn Staffordshire bull 
terrier cross 
4cm diameter mass noted near left anal gland one 
month prior; mild progression to now; excisional 
biopsy diagnosed undifferentiated adenocarcinoma 
Thoracic radiographs, abdominal 




Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 




Tumours of the 
Skeletal System 
Harley Hyland 
11yo Mn Corgi cross 
Firm swelling over right dorsal skull noticed a 
week ago; skull radiographs showed discrete boney 
lesion 
CT scan head and thorax; incisional 
biopsy of mass; CBC, Biochemistry, 
U/A 






Haemangiosarcoma Roxy Pepper 
5yo Fn Kelpie cross 
One month history of swelling over right lateral 
stifle; excisional biopsy = haemangiosarcoma 
CBC, biochemistry, cardiac troponin 









Soft Tissue Sarcomas Meggie Bacich 
12yo Fn German shepherd 
cross 
12 month history of mass on left shoulder with 
rapid growth in the last 4 weeks; excisional biopsy 
= haemangiopericytoma, grade 2, incomplete 
excision 
CBC, Biochemistry, U/A; FNA left 
prescapular lymph node; thoracic 
radiographs 
Haemangiopericytoma, 
Grade 2; T1aN0M0, Stage 
I 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 





Cancer of the Oral 
Cavity 
Jessie Peacock 
10yo Mn DSH 
One month history of ulcerative lesion on the hard 
palate, non responsive to corticosteroids; incisional 
biopsy = high grade fibrosarcoma 
CBC, Biochemistry, U/A; CT scan 
head and thorax 
Fibrosarcoma, high grade Electrochemotherapy followed by 
metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 






Haemangiosarcoma Storm O’Keefe 
7yo Fn German shepherd 
Acute onset lethargy; exploratory laparotomy for 
haemabdomen found bleeding splenic mass; 
splenectomy = haemangiosarcoma  
None Haemangiosarcoma; 
T2NxMx; Stage II or 
higher 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 
daily for life. Recurrence of haemabdomen 2 





Mast Cell Tumours Connan Luculano 
10yo Mn Pitt bull terrier 
Mass on right hindleg 3-4 years; excisional biopsy 
= mast cell tumour, grade 2 (low grade); also 
complete excision of a cutaneous 
haemangiosarcoma from prepuce 
None MCT Grade 2 (low grade); 
T1NxMx; Stage Ia 







Hepatic Tumours Molly Gibson 
12yo Fn Golden retriever 
One week history of lethargy, inappetance, 
vomiting, diarrhea and PU/PD; initial abdominal 
ultrasound showed multiple hepatic masses, 
enlarged mesenteric nodes and hypoechoic 
pancreas 
CBC, biochemistry, PT/PTT; repeat 
abdominal ultrasound; FNA solitary 
hepatic mass seen on ultrasound; 
thoracic radiographs 
Hepatic carcinoma Supportive therapy with IVF. Vomiting and 
diarrhea resolved; appetite returned but 






Lymphosarcoma Panther Coles 
18yo Mn DMH  
One week history of mass on lateral right hock; 
FNA inconclusive but suggestion of round cell 
tumour 
CBC, Biochemistry, U/A; T4; 
Thoracic radiographs; abdominal 
ultrasound; incisional biopsy of mass 
Poorly differentiated round 
cell neoplasm; likely 
histiocytic or lymphocytic 
origin. 





Nasal Tumours Molly Laurie 
9yo Fn Old English Sheep 
Dog 
3 month history of snoring, snorting then sneezing 
and now 2 bouts of epistaxis; nasal cavity 
radiographs showed soft tissue density caudal right 
nasal cavity 
CBC, biochemistry, U/A; CT scan of 








Lymphosarcoma Beau Elliott 
12yo Mn Staffordshire bull 
terrier cross 
Generalized lymphadenopathy; fine needle aspirate 
cytology suggestive of lymphoma 
CBC Lymphosarcoma; Stage 
IIIa or higher 





Mast Cell Tumours Murray McWaters 
5yo Mn Staffordshire bull 
terrier  
 Grade 2 (Low grade) mast cell tumour completely 
excised from scrotum; another lesion still present 
adjacent to it 
FNA lesion on scrotum; abdominal 
ultrasound 
MCT Grade 3; T1N0M0; 
Stage Ia 











12yo Fn Staffordshire bull 
terrier  
Skin lesion present on ventrum for 8 months, 
slowly progressive into 2cm ulcerated lesion with 3 
other smaller lesions adjacent also noted at 
excision; histopathologic diagnosis of squamous 
cell carcinoma 
Thoracic radiographs, abdominal 
ultrasound 
Squamous cell carcinoma Suncream; sunshirt; keep out of direct sun 





Tumours of the 
Skeletal System 
Kane Francis 
5yo Mn Kelpie cross 
One month history of progressive lameness of left 
foreleg, non-responsive to NSAIDs; radiographs 
show lytic distal radial lesion 
CBC, biochemistry, U/A; FNA left 
prescapular node; FNA bone lesion 
Reactive lesion probably in 
response to trauma or 
previous inflammation 
Referred for limb amputation; non neoplastic 




Cancer of the Oral 
Cavity 
Piper Richards 
9yo Mn Corgi 
Flat lesion noted on underside of tongue during 
routine dental prophylaxis; incisional biopsy = 
squamous cell carcinoma  
CBC, Biochemistry; 
CT scan head and thorax 







Tumours of the 
Skeletal System 
Beau Mann 
12yo Mn Labrador 
3 weeks history of progressive hind limb 
weakness; one week history of lack of voluntary 
urination and defecation; bone lesion in dorsal 
body of L6, and 2 discrete masses of cranial left 
lung seen on radiographs 
None Open Palliation with carprofen, tramadol and 
amantadine. Owner euthanased 3 days later 
25/08/08 
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Lymphosarcoma Zara Cridland 
4yo Fn Golden retriever 
3 week history of Generalized lymphadenopathy; 
FNA of node suggestive of lymphoma 
None Lymphosarcoma; Stage 
IIIa or higher 





Mast Cell Tumours Nikita Andrew 
5yo Fn Staffordshire bull 
terrier 
Grade 2 (low grade) mast cell tumour completely 
excised from left lateral thigh 
Abdominal ultrasound MCT Grade 2 (low grade); 
T2N0M0; Stage Ia 





Mast Cell Tumours Jazz Field 
7yo Mn Staffordshire bull 
terrier  
3 month history of mass over caudal left thigh, 
slowing growing then became ulcerated; biopsy 
diagnosis of mast cell tumour, grade 3, complete 
excision 
CBC, Biochemistry, U/A; Abdominal 
ultrasound; FNA regional node; bone 
marrow aspirate 
MCT grade 3; T2N0M0; 
Stage Ia 
Vinblastine/Lomustine protocol; 
prednisolone. Completed 4 out of 10 
treatments then owner declined further 




Soft Tissue Sarcoma Cindy Properjohn 
12yo F Kelpie cross 
Mass excised from right medial antebrachium; 
histopathologic diagnosis of haemangiopericytoma. 
CBC, Biochemistry, U/A;  
FNA right prescapular node; thoracic 
radiographs x 3 
Haemangiopericytoma, 
Grade 2; T1aN0M0, Stage 
I 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 





Tumours of the 
Skeletal System 
Boomer Jebb 
5yo Fn Staffordshire bull 
terrier cross 
6 week history of limping on right foreleg. 
Radiographs demonstrate lytic lesion of proximal 
humerus with periosteal proliferation 
Jamshidi bone biopsy; thoracic 
radiographs; lateral radiograph of 
right humerus; FNA right prescapular 
lymph node; CBC, biochemistry, U/A 
Only reactive bone seen on 
biopsy 
Referred for limb amputation after repeat 
radiographs one month later showed disease 
progression within the humerus but owner 










8yo Mn JRT 
First actinic squamous cell carcinoma removed 
from ventrum 18 months prior; 2 surgeries since 
None Cutaneous squamous cell 
carcinoma 
Suncream, keep out of direct sun where 
possible; piroxicam. Reassessed 3 months 
later: skin less erythematous but several 
small ulcerations on ventrum so treated with 







Tumours of the Male 
Reproductive System 
Toby Green 
10yo Mn Border Collie 
4 week history of stranguria, then faecal tenesmus; 
abdominal ultrasound demonstrated enlarged, 
mineralized prostate with regional 
lymphadenopathy; FNA prostate and prostatic 
wash showed mild inflammation; 7 days 
enrofloxacin prior to presentation 
None Open: neoplasia vs. 
prostatitis 
Owner declined further diagnostics and 






Mast Cell Tumours Sadoko Agnew 
12yo Fn Sheltie 
3 months ago developed several lumps on ventrum: 
5 masses excisional biopsy: 4 = steatitis, 1 = grade 
II (low grade) mast cell tumour with incomplete 
excision 
CBC; Abdominal ultrasound MCT grade 2 (low grade); 
T1NxM0; Stage Ia 
Vinblastine x 8; prednisolone. No recurrence 
at time of death June 2011 
02/09/08 
236 
Cancer of the Nasal 
Planum 
Milo Gartrell 
9yo Mn DSH 





Soft Tissue Sarcomas Max Antonio 
11yo Mn DSH cat 
One month history of swelling on distal 
antebrachium; excisional biopsy = intermediate 
grade fibrosarcoma  
None Fibrosarcoma, Grade 2; 
T1aNxMx, Stage I or 
higher 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 
daily for life. Tumour recurrence at proximal 







Mast Cell Tumours Delta Hawes 
4yo Fn Labrador 
Superficial excoriation present for years, last 6 
months became a mass which then became 
ulcerated; another 2 masses found at surgery in 
right and left caudal mammary tissue; excision of 
all 3 masses: grade III mast cell tumour with 
inguinal node metastasis 
CBC, biochemistry; abdominal 
ultrasound 
Mast Cell Tumour, grade 
III; T0N2bM0; Stage IIb 





Mast Cell Tumours Chloe Rothwell 
13yo Fn Maltese cross 
Mass on ventrum present for 6 months with rapid 
growth in last 3 weeks; marginal excision grade II 
mast cell tumour 
CBC, Biochemistry; Abdominal 
ultrasound; FNA spleen; bone marrow 
aspirate 
Mast Cell Tumour, grade 
II; T0N0M0; Stage Ia 






Lymphosarcoma Maxine Millar 
11yo Fn Pug 
 
Weight loss over the last month despite good 
appetite; diarrhoea for 2 weeks; polyuria, 
hyposthenuria and UTI; solitary jejunal mass 
diagnosed on abdominal ultrasound; excisional 
biopsy = lymphosarcoma 
CBC, Biochemistry, U/A; urine 
M/C/S; bone marrow aspirate 
Lymphosarcoma Surgical excision of primary tumour. 
Developed complications post operatively 




Tumours of the 
Skeletal System 
Cajun D’Mello 
9yo M Rottweiler 
One week history of marked lameness right 
foreleg; radiographs showed very subtle lysis and 
periosteal reaction of proximal humerus 










11yo Fn Staffordshire bull 
terrier  
Repeatable lymphocytosis, first noted on blood test 
prior to anaesthetic; mild bilateral popliteal node 
enlargement 
CBC, Biochemistry; bone marrow 
aspirate; abdominal ultrasound; FNA 









Lymphosarcoma Jaks Coghlan 
9yo Mn Staffordshire 
terrier cross 
One week history of Generalized 
lymphadenopathy; FNA suggestive of lymphoma 







Soft Tissue Sarcomas Dolly Piper 
9yo Fn Bichon Friese 
Mass on chest first developed 3 years ago; resected 
3 times since then; most recent excision was 5 
months ago; histopathology suggests 
haemangiopericytoma, intermediate to high grade, 
incomplete excision 
CT scan primary mass and full thorax Haemangiopericytoma, 
Grade 2-3; T2bN0M0, 
Stage III 
Referred for marginal surgical excision 








Cancer of the Oral 
Cavity 
Ringo Plummer 
14yo Fn DSH 
Swelling of right upper lip noted by referring vet at 
routine examination; incisional biopsy diagnosed 
fibrosarcoma 
Urea, Creatinine, U/A; Blood 
pressure; CT scan head and thorax 
Fibrosarcoma Electrochemotherapy. Assessment one 
month after procedure indicated disease 
progression; started metronomic 
chemotherapy: 10mg/m2 cyclophosphamide 
sid, 0.2mg/kg piroxicam eod for life; no 
response to treatment; palliated then 




Mesothelioma Abbey Lennon 
12yo Fn golden retriever 
 
Presented after pericardectomy for pericardial 
effusion; histopathologic diagnosis of 
mesothelioma 
CBC Pericardial mesothelioma Intrathoracic carboplatin every 3 weeks x 6; 
piroxicam 0.3mg/kg daily. Recurrent pleural 






Lymphosarcoma Chad Anderson 
9yo Mn Corgi 
3 month history of progressive skin lesions, non 
responsive to antibiotics or prednisolone; 
histopathologic diagnosis of epitheliotropic 
lymphoma  
None  Epitheliotropic lymphoma Isotretinoin 2mg/kg daily; omega 3 fish oil. 
Deterioration of condition before retinoids 
could take effect; started on interferon. 
Continued disease progression and 







Mast Cell Tumours Buddy Bannister 
7yo Mn mastiff cross 
Mass over right rump present over a year; 
excisional biopsy diagnosis of grade 1 mast cell 
tumour, complete excision; mass over left hock 
present 3 months without rapid growth, excisional 
biopsy diagnosis of grade 2 (low grade) mast cell 
tumour, incomplete excision 
None MCT: one grade 1, one 
grade 2 (low grade); 
T0NxMx; Stage IIIa 





Lymphosarcoma Pearl Vivian 
11yo Fn flat coated 
retriever 
3 week history of progressive lethargy and 
inappetance; Generalized lymphadenopathy noted 
one week ago; FNA suggestive of lymphoma 
None  Lymphosarcoma; stage 
IVb or higher 





Hepatic Tumours Ben Ryan 
12yo Mn golden retriever 
cross 
3 week history of progressive lethargy and 
inappetance; bloods unremarkable; abdominal 
ultrasound detected 8cm diameter vascular mass 
within abdomen 
CT scan thorax and abdomen Hepatocellular 
adenocarcinoma 







Cancer of the Oral 
Cavity 
Jock Lee 
9yo Mn Staffordshire bull 
terrier  
Swelling of gum over upper right canine tooth for a 
couple of months; punch biopsy suspected 
osteosarcoma but the possibility of an odontogenic 
tumour with bone production could not be 
excluded 
CT scan oral cavity and thorax Low grade undifferentiated 
osteogenic sarcoma 
Radiographically benign, chronic bony 
lesion of right upper maxilla adjacent to the 
canine tooth seen on CT; not typical of an 
osteosarcoma; dog referred for marginal 










Tumours of the 
Mammary Gland 
Chicky Lisson 
10yo Fn Cocker spaniel 
3 month history of 2cm mass middle left mammary 
gland; excised by referring vet and diagnosed as 
mammary adenocarcinoma 
None Mammary papillary 
intraductular 
adenocarcinoma, low MR, 
no distinct vascular 
involvement, tumour cells 
can be seen in the 
surrounding tissues but 
complete excision of 
primary. 













Nasal Tumours Maxwell Kennedy 
8yo Mn Maltese cross 
 
5 week history of increased upper respiratory noise 
and blood tinged nasal discharge; CT scan 
demonstrated large mass obliterating right nasal 
cavity; biopsy diagnosed carcinoma 
CBC Poorly differentiated 
carcinoma 
Carboplatin and Gemcitabine, alternating 
with doxorubicin every 3 weeks x 6; 
piroxicam 0.3mg/kg daily. Repeat CT scan 
after 2 cycles of treatment indicating disease 
progression; valproic acid added to protocol; 
pamidronate given as analgesic; showed 
improvement after third doxorubicin / 
valproic acid treatment, therefore dropped 
carboplatin from protocol; developed 
seizures and was euthanased 20/1/09 
25/09/08 
254 
Lymphosarcoma Harley Healy 
6yo Mn Rottweiler 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
CBC, biochemistry, U/A; bone 
marrow aspirate 





Cancer of the Nasal 
Planum 
Manja Tan 
8yo Fn DMH cat 
‘Scratch’ on the nasal planum for a few months but 
only rapid growth in the last month; incisional 
biopsy diagnosis of squamous cell carcinoma 
Urea, Creatinine Squamous Cell Carcinoma Electrochemotherapy. No reduction in 
tumour size. Treated with aggressive 
cryotherapy; marked sloughing of nasal 






Tumours of the 
Endocrine System 
Max Healy 
12yo Mn golden retriever 
Mass measuring 5.5cm3 ventral neck first noted by 
referring vet when taking jugular blood sample; 
FNA suggestive of cells of ‘neuro-endocrine’ 
origin 
T4/TSH; CT scan neck and thorax Thyroid adenocarcinoma Referred for surgical excision of mass; 
followed by adjuvant doxorubicin every 3 
weeks x 6. Repeat thoracic radiographs 





Lymphosarcoma Scylla Walsh 
10yo Fn German shepherd 
6 days history of lethargy, inappetance, pyrexia, 
lymphadenopathy, hepatosplenomegaly; FNA of 
nodes suggestive of lymphoma 
No further diagnostics performed Lymphoma, Stage IVb or 
higher 













10yo Mn blue heeler 
Several month history of mass on medial left elbow 
with recent rapid increase in size now causing 
lameness of the left foreleg. FNA of mass 
suggestive of soft tissue sarcoma; FNA of enlarged 
left prescapular (regional) node showed severe 
eosinophilic lymphadenitis with reactive lymphoid 
hyperplasia 
None  Open – soft tissue sarcoma 
vs. mast cell tumour vs. 
fungal granuloma 







Tumours of the 
Skeletal System 
Sandy Gyurka 
6yo Fn Labrador 
2 month history of left foreleg lameness, with no 
improvement after anti-inflammatory therapy; 
radiographs of proximal left humerus showed mild 
periosteal reaction cranial mid humerus and DJD 
changes to shoulder joint 
Repeat radiographs 3 weeks later 
showed stable disease 
Degenerative joint disease 
left shoulder joint 






Mast Cell Tumours Biscuit Phillips 
11yo Fn Pug 
Mass present on right foreleg for a year with very 
slow growth; FNA suggested mast cell tumour; 
wide excisional biopsy diagnosis of mast cell 
tumour, grade 2 (low grade) incomplete excision 
CBC, biochemistry, urinalysis; FNA 
mass ventral chest; FNA right 
prescapular node abdominal 
ultrasound; bone marrow aspirate 
MCT, Grade 2 (low grade); 
T1N0M0; Stage Ia 





Hepatic Tumours Abbey Webb 
11yo Fn Dalmatian 
Abdominal swelling and diarrhoea 7 days prior to 
presentation; abdominal ultrasound detected 
solitary hepatic mass 
CT thorax and abdomen; ultrasound-
guided FNA hepatic mass 
Massive hepatic or bile 
duct carcinoma with 
regional lymphadenopathy 
Palliation: codeine 1mg/kg daily, Hills l/d. 
Enjoyed good quality of life for 2 months 
then became uncomfortable, lethargic and 




Mast Cell Tumours Millie Dawes 
10yo Fn Maltese cross 
Mass over right shoulder for a year with recent 
slow growth; histopathologic diagnosis of mast cell 
tumour, grade 2 (low grade), incomplete excision 
None MCT, Grade 2 (low grade); 
T0NxMx; Stage Ia 







Lymphosarcoma Tippy Freeman 
12yo Fn Corgi 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
CBC, Biochemistry  Lymphoma; Stage IVa (or 
higher) 
Doxorubicin every 3 weeks x 6. Initial 
response to treatment; required 10% dose 
reduction due to nausea and vomiting; 






Lymphosarcoma Kane Berinson 
6yo M German shepherd 
Generalized lymphadenopathy; FNA suggestive of 
lymphoma 
CBC, Biochemistry, U/A; node 
biopsy for histopathology and 
immunohistochemistry; bone marrow 
aspirate 
Lymphoma, Centroblastic 





Tumours of the 
Skeletal System 
Ted E Bear Kingsbury 
9yo M golden retriever 
Firm swelling around right hock noted a few days 
prior to presentation; no lameness; no injury 
known 
Thoracic radiographs; hock 
radiographs 







Mast Cell Tumours Bella Svenningson 
7yo Fn Labrador 
Had a high grade mast cell tumour incompletely 
removed from left inguinum 12 months prior; 
treated with adjuvant 
Vinblastine/LOMUSTINE/prednisolone 
chemotherapy; now mass present again in left 
inguinum 
FNA mass; abdominal ultrasound; 
bone marrow aspirate; CBC 
MCT, Grade 3; rTxN1M1; 
Stage IVa 
Palliation: prednisolone 2mg/kg daily, 
tapering; omega 3 fatty acids; 






Hepatic Tumours Kitza Greble 
12yo Fn Staffordshire bull 
terrier cross 
Had a solitary hepatic mass removed 6 weeks prior 
to presentation after it ruptured; histopathologic 
diagnosis of hepatic adenoma or low grade 
adenocarcinoma 
CT scan thorax and abdomen to assess 
if recurrent or progressive disease 
present 







Mast Cell Tumours Gemma O’Brien 
13yo Fn Sheltie 
One month history of sneezing and open mouth 
breathing; incisional biopsy diagnosis of high 
grade mast cell tumour 
CBC MCT, Grade 3; 
T1NxMx; Stage 
Vinblastine, Lomustine q3wks x 5 cycles; 
prednisolone. Excellent initial clinical 
improvement; developed sneezing and nasal 
discharge again at last treatment; within 2 
weeks developed seizures and was 









9yo Fn Staffordshire bull 
terrier 
3 month history of mass on outer lower left lip; 
histopathologic diagnosis of malignant melanoma, 
MI 3/10hpf, nuclear atypia 3/10hpf; complete but 
close excision 




Soft Tissue Sarcomas Rocky Leotta 
12yo M Bull Arab 
Recurrent soft tissue sarcoma on left stifle first 
removed 2006; now measures 10x10cm; newer 
mass medial right thigh 
None Soft tissue sarcoma, Grade 
1; rT2bNxMx, Stage III or 
higher 








Cancer of the Oral 
Cavity 
Harley Wovodich 
11yo Mn Labrador 
One month history of mass on left side of face but 
involving caudal hard palate; weight loss despite 
eating well; histopathologic diagnosis of low grade 
spindle cell tumour 
None Low grade spindle cell 
tumour – suspect 
“histologically low grade, 
behaviourally high grade” 
sarcoma, or amelanotic 
melanoma 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 







Ocular Tumours Sophie Scrimgeour 
10yo Fn Burmese cat 
2 month history of mass on dorsomedial iris; FNA 
suggestive of lymphoma; no other abnormalities on 
physical examination; FeLV and FIV negative 
CBC, U/A; abdominal ultrasound Ocular lymphoma UW-25. Only one treatment given as Sophie 
experienced grade 3 gastrointestinal toxicity; 
she then developed marked increase in 
intraocular pressure and had an enucleation. 






Soft Tissue Sarcoma Ruggie Mihaly 
13yo Fn DSH cat 
One month history of rapid growth of mass over 
left metatarsals; histopathologic diagnosis of high 
grade fibrosarcoma; left popliteal node mildly 
enlarged 
CBC, Biochemistry, U/A; FNA left 
popliteal node 
Fibrosarcoma, Grade 3; 
T1bN0Mx, Stage II 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 
daily for life. Stable disease until February 
2009; owner declined repeat staging and 




Soft Tissue Sarcoma Desmo Storey 
10yo Mn Labrador 
One month history of firm but mobile mass on 
right thorax; FNA suggestive of soft tissue 
sarcoma; smaller mass in right axilla not tested 
FNA mass in right axilla; CBC, U/A; 
CT scan thorax; abdominal 




Referred for wide excision of mass; no 






Lymphosarcoma Ziggy Buckley 
9yo Mn Boxer 
2 week history of inappetance, diarrhoea and 
weight loss; abdominal ultrasound showed multiple 
nodules along GIT and mesenteric 
lymphadenopathy; intestinal biopsy diagnosed 
diffuse, high grade, large cell lymphoma 
CBC Diffuse, high grade, large 
cell lymphoma 
UW-19; admitted to ICU for intravenous 
fluid therapy for 24 hours. No improvement 







Lymphosarcoma Rex Pasco 
8yo Mn Jack Russell terrier 
cross 
One month history of lethargy and inappetance; 
then owner noticed enlarged superficial nodes; 
FNA suggestive of lymphoma; incisional biopsy 
showed no distinct lymph node tissue, only 
necrotising cellulitis with encapsulation. 
CBC, abdominal ultrasound, bone 
marrow aspirate 
Presumptive diagnosis of 
lymphoma; Stage IVb 






Mast Cell Tumours Zan Austin 
12yo Fn Kelpie cross 
 
One month history of stertor and snoring; CT scan 
showed large mass occluding the nasopharynx and 
extending into the left nasal cavity; incisional 
biopsy diagnosed MCT, high grade 
CBC, Biochemistry, U/A MCT, Grade 3; T1NxMx; 
Stage 3a 
Imatinib mesylate 4.4mg/kg daily for 14 
days. Euthanased 12/11/08 due to 







Mast Cell Tumours Axle Riley 
8yo M Staffordshire Bull 
Terrier 
12 months prior had 3 low/intermediate grade mast 
cell tumours completely removed from right 
thorax; developed a mass between toes 3 and 4 on 
left fore foot 3 weeks ago; FNA suggested MCT; 
excisional biopsy diagnosed MCT grade 2 (low 
grade), incomplete excision 
CBC, Biochemistry, U/A; FNA left 
prescapular node; abdominal 
ultrasound 
MCT Grade 2 (low grade); 
T1N0M0; Stage Ia 








Lymphosarcoma Max Haynes 
7yo Mn Rottweiler 
2 week history of Generalized lymphadenopathy; 
FNA diagnosed lymphoma 
CBC, Biochemistry, U/A Lymphosarcoma, Stage 
IIIa or higher 
Doxorubicin q3wks x 6. Entered remission 
after one cycle; became acutely lame on 
right hindleg and radiographs revealed an 
aggressive monostotic bone lesion of the 
proximal tibia, presumed osteosarcoma; 
administered doxorubicin and pamidronate; 
euthanased 2 weeks later 
30/10/08 
280 
Mast Cell Tumours Hannah Carle 
6yo F Boxer 
6 week history of mass under neck, waxing and 
waning; excisional biopsy diagnosed MCT 
FNA right and left submandibular 
lymph nodes 











6yo Fn Maltese cross 
Mass over left cheek for a couple of years 
unchanged, then mass over left shoulder noticed by 
groomer. Excisional biopsy of both masses 
suggested baso-squamous carcinoma, with nodal 
involvement 
CBC, Biochemistry, U/A; CT scan 
head and thorax 
Baso-squamous carcinoma Gemcitabine and carboplatin protocol, every 
3 weeks x 6. Developed delayed neutropenia 
therefore interval between treatments 





Lymphosarcoma Leo Hurley 
10yo M golden retriever 
2 inguinal masses detected by groomer a week ago; 
FNA suggestive of lymphoma. Dog also had 
undescended testes and never castrated. 
Abdominal ultrasound Lymphosarcoma Referred back to original vet for excisional 
biopsy of both masses. Owner declined 
histopathology but surgeon said they visually 




Mast Cell Tumours Jessie Payne 
10yo Fn Papillion 
Mass over right shoulder noticed by owner 3 weeks 
prior; excisional biopsy diagnosed mast cell 
tumour, grade 2 (low grade), marginal excision 
CBC, biochemistry; FNA left 
prescapular lymph node 
MCT, grade 2 (low grade); 
T1N0M0, Stage Ia 








12yo Fn Jack Russell 
terrier 
2 month history of lower urinary tract signs, then 
PU/PD in the last month; abdominal ultrasound 
showed bladder mass, enlarged MILNs and 
hydronephrosis 
None Bladder mass – suspected 
metastatic and obstructive 
TCC 
Piroxicam 0.3mg/kg daily. Good response to 





Lymphosarcoma Phoebe Simenson 
11yo Fn Border Collie 
3 week history of enlarged lymph nodes and ‘rash’ 
on belly; fine needle aspirate cytology diagnosis of 
lymphoma; appeared to have bruising on caudal 
ventrum 
None Lymphosarcoma; Stage 
IVa or higher 







Lymphosarcoma Kira Flynn 
11yo Fn German shepherd 
Two small masses on neck and one on right 
shoulder developed 3 weeks prior. FNA suggestive 
of lymphoid neoplasia. Excisional biopsy of 
masses confirmed diffuse intermediate to high 
grade immunoblastic lymphoma 
IHC (CD3, CD79a), thoracic 
radiographs, abdominal ultrasound, 
bone marrow aspirate and concurrent 
CBC 
Lymphosarcoma, B cell; 
Stage IVa 
UW-19. No reduction in spleen size after 6 
treatments so switched to Lomustine every 3 
weeks; still no clinical improvement. Owner 
declined splenectomy and lomustine was 







Histiocytic sarcoma Grace Jones 
9yo Fn Flat Coated 
Retriever 
3 month history of progressive lameness of right 
foreleg with recent soft tissue swelling of area; 
incisional biopsy diagnosis of undifferentiated 
sarcoma; elbow radiographs showed lysis of lateral 
humeral condyle 
Thoracic radiographs, abdominal 
ultrasound; CBC, Biochemistry 
Undifferentiated sarcoma 
of the bone 
Lomustine every 3 weeks x 6; pamidronate 
1.3mg/kg every 3 weeks; carprofen; codeine. 
Developed draining fistulae from both 





Lymphosarcoma Fifi Laforet 
8yo Fn Jack Russell terrier 
cross 
2 week history of increased size of lymph nodes; 
FNA suggestive of lymphoma; CP2 within normal 
range 
None Lymphoma, Stage IIIa or 
higher 
HDC-BMT. Recurrence after 6 months. 







Lymphosarcoma Chloe Aungier 
12yo Fn German Shepherd 
5 month history of progressive inappetance, weight 
loss, weakness then dyspnoea and cardiac 
dysrrhythmia; abdominal radiographs showed 
small intestines pushed dorsally, with suspicion of 
cranial abdominal mass; mild anaemia and marked 
lymphocytosis on recent bloods 
Abdominal ultrasound; FNA of 
diffusely enlarged spleen 
Lymphoma None. Owner declined further diagnostics 






Tumours of the 
Skeletal System 
Misty Russo 
8yo Fn Labrador 
Large mass on right thorax noted by referring 
veterinarian at routine vaccination. Owner did 
report that the dog had been slowing down for the 
last month and reluctant to go for walks. Biopsy of 
mass diagnosed an osteogenic sarcoma. 






Cancer of the Nasal 
Planum 
Wallace Tolkein 
12yo Mn DLH 
12 month history of would on nose that has 
become progressively more ulcerated; sneezing and 
occasional bleeding has commenced in the last 2 
weeks 







Lymphosarcoma Obi Cole 
3yo Mn Ridgeback cross 
Generalized lymphadenopathy for 2 weeks; FNA 
suggestive of lymphoma 
CBC, biochemistry; Abdominal 
ultrasound; bone marrow aspirate 
High Grade B-cell 
Centroblastic polymorphic 
lymphoma; Stage IIIa 
UW-19. Recurrence 12 months after 
diagnosis. Restarted UW-19 with initial 







Soft Tissue Sarcoma Pippa Hutchinson 
6yo Fn Labrador 
Mass on caudal left thigh for 4 weeks; excisional 
biopsy diagnosed high grade soft tissue sarcoma, 
incomplete excision 
CBC, biochemistry; thoracic 
radiographs x 3; abdominal ultrasound 
Soft tissue sarcoma, grade 
3;  
VAC protocol; followed by metronomic 
chemotherapy: 10mg/m2 cyclophosphamide, 
0.3mg/kg piroxicam daily for life. Grade 4 





Lymphosarcoma Kira Mannino 
8yo Fn Staffordshire bull 
terrier 
6 month history of enlarged submandibular nodes, 
recently enlarging; FNA suggestive of lymphoma 
None Lymphosarcoma, Stage 
IIIa or higher 







Haemangiosarcoma Denim Tassone 
12yo Mn blue heeler cross 
3 weeks ago presented to referring vet collapsed; 
diagnosed with splenic mass; splenectomy 
performed, giving histopathologic diagnosis of 
haemangiosarcoma; hepatic nodules seen on 
abdominal ultrasound but not biopsied 
CBC, biochemistry; thoracic 
radiographs x 3; abdominal ultrasound 
Splenic 
haemangiosarcoma; 
T2N0Mx, Stage II or 
higher 
Monitoring. Recurrence of haemabdomen 





Lymphosarcoma Cosmo Ward 
13yo Mn Jack Russell 
terrier 
6 week history of increased sneezing and snoring 
which then developed into a serosanguinous 
discharge from the right nostril; rhinoscopic guided 
biopsies diagnosed lymphoma 
None Intranasal lymphoma Palliation: prednisolone 2mg/kg daily for 7 





Soft Tissue Sarcomas Elsa Winter 
9yo Fn Bichon Friese 
3 month history of mass between toes 3 and 4 of 
right fore foot. No response to antibiotics. 
Excisional biopsy diagnosed soft tissue sarcoma, 
intermediate-high grade, incomplete excision  
CBC, Biochemistry, U/A; thoracic 
radiographs x 3 
Soft Tissue Sarcoma, 
Grade 2-3;  
Doxorubicin q3weeks x 6; followed by 
metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 





Haemangiosarcoma Bear Brown 
8yo Mn Great Pyrenees 
One week prior became inappetant and lethargic. 
Diagnosed with pericardial and pleural effusion. 
Ultrasound showed heart based mass and many 
splenic nodules 
None Open: presumed metastatic 
haemangiosarcoma; 





Soft Tissue Sarcomas Sammy Abreu 
8yo Fn Samoyed 
12 month history of mass slowly increasing in size 
over right thorax; excisional biopsy diagnosed soft 
tissue sarcoma, grade 2, incomplete excision 
CBC, Biochemistry, U/A; thoracic 
radiographs x 3 
Soft Tissue Sarcoma, 
Grade 2;  
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 





Perianal Tumours Zep Willis 
9yo Mn Kelpie cross 
2 month history of inappetance and lethargy then 
marked weight loss. Abdominal ultrasound showed 
multiple hepatic and splenic masses; 1cm mass 
near right anal sac detected on examination 
Thoracic radiographs x 3; Abdominal 
ultrasound; FNA liver and spleen; 
incisional biopsy right anal mass 
Perianal carcinoma;  Owner elected naturopathic treatment. 
Persistent blood ooze from biopsy site; 
coagulopathy diagnosed; blood transfusion 




Cancer of the Oral 
Cavity 
Choo Choo Panetta 
18yo Fn DLH  
2 week history of oral mass; excisional biopsy 
diagnosed oral malignant melanoma. Concurrent 
hyperthyroidism. 




Lymphosarcoma Sweep Green 
6yo Mn Field spaniel 
One month history of generalized 
lymphadenopathy; FNA diagnosis of lymphoma 
CBC, Biochemistry, U/A; node 
biopsy for HP and IHC; bone marrow 
aspirate 
Lymphosarcoma;  UW-19. Recurrence prior to finishing 






Cancer of the Oral 
Cavity 
Samson Vicario 
7yo M Bull terrier 
Mass seen by referring vet 2 months prior, 
measuring 3cm diameter; owner declined biopsy; 
mass now doubled in size; incisional biopsy 
diagnosis of fibrosarcoma 





Lymphosarcoma Amba-Rose Hood 
6yo Fn German shepherd 
cross 
Inguinal masses and bruising noted by owner after 
dog groomed 2 weeks ago. Referring vet noted 
generalized lymphadenopathy; FNA diagnosed 
lymphoma 
None Lymphosarcoma Palliation: 2mg/kg prednisolone daily, 




Lymphosarcoma Bronson Scrivens 
11yo Mn Weimeraner 
Inappetance which owner thought was dental 
disease; referring vet noted lymphadenopathy; 
FNA diagnostic of lymphoma 
None Lymphosarcoma Palliation: 2mg/kg prednisolone daily, 






Tumours of the 
Mammary Gland 
Sandie Solly 
12yo Fn Maltese cross 
Rapidly growing mass over left mammary gland 2; 
excisional biopsy diagnosed mammary carcinoma, 
incomplete excision 
Thoracic radiographs x3; FNA 





excision, MR >6/hpf, cells 







Lymphosarcoma Heidi Cahill 
7yo Fn Australian Cattle 
dog 
Acute onset, 4 week history of vomiting. 
Endoscopic guided gastric biopsies diagnosed T 
cell lymphoma 
CBC, Biochemistry Lymphosarcoma UW-19, including L’asparaginase at first 
treatment. Clinical disease progression; 
developed generalized lymphadenopathy 






Lymphosarcoma Amy Pitt 
6yo Fn Standard Poodle 
Developed diarrhea which resolved after a few 
days but was then inappetant and lethargic; 
Generalized lymphadenopathy noted; node biopsy 
diagnosed lymphoma 
CBC, Biochemistry; IHC on biopsy 
sample; Bone marrow aspirate 







Mast Cell Tumours Chester Downes 
11yo Mn Greyhound cross 
Mass present on right lateral thigh for 2-3 years 
with recent growth; excisional biopsy diagnosis of 
grade 2 mast cell tumour, incomplete excision 









8yo Mn Blue heeler 
One month history of pollakiuria; haematuria 
started one week ago; abdominal ultrasound 
demonstrated mass in trigone of bladder, irregular 
medial iliac nodes and hepatic nodules 
None Open – suspected 
transitional cell carcinoma 





Soft Tissue Sarcomas Dicey Jeffress 
13yo Fn Wolfhound cross 
Two week history of mass over right elbow; 
excisional biopsy diagnosis of intermediate grade 
soft tissue sarcoma 
CBC, Biochemistry, U/A; UPCR; 
thoracic radiographs x 3 
Soft tissue sarcoma, grade 
2 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 





Soft Tissue Sarcomas George Wyman 
14yo Mn crossbreed 
6 month history of mass adjacent right tail base 
with rapid growth in the last 2 months. Abdominal 
mass also palpable on physical examination 
Abdominal ultrasound; CT scan 
thorax and abdomen; CBC, 
biochemistry; FNA intra-abdominal 
mass; incisional biopsy mass adjacent 
tail base 
Mass near tail base = 
fibrosarcoma, Grade 3; 
abdominal mass = open 







Mast Cell Tumours Grover Norris 
13yo Fn cross breed 
3 week history of licking side then developing a 
sore. FNA suggestive of mast cell tumour, 
therefore wide excision and histopathology 
performed = mast cell tumour, high grade, 
complete excision 






Cancer of the Oral 
Cavity 
Angus Connolly 
8yo Mn Rottweiler 
3 week history of increased licking then oral mass 
noted in right angle of jaw. Incisional biopsy 
diagnosis of oral malignant melanoma, MI 20/10, 
nuclear atypia 5/10 






Mast Cell Tumours Rex Wallington 
9yo Mn Bichon Frise 
10 weeks prior developed mass over right tibia; 
excisional biopsy diagnosed mast cell tumour, 
grade 2, incomplete excision. Recurrence of mass 
started in the last 10 days 






Mast Cell Tumours Zoe Sobkowiak 
4yo Fn Labrador 
2 weeks ago owner noticed mass over right 
antebrachium; saw referring vet 2 days later for 
excisional biopsy – mast cell tumour, grade 2 (low 
grade), incomplete excision 






Lymphosarcoma Bella Mansell 
1yo Fn Bombay cat 
One week history of lethargy and dyspnoea; cranial 
mediastinal mass detected on thoracic radiographs 
and ultrasound; FNA diagnosis of lymphoma 
CBC, Biochemistry  Lymphosarcoma UW-25. Experienced anorexia and nausea 
during the first cycle so 10% dose reductions 
applied; rapid clinical response however; 
repeat thoracic radiographs after first cycle 





Lymphosarcoma Oscar Ellis 
6yo M Maltese terrier 
One week history of enlarged submandibular 
lymph nodes (other nodes normal); FNA 
suggestive of lymphoma; marked periodontal 
disease seen on physical examination  
CBC, Biochemistry, U/A; node 
biopsy for histopathology and IHC; 




Referred back to original vet for dental 







Tumours of the Skin 
and Subcutaneous 
Tissues 
Puss in Boots Hill 
14yo Mn DSH cat 
4 month history of waxing and waning mass under 
the chin; not irritating cat; excisional biopsy 
diagnosed sweat gland adenocarcinoma, 
incomplete excision 
FNA right submandibular lymph 
node; thoracic radiographs 
Sweat Gland 
Adenocarcinoma 
Referred for CT scan head, followed by 
further local surgery; repeat histopathology 
confirmed no evidence of adenocarcinoma. 
Repeat surgery showed no evidence of 







Haemangiosarcoma Caveat Culshaw 
8yo Mn Boxer 
3 week history of bouts of lethargy which he 
seemed to recover from. Abdominal mass palpated 
by referring vet; abdominal ultrasound detected 
large, cavitatory mass in right dorsocaudal 
abdomen, with evidence of haemorrhage; FNA of 
mass suspected sarcoma 
CBC, Biochemistry; thoracic 
radiographs 
Haemangiosarcoma Referred for exploratory laparotomy and 
mass excision; small hepatic nodules 
visualized at surgery and also biopsied; 
followed by adjuvant VAC protocol. 







Soft Tissue Sarcomas Harley Brown 
12yo Mn Labrador cross 
Unknown duration of mass over left shoulder but 
did have growth over the one month since noted; 
FNA of mass suggestive of haemangiopericytoma 
CBC, Biochemistry; FNA right 




Initial punch biopsies diagnosed lipoma, 
therefore referred back to original vet for 
marginal excision of mass and 
histopathology. Commenced metronomic 
chemotherapy: 10mg/m2 cyclophosphamide, 





Mast Cell Tumours Mopsy Trezona 
8yo Fn Maltese cross 
One month history of mass over left side of face, 
non responsive to antibiotics or dental prophylaxis; 
excisional biopsy diagnosed mast cell tumour, 
grade 2 (high grade) 
CBC, Biochemistry; FNA left 
submandibular node; abdominal 
ultrasound; FNA splenic nodule; bone 
marrow aspirate 
MCT, grade 2 (high 
grade); T0N1M0 
Palliation: omega-3 fish oil; 
chlorpheniramine, prednisolone and 





Lymphosarcoma Samwise Michalka 
4yo Mn Russian Blue cat 
Mass noticed by owner caudal to left ear; saw 
referring vet the next day who also found mass left 
prescapular region; FNA suggestive of lymphoma 
Excisional biopsy of both masses for 
histopathology and IHC 
Reactive Lymphoid 
Hyperplasia 





Mast Cell Tumours Hulk Reeves 
5yo M Rottweiler 
3 week history of mass adjacent right tail base with 
frequent bleeding; incisional biopsy non-diagnostic 
but dog experienced bleeding from bladder and 
lungs post-operatively 
CBC, Biochemistry; abdominal 
ultrasound 
Open – MCT, 
haemangiosarcoma 









Tumours of the 
Skeletal System 
Sophie Lemmey 
7yo Fn Labrador 
4 week history of lameness of right foreleg; 
radiographs showed aggressive monostotic lesion 
of the mid radius; bone biopsy diagnosed 
osteosarcoma 
CBC, Biochemistry; thoracic 
radiographs; pelvic radiographs; FNA 
right prescapular node 
Osteosarcoma; T3M0 Doxorubicin x 2, Carboplatin x 4; 
pamidronate. Progressive lameness with 
medical therapy only at treatment 3; repeat 
thoracic radiographs still showed no 
evidence of metastatic disease, so referred 
for limb amputation, then continued second 




Cancer of the Oral 
Cavity 
Zella Rothwell 
7yo Fn Bernese Mountain 
Dog 
2 week history of salivation from right side of 
mouth and gingival proliferation over right lower 
jaw 
CT scan head, thorax and abdomen; 
biopsy of gingival mass, sublingual 
mass and node on left side of neck 
Lymphosarcoma Owner declined definitive treatment. 






Soft Tissue Sarcomas Connie Dixon 
10yo Fn cross breed 
3 month history of slowly growing mass adjacent 
right tail base; incisional biopsy diagnosis of soft 
tissue sarcoma, intermediate grade 
None Soft Tissue Sarcoma, 
Grade 2;  
Referred for marginal excision of mass. 
Then commenced metronomic 
chemotherapy: 10mg/m2 cyclophosphamide, 










8yo Fn Labrador cross 
Rapid growth of mass over left medial upper 
eyelid; excisional biopsy diagnosed squamous cell 
carcinoma, incomplete excision; started to re-grow 
within 7 days of biopsy 
FNA left submandibular lymph node; 
thoracic radiographs 
Squamous Cell Carcinoma;  Referred for wide excision, necessitating 
enucleation of the eye. Within a week of 
initial consult before surgical opinion sought 
there was marked disease progression and 




Soft Tissue Sarcomas Lucy Brown 
9yo Fn Cocker Spaniel 
3 month history of mass over right thorax slowly 
increasing in size. Excisional biopsy diagnosed 
grade 1 haemangiopericytoma, incomplete excision 
CBC, Biochemistry Haemangiopericytoma, 
Grade 1 





Perianal Tumours Sam Jenna 
13yo Mn Poodle 
Weight loss over the last 3 months; cough for one 
month; perianal mass noted one week ago; FNA 
suggestive of apocrine gland adenocarcinoma 
None Apocrine gland 
adenocarcinoma 







Mast Cell Tumours Kiefer Craven 
10yo Fn Staffordshire bull 
terrier 
Mass on lateral left thigh for 6 months; mass over 
left flank present for 6 weeks. FNA of flank mass 
diagnosed MCT; FNA of thigh mass inconclusive 
Referred for marginal excisional 
biopsy of thigh mass, and wide 
excision of flank mass 
Flank = MCT,  grade II 
(low grade), complete 
excision 
Thigh = fibroadnexal 
dysplasia 











7yo Fn Rottweiler 
2 month history of developing mass on toe 2 right 
forefoot, non responsive to antibiotics; radiographs 
showed lysis of P3; metacarpophalangeal 
amputation performed; HP= paronychial squamous 
cell carcinoma 
FNA regional node; thoracic 
radiographs 
Paronychial squamous cell 
carcinoma; T4NxMx 







Mast Cell Tumours Kali Goddard 
7yo Fn Boxer 
Mass over caudal left thigh present for one week; 
excisional biopsy diagnosed high grade MCT, 
marginal excision. Several smaller masses have 
since developed over right shoulder, neck and chest 
FNA 2 of the masses over neck and 
shoulder 
MCT, grade 3; Stage IIIa 
or higher 







Tumours of the 
Intestinal Tract 
Zed Paull 
11yo Mn Labrador cross 
Three week history of vomiting and diarrhoea, 
marked weight loss and progressive inappetance 
and lethargy; marked mesenteric lymphadenopathy 
and a focal intestinal thickening seen on abdominal 
ultrasound 
CBC, Biochemistry; Thoracic 
radiographs; Abdominal ultrasound; 
FNA mesenteric nodes and spleen 
Lymphosarcoma; Stage Vb UW-19, including l’asparaginase week 1; 
prednisolone. Clinical deterioration after the 





Cancer of the Oral 
Cavity 
Aggro Butcher 
16yo Mn DSH 
Two week history of behaviour change and large 
ulcerating mass developing within the left 
mandible; biopsy diagnosis of squamous cell 
carcinoma 
CBC Squamous Cell Carcinoma;  Neoadjuvant chemotherapy: gemcitabine and 
carboplatin; pamidronate also administered; 
meloxicam; buprenorphine. Rapid 




Tumours of the 
Intestinal Tract 
Leo Alexander 
7yo Mn Bengal 
Three month history of weight loss and increasing 
vomiting; focal small intestinal mass seen on 
abdominal ultrasound 






Perianal Tumours Ebony States 
11yo Fn Cocker spaniel 
Chronic anal gland problems for 12 months; acute 
swelling over left perianal region one week ago; 
referring vet palpated mass in location of left anal 
sac; FNA showed pyogranulomatous reaction 
CBC, Biochemistry, ionized calcium, 
U/A; thoracic radiographs; abdominal 
ultrasound; FNA liver and spleen 
which were slightly irregular 
Chronic pyogranulomatous 
anal sacculitis with 
furunculosis 
Staging clear so referred for excision of mass 






Soft Tissue Sarcomas JD Berryman 
9yo Mn cross breed 
Mass over right lateral thigh present for 3 months; 
excisional biopsy diagnosis of intermediate grade 
soft tissue sarcoma, incomplete excision 
CBC, Biochemistry Soft tissue sarcoma, 
intermediate grade;  
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.25mg/kg piroxicam 
daily for life (reduced dose due to 




Lymphosarcoma Ben More 
13yo Mn Border Collie 
3 week history of increased nodes; progressive 
lethargy and inappetance over the last week; FNA 
suggestive of lymphoma 
Node biopsy for histopathology and 
IHC 
Lymphosarcoma, B cell 
centroblastic polymorphic; 
Stage IVb or higher 
UW-19, including prednisolone. Owner 
stopped treatment after first dose of 





Soft Tissue Sarcomas Arnie Gambin 
7yo Mn Boxer 
2 month history of slowly growing mass over 
lateral left stifle; FNA suggestive of soft tissue 
sarcoma 
CT scan left hindleg and thorax; FNA 
left popliteal node 
Soft tissue sarcoma, grade 
1, moderate margins 
Staging clear so referred for surgical 
excision; moderate margins achieved for low 





Ocular Tumours Max Taylor 
14yo Mn cross breed 
3 weeks history of sore right eye and mass growing 
over dorsal right limbus; 12 month history of mass 
over left thorax, now starting to ooze 
CBC, Biochemistry; CT scan head Eye: malignant melanoma 
Thorax: MCT, grade 3 
Referred for enucleation and histopathology 
20/02/09 
342 
Haemangiosarcoma Bronson Roe 
7yo M Boxer 
Invasive subcutaneous haemangiosarcoma 
removed from right thorax with incomplete 
margins 




Haemangiosarcoma Cassey Madsen 
13yo Fn golden retriever 
Collapse one week ago due to haemabdomen; 
abdominal ultrasound found large splenic mass 





Lymphosarcoma Junior Laird 
11yo Fn Staffordshire 
terrier cross 
Two week history of generalized lymphadenopathy 
in a well dog; FNA diagnosis of lymphoma 
None Lymphosarcoma; Stage 
IIIa or higher 




Tumours of the 
Endocrine System 
Lucy Mason 
9yo fn German shorthaired 
pointer 
Ventral neck mass noted a week ago; mass 
measures 7x5.5cm but mobile in dorsoventral 
plane  




Referred for excision of mass; adjuvant 
chemotherapy using doxorubicin every 3 






Hepatic Tumours Poco Papvassiliou 
19yo M Tibetan terrier 
One month history of vague clinical signs; one 
week history of lethargy, inappetance and weight 
loss; thoracic radiographs showed diffuse nodular 
pattern. Abdominal ultrasound showed multifocal, 
cavitary masses in liver and spleen 
None Suspected 
haemangiosarcoma 





Perianal Tumours Jasper Groucutt 
9 year old Mn Labrador 
cross 
Short history of passing smaller but more frequent 
stools; then mass noted near right side of anus a 
week ago; incisional biopsy diagnosed perianal 
gland adenocarcinoma 
Thoracic radiographs; abdominal 











Mast Cell Tumours Eddie Schwarz 
9yo Mn Kelpie cross 
Two masses present for 1-2 months; left axilla 
complete excision of grade 2 (low grade) MCT; 
left lateral thigh incompletely excised grade 2 (low 
grade) MCT; another mass noticed medial left 
thigh 
FNA mass medial left thigh MCT grade 2 (low grade); 
TNxMx; Stage IIIa 









Tumours of the Male 
Reproductive System 
Wilson Murphy 
10yo Mn Border Collie 
Developed right-sided Horner’s syndrome one 
month prior with no underlying cause found. Then 
became lame in left hind leg. Diffuse intermuscular 
mass detected and biopsied: undifferentiated 
neoplasm, pancytokeratin IHC positive. Developed 
bleeding from penis within last 24 hours 
None Metastatic carcinoma; 
primary not located 
Owner declined further diagnostics and 




Lymphosarcoma Nitus Golovanevskiy 
8yo M German shepherd 
cross 
Splenic mass detected on abdominal palpation 
during routine examination; splenectomy 
diagnosed splenic marginal zone lymphoma 
None Splenic marginal zone 
lymphoma 







Tumours of the Male 
Reproductive System 
Zane Thornton 
10yo Mn Boxer 
One month history of dribbling urine. Initial 
prostatic wash was cultured and treated with 
appropriate antibiotics. Still dribbling urine so 
repeat prostatic wash performed and diagnosed 
prostatic carcinoma on cytology 
CBC, Biochemistry Prostatic carcinoma Gemcitabine and carboplatin, every 3 weeks 




Lymphosarcoma Bundy Seath-Shepherd 
3yo Mn Rhodesian 
Ridgeback cross 
Mass present on ventral thorax for one month; 
became progressively enlarged and inflamed; 
excisional biopsy diagnosed B cell lymphoma 
None Cutaneous B cell 
lymphoma 





Mast Cell Tumours Nikki Jovanovic 
10yo Fn Beagle 
Subcutaneous mass on right ventral thorax 
measuring 3cm diameter noted by referring vet on 
routine examination; FNA suggested MCT 
Marginal excisional biopsy for 
histopathology and grading 






Soft tissue Sarcomas Lucy Fenner 
13yo Fn cross breed 
 
3cm mass over lateral left thigh for two weeks. 
FNA diagnosed soft tissue sarcoma. Wide excision 
and histopathology = grade 1 soft tissue sarcoma, 
incomplete excision 
CBC, Biochemistry, U/A; thoracic 
radiographs 
Soft Tissue Sarcoma, grade 
1 









Soft tissue Sarcomas Gemma Muratore 
6yo Fn CKCS 
Mass over lateral left hock noted 2 weeks prior to 
presentation to referring vet. Initial FNA 
suggestive of soft tissue sarcoma. Wide excision 
and histopathology confirmed diagnosis of low 
grade STS, incomplete excision 
CBC, Biochemistry Soft Tissue Sarcoma, grade 
1 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 






Mast Cell Tumours Harry Hill 
5yo Mn golden retriever 
Mass over left thigh for 2 weeks; FNA diagnosed 
MCT. At surgery another smaller mass found 
nearby. Both removed with wide margins; 
histopathology diagnosed grade 2 (low grade) mast 
cell tumours, complete excision 
FNA left popliteal node; abdominal 
ultrasound 
MCT, grade 2 (low grade) 
x 2; Stage IIIa 






Haemangiosarcoma Rajah Du Cloux 
6yo Mn German Shepherd 
Acute onset lethargy and abdominal enlargement. 
Haemabdomen diagnosed and exploratory 
laparotomy diagnosed bleeding splenic mass; 
splenectomy; histopathologic diagnosis of 
haemangiosarcoma 
CBC. biochemistry Haemangiosarcoma; 
T2N0M0, Stage II 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 





Mast Cell Tumours Thor Ward 
9yo Fn cross breed 
Rapid appearance and growth of mass over the left 
caudal thigh; FNA diagnosed mast cell tumour 
with pyogranulomatous inflammation 




Prednisolone 2mg/kg daily was administered 
for 7 days; marked reduction in 
inflammation and size of mass but owner 






Mast Cell Tumours Billy Sillem 
7yo Mn Staffordshire bull 
terrier 
Grade 2 MCT completely resected from right 
lateral thigh 6 months ago. Recent appearance of 
mass in right inguinum; wide excision for 
histopathology diagnosed grade 3 MCT, 
incomplete excision 






Mast Cell Tumours Sheeba Ratcliffe 
8yo Fn American pit bull 
terrier 
Mass first developed over proximocaudal right 
foreleg 2 years ago but resolved and recurred 2 
months ago to be inflamed and ulcerated. 
Excisional biopsy by referring vet diagnosed MCT, 
grade 2 (low grade), 2mm margins 
FNA right prescapular node; 
abdominal ultrasound 






Perianal Tumours Ollie Mellet 
12yo Mn Maltese cross 
Mass in location of left anal gland detected on 
routine checkup; FNA suggestive of anal sac 
adenocarcinoma 
Thoracic radiographs; abdominal 
ultrasound; urinalysis + M/C/S 
Anal Sac Adenocarcinoma Referred for excision of mass. Incomplete 
excision. Carboplatin every 3 weeks x 6 




Lymphosarcoma Murphy Lai 
12yo Mn Jack Russell 
terrier 
2 week history of Generalized lymphadenopathy; 
popliteal node excision diagnosed diffuse 
intermediate to high grade large cell lymphoma 
IHC on previous biopsy; CBC, 
Biochemistry; abdominal ultrasound; 
bone marrow aspirate 
Lymphosarcoma; 





Mast Cell Tumours Ned Jensen 
2yo Mn domestic cat 
One month history of mass inside upper right lip. 
Excisional biopsy diagnosed mast cell tumour, 
incomplete excision 
CBC, Biochemistry; thoracic 
radiographs; abdominal ultrasound; 
FNA right submandibular node 
Mast Cell Tumour; 
T0N1M0 
Referred for surgical excision of the primary 
lesion and regional node; followed by 






Tumours of the 
Intestinal Tract 
Meiling Burleigh 
16yo Fn Siamese cat 
3 month history of vomiting with increasing 
frequency; then developed soft stools with mucus 
and occasional haematochezia; abdominal 
ultrasound diagnosed circumferential thickening of 
descending colon and regional lymphadenopathy 
None Open (suspect lymphoma 
or carcinoma) 





Nasal tumours Monty Henderson 
12yo M golden retriever 
One month history of progressive proptosis of the 
left eye; ultrasound of eye diagnosed retrobulbar 
mass; abdominal ultrasound diagnosed left adrenal 
mass 
CT scan head and abdomen; FNA 
retrobulbar mass 






Soft Tissue Sarcomas Noire Achleitner 
9yo Fn domestic cat 
3 month history of rapidly growing mass over right 
thorax. FNA suggestive of mesenchymal 
neoplasm. Wide excision and histopathology 
diagnosed high grade fibrosarcoma, close margins 
CBC, Biochemistry, U/A; thoracic 
radiographs; FNA right axillary node 
Fibrosarcoma, high grade; 
TN0M0 




Lymphosarcoma Jack Edmondson 
9yo M cross breed 
Weakness/collapsing episodes which first started 
4-5 months ago, now with increasing frequency. 
Blood tests diagnosed biclonal gammopathy 
U/A; thoracic radiographs; abdominal 
ultrasound; FNA mass within 
abdomen; bone marrow aspirate 
Lymphoma Referred for surgical excision of mass. Pre-
op CT scan showed mass attached to tail of 





Histiocytic Sarcoma Bailey Barnett 
9yo M Doberman 
3 month history of vague lethargy. Blood tests 
unremarkable. Recently splenomegaly noted and 
splenectomy performed, HP = histiocytic sarcoma; 
also suspected to have vWD  
CBC, Biochemistry, U/A; IHC on 
splenic biopsy; abdominal ultrasound; 
bone marrow aspirate 
Splenic histiocytic sarcoma Lomustine every 3 weeks x 8 
03/04/09 
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Tumours of the Male 
Reproductive System 
Puck Wall 
15yo Mn Kelpie cross 
2-3 week history of stranguria, then complete 
urinary obstruction 
None Prostatic carcinoma Piroxicam 0.3mg/kg. Re-obstructed after 24 














2yo Fn Jack Russell terrier 
 
Has had a sore on the caudal left thigh since a pup; 
has three times grown into a granulomatous lesion 
which has been resected each time. HP only on 
first biopsy = marked, focally extensive, chronic, 
epidermal and adnexal papillomatous hyperplasia 
and hyperkeratosis with marked acantholysis and 
cystic hyperkeratosis and pyogranulomatous 
furunculosis. Referred for suspected underlying 
papillomavirus 
None Open Appearance and history was not consistent 
with papillomavirus. Plan was to re-biopsy 
for HP and PCR, but owner reported lesions 
had not progressed so no further diagnostics 





Mast Cell Tumours Rustee Eaves 
5yo Fn Boxer 
Mass present on lateral left hind for one year with 
recent growth and irritation; FNA suggested MCT 
so referring vet performed wide excision; HP = 
MCT, grade 2 (low grade), complete excision 
FNA regional lymph node (popliteal); 
FNA small nodule along suture line 
MCT, grade 2 (low grade) No further treatment required; monitor for 




Soft Tissue Sarcomas Shay Purslowe 
10yo Fn Rottweiler cross 
One month history of 3 masses developing over the 
right dorsal antebrachium. Incisional biopsies 
diagnosed undifferentiated sarcomas. 




Marginal excision of primary tumours and 






Soft Tissue Sarcomas Jinx Letherby 
15yo Fn DSH 
Mass removed from dorsal neck 6 months ago, no 
histopathology performed. Regrew in the last 
month and now measures 6x6.5cm and overlies left 
shoulder 
CBC, Biochemistry, U/A; CT scan 
left shoulder and thorax 
Open – suspect high grade 
soft tissue sarcoma with 
pulmonary metastases 





Tumours of the 
Skeletal System 
Winnie Saunders 
10yo Fn Rhodesian 
ridgeback  
Acute onset swelling and lameness of right 
proximal antebrachium; radiographs showed 
monostotic, geographical lytic lesion of proximal 
ulna with pathological fracture 
None Open Owner elected euthanasia 
08/04/09 
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Lymphosarcoma Bono McDonald 
9yo Mn cross breed 
Generalized lymphadenopathy in a well dog; no 
diagnostics before referral 
CBC, Biochemistry, U/A; FNA node Lymphosarcoma, Stage 
IIIa or higher 










Tumours of the 
Intestinal Tract 
Dingo Menezes 
12yo Mn cross breed 
2 month history of inappetance progressing to 
vomiting and diarrhoea and weight loss. 
Abdominal ultrasound showed multiple areas of 
small intestinal thickening and enlarged mesenteric 
nodes. FNA of nodes diagnosed lymphoma 
CBC, Biochemistry, electrolytes, 
U/A; Serum folate and B12 assay 
Intestinal lymphoma UW-19 including L’asparaginase and 
prednisolone. Dog developed increased fresh 
blood loss through bowel after first 
chemotherapy treatment and was 
administered a blood transfusion; repeat 
abdominal ultrasound after 2 treatments 
showed partial remission but dog did not 
improve clinically and had persistent melena 




Perianal Tumours Beau Cunningham 
12yo Mn Cocker spaniel 
Right anal gland disease for 3 years with recent 
mass development; FNA suggestive of anal sac 
adenocarcinoma; possible PU/PD 
CBC, Biochemistry, iCa, U/A; 
thoracic radiographs; abdominal 
ultrasound 
Anal Sac Adenocarcinoma Referred for excisional biopsy of mass. Dog 
developed post-operative complications and 











10yo Fn DSH 
4 week history of lethargy, then inappetance. 
Multiple dermal nodules and abdominal mass 
palpable. FNA skin and abdominal mass 
suggestive of lymphoma. Biopsy of cutaneous 
nodule confirmed discrete cell neoplasia. 
CBC, Biochemistry, U/A; IHC (CD3, 
CD79a) on previous biopsies 
Cutaneous T cell 
lymphoma with abdominal 
involvement 
Owner declined further diagnostics. Elected 
to treat with oral cyclophosphamide every 3 
weeks x 6 doses. Marked clinical 
improvement for the first 24 hours after the 







Renal Cancer Fuzzy Wuzzy Busby 
11yo Mn Persian cat 
Lethargy and inappetance for one week. Bilateral 
renomegaly palpated. Abdominal ultrasound 
diagnosed changes of the kidneys pathognomonic 
for lymphoma. Started on prednisolone prior to 
referral 
CBC, Biochemistry, electrolytes, U/A Renal lymphoma Intravenous fluids for 24 hours; oral 
cyclophosphamide every 3 weeks x 6 doses; 
oral prednisolone as tapering course over 
first month. Improved clinically after first 




Lymphosarcoma Darcy Roberts 
8yo Mn Border Collie 
cross 
Generalized lymphadenopathy for 2 weeks; 
otherwise well dog; FNA suggestive of lymphoma 
Node biopsy for HP and IHC; 
abdominal U/S; bone marrow 
aspirate; CBC, Biochemistry, U/A 
Lymphoma, B cell 






Mast Cell Tumours BJ Nash 
12yo Mn Shih Tsu 
7 months ago had mass develop lateral left thigh; 
FNA suggestive of MCT but excisional biopsy 
showed only myositis and pyogranulomatous 
reaction 
FNA left popliteal node  Prednisolone 2mg/kg sid for 7 days then 
tapering; soft tissue swelling reduced leaving 




Lymphosarcoma Daisy Nairn 
9yo Fn Rottweiler 
3-4 week history of enlarged nodes; FNA 
suggestive of lymphoma 
CBC, Chemistry Lymphoma Oral Lomustine every 3 weeks x 6. Grade 4 






Lymphosarcoma Rusty Morgan 
10yo Mn Cocker Spaniel 
One week of lethargy; enlarged nodes noted 
yesterday; FNA suggestive of lymphoma; CP2 
unremarkable 
Node biopsy for HP and IHC Lymphoma UW-19. Marked ileus and abdominal pain 
after first vincristine; abdominal radiographs 
and ultrasound showed no abdnormalities; 





Mast Cell Tumours Holly Groman 
15yo Fn cross breed 
3 years ago had a grade 2 MCT incompletely 
resected from right upper lip. No concerns until 3 
months ago when mass developed in same location 
with FNA suggestive of MCT. 
Incisional biopsy of mass; FNA right 
submandibular lymph node 
MCT Owners elected palliation: 2mg/kg 
prednisolone sid for 7 days then 1mg/kg sid 






Lymphosarcoma Bella Rees 
7yo Fn Boxer 
1-2 week history of pruritic nodular skin disease 
with generalized lymphadenopathy. FNA 
suggestive of lymphoma. Node biopsy confirmed 
the diagnosis. 
CBC, bone marrow aspirate Lymphoma, Stage Vb UW-19; owner stopped treatment after first 
dose when results of marrow aspirate 




Lymphosarcoma Amber Rodda 
5yo Fn Dobermann 
2 days of enlarged superficial nodes; FNA 
suggestive of lymphoma 







Mast Cell Tumours Emmy Saunders 
5yo Fn Staffordshire Bull 
Terrier 
Mass present over lateral left thigh for 12 months 
with rapid growth in the last month; excisional 
biopsy diagnosed grade 2 (high grade) MCT, 
narrow margins 
CBC, Biochemistry; FNA left 
inguinal node; abdominal ultrasound 
MCT Grade 2 (high grade); 
TNM 




Tumours of the 
Intestinal Tract 
Smudge Jelly 
14yo Mn DSH 
2 months of inappetance progressing in the last 
week; abdominal mass encircling small intestinal 
segment 
CBC, Biochemistry, U/A; FNA 
intestinal mass 
Lymphosarcoma UW-25. Persistent anorexia so oesophageal 





Lymphosarcoma Basil Smith 
8yo Mn Beagle 
3 months of increasing upper airway noise; one 
month of generalized lymphadenopathy and 
hepatosplenomegaly; node biopsy diagnosed 
lymphoma; treated with prednisolone 
CBC, Biochemistry, U/A; bone 
marrow aspirate 
Lymphoma, centroblastic, 










8yo Fn Jack Russell terrier 
One month of lesion on right metatarsal pad; 
biopsy could not distinguish between carcinoma 
and round cell tumour (possible plasmacytoma) 







Tumours of the 
Intestinal Tract 
Lola Rennick 
11yo Fn Burmese 
One week of anorexia and dyspnoea; pleural 
effusion and abdominal masses noted; abdominal 
ultrasound diagnosed cranial mesenteric 
lymphadenopathy; FNA of nodes diagnosed 
lymphoma 




Tumours of the 
Mammary Gland 
Stubbree Lim 
13yo Fn Samoyed 
3 month history of 2 caudal mammary masses 
which have grown in this time; 2 lateral thoracic 
radiographs suggest 3 small pulmonary nodules 










12yo Fn Cocker spaniel 
Had several masses removed 6 months ago which 
were not tested. 2 new lumps grew over dorsum in 
the last 2 weeks, different appearance; excisional 
biopsy diagnosed cutaneous lymphoma 
IHC Cutaneous T cell 
lymphoma 
Initial monitoring; new lesion developed 
over left stifle, FNA consistent with 
lymphoma; no response after one week to 









12yo Fn cross breed 
2 oral lesions developed a few months ago and 
were removed – HP = oral plasmacytomas; one 
regrew and was removed a second time; on third 
regrowth – referred for assessment 






Cancer of the Oral 
Cavity 
Tyne Wigglesworth 
13yo Fn Greyhound cross 
Had trouble eating 3 months ago so dental 
prophylaxis performed and 2 upper right molar 
teeth removed; gum didn’t heal post operatively so 
biopsy of maxilla taken - SCC 
CBC, Biochemistry; CT scan head 
and thorax 
Oral squamous cell 
carcinoma 
Carboplatin and pamidronate every 3 weeks 
x 6; piroxicam 0.3mg/kg daily for life. 
Owner stopped chemotherapy after 2 doses 




Cancer of the Oral 
Cavity 
Kinta Wills 
13yo Fn Rhodesian 
Ridgeback cross 
Large, black mass attached to right inner cheek 
noted on routine examination 
Excisional biopsy of mass; FNA right 
submandibular lymph node 
Oral melanocytoma with 
nodal metastasis 





Mast Cell Tumours Holly Oates 
9yo Fn Kelpie cross 
Subcutaneous mass removed from right 
prescapular region; HP = high grade mast cell 
tumour, possible metastatic lesion to node 
CBC, Biochemistry, U/A; thoracic 
radiographs; abdominal ultrasound; 
bone marrow aspirate cytology 
MCT, grade 3 Imatinib 5.5mg/kg sid for 14 days; 






Lymphosarcoma Cobi Rose 
4yo Fn Boxer 
One week history of lymphadenopathy; FNA 
suggestive of lymphoma; HP on popliteal node 
biopsy confirmed diffuse high grade large 
immunoblastic lymphoma 
CBC, Biochemistry; bone marrow 
aspirate 
Diffuse high grade large 
immunoblastic lymphoma; 
Stage V 








11yo Fn DLH cat 
Sudden onset lethargy and inappetance; improved 
with antibiotics but monoclonal gammopathy 
diagnosed on blood tests 
CBC, Biochemistry, U/A; thoracic 
radiographs; abdominal ultrasound; 
bone marrow aspirate cytology 




Mast Cell Tumours Shamus Adams 
8yo Mn Beagle 
Small mass attached to base of right pinna for 12 
months; recent change in appearance to become 
more firm and fixed. 
CBC, Biochemistry, U/A; abdominal 
ultrasound; FNA right submandibular 
node 










12yo Fn Jack Russell 
terrier 
One month history of stranguria and haematuria 
not responsive to antibiotics. Abdominal 
ultrasound showed mass attached to bladder apex 
 Open – suspect transitional 
cell carcinoma; DDx SCC, 
rhabdomyosarcoma, 
granulomatous or polypoid 
cystitis 




Lymphosarcoma Scooby Borushek 
9yo Mn Cocker spaniel 
2-3 week history of black mass attached to lower 
right lip; excisional biopsy for HP and IHC 
diagnosed T cell lymphoma 
FNA superficial lymph nodes; 
thoracic radiographs; abdominal 
ultrasound; bone marrow aspirate 








Tumours of the 
Intestinal Tract 
Pushkin Kelsall 
9yo Mn Russian Blue cat 
2 months history of progressive weight loss, 
inappetance and now anorexia. No vomiting or 
diarrhoea. Abdominal ultrasound showed small 
intestinal mass and regional lymphadenopathy; 
FNA diagnosed lymphoma 
CBC, Biochemistry, U/A Intestinal lymphoma UW-25. Achieved partial remission after 
first cycle of treatment but had persistent 







Lymphosarcoma Buzz Bower-White 
8yo Mn Boxer 
Mass noted under neck 4 weeks ago. FNA 
suspected lymphoma. Incisional biopsy performed 
with IHC that confirmed T cell lymphoma 
CBC, Biochemistry, U/A; Thoracic 
radiographs; Abdominal ultrasound; 
Bone Marrow aspirate 
Solitary Cutaneous T cell 
Lymphoma 
UW-19. Minimal response after first cycle so 
l’asparaginase administered with vincristine 
treatment 5. Complete remission achieved 
therefore vincristine/l’asparaginase given 




Haemangiosarcoma Jake Kriwopischin 
13yo Mn German Shepherd 
Acute onset collapse 5 days ago; bleeding splenic 
mass diagnosed and splenectomy performed; 
thoracic radiographs unremarkable 
CBC, Biochemistry Haemangiosarcoma Owner declined further diagnostics and 
therapy. Likely recurrence 24/06/09 so 






Tumours of the 
Endocrine System 
Bedford Berryman 
9yo Mn Beagle 
Mass noted under neck 5 months ago; FNA ‘non-
diagnostic’. Growth of mass and progressive upper 
airway dyspnoea. Neck ultrasound demonstrated 
right thyroid mass; repeat FNA suggested thyroid 
carcinoma 




Doxorubicin every 2 weeks x 6. Euthanased 





Haemangiosarcoma Woody Barry 
11yo Mn Cocker spaniel 
Acute onset lethargy. Initial bloods unremarkable; 
abdominal ultrasound diagnosed splenic mass and 
haemabdomen; splenectomy performed; small 
masses visualized in liver at time of surgery 
 CBC, Biochemistry, U/A Haemangiosarcoma  Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 






Tumours of the Male 
Reproductive System 
Jack Martin 
12yo Mn Kelpie 
3 week history of flat, ribbon-like faeces and faecal 
tenesmus 
CBC, Biochemistry; thoracic 
radiographs; lumbar spinal 
radiographs; needle core biopsy of 
prostate for HP and C+S 
Prostatic carcinoma Carboplatin/gemcitabine q3weeks x 6. Grade 
4 gastrointestinal side effects after first dose 





Lymphosarcoma Sam Duncan 
5yo Mn Bernese Mountain 
Dog 
One week history of generalized lymphadenopathy. 
FNA diagnosis of lymphoma 
CBC, Biochemistry, U/A Lymphosarcoma; Stage 
IIIa 








Mast Cell Tumours Benson Hughes 
11yo M Labrador 
Mass on scrotum for a couple of years that was 
slowly growing, then grew fairly large so was 
removed 18 months ago. No HP done; no 
recurrence. 2 days ago a mass was noted in groin. 
Saw RV and both inguinal nodes palpated to be 
enlarged. FNA of both suggest MCT 
Abdominal ultrasound MCT, grade unknown; 
primary lesion unknown; 
metastasis to both inguinal 
nodes and left medial iliac 
node 
 2 weeks imatinib and prednisolone, 
followed by Vinblastine/lomustine protocol. 
Recurrence and new skin lesions by 
treatment 4; repeat abdominal ultrasound 









9yo Mn Labrador 
3 weeks history of lethargy, then pyrexia and 
weight loss over the last 10 days. CBC indicated 
pancytopenia with large number of large 
lymphoblasts in circulation; presumed ALL 
Bone marrow aspirate; CBC Acute Lymphoblastic 
Leukaemia 
UW-19 with L’asparaginase and 






Tumours of the 
Mammary Gland 
Sheeba Dimopoulos 
12yo Fn Rottweiler 
Mass present and progressive within mammary 
gland 2 left side; referring vet radiographs 
suspected metastatic disease but on assessment by 
radiologist, more likely osteomas 
CBC, Biochemistry; FNA left axillary 
node; abdominal ultrasound 
 Referred back to referring vet for surgical 
excision of mass and also removal of pea-





Ocular Tumours Jetsom Kuparinen 
14yo Fn DSH 
Mass first present 6 months prior, then marginal 
excision 3 months ago; HP = SCC, narrow 
margins. Recurrent and progressive local disease. 
Cat also PU/PD and occasional vomiting 
CBC, Biochemistry, T4, U/A Squamous cell carcinoma Owner declined referral for complete 
surgical excision. Returned one month later 







Renal Tumours Keanu Port 
2yo Mn Russian Blue cat 
3-4 week history of PU/PD and progressive 
inappetance; bilateral renomegaly; mesenteric 
lymphadenopathy; routine blood and urine tests 
indicate renal failure, and moderate/marked 
anaemia 
None Open – DDx lymphoma, 
myeloma, renal carcinoma, 
renal amyloidosis 
Owner declined further diagnostics and 






Lymphosarcoma Kane Evans 
7yo M German Shepherd 
2 week history of inappetance and marked weight 
loss. Generalized lymphadenopathy and bilateral 
uveitis. FNA diagnosis of lymphoma. Circulating 
atypical mononuclear cells 
CBC Lymphosarcoma, likely 
StageVb 
UW-19 including prednisolone. Recurrence 








Lung Tumours Ruby Bovell 
16yo Fn DSH cat 
Swelling above the left carpus 6-8 weeks ago. 
Radiographs of antebrachium showed soft tissue 
swelling around the distal antebrachium with 
periosteal reaction of the underlying radius, 
extending on the medial cortex from mid-diaphysis 
to distal metaphysis. Incisional biopsy = 
undifferentiated carcinoma, pancytokeratin positive 
Abdominal ultrasound; thoracic and 
left antebrachium radiographs 
Solitary pulmonary nodule 
– open diagnosis; 
carcinoma distal 
antebrachium suspected to 
be metastatic lesion 
Referred for amputation of the limb. Owner 




Tumours of the 
Skeletal System 
Kosta Brouwer 
9yo Mn Rottweiler 
One month history of lameness left foreleg. Initial 
improvement on NSAIDs then deterioration. Mid-
humeral bone lesion seen on radiographs 
Repeat radiographs of the left 
humerus one month after presentation 
Open – suspected 
osteosarcoma 









5yo Mn Manchester terrier 
6 month history of mass right flank slowly 
increasing in size; excisional biopsy diagnosis of 
malignant melanoma, complete excision, mitotic 
index 7/10hpf, nuclear atypia 3/10hpf 
Thoracic radiographs; abdominal 
ultrasound 




Cancer of the Salivary 
Glands 
Odette Hancock 
9yo Fn DSH cat 
3-4 week history of mass palpable in the right 
submandibular region and a change to the purr; 
FNA of masses suggestive of carcinoma 
CT scan head, neck and thorax; 




Carboplatin and gemcitabine. No response to 










13yo schnauzer cross 
3 month history of swollen toe 5 right hind foot, 
partially responsive to antibiotic therapy; toe 
amputated and sent for HP = subungual squamous 
cell carcinoma, likely complete exicision 





Mast Cell Tumours Tina Quinn 
11yo Fn Whippet 
Mass on left side present 3-4 weeks and doubled in 
size in that time. Wide excision of mass; HP = 
grade 3 MCT, complete excision 
CBC, Biochemistry, U/A; thoracic 
and abdominal radiographs 




Mast Cell Tumours Duke Mudford 
8yo Mn cross breed 
Two masses on ventral abdomen present 4 months 
with minimal growth. Excision of masses; HP = 
low grade, Grade 2 MCTs narrow margins 
None MCT x 2, Grade 2 (low 
grade); Stage IIIa 








Tumours of the 
Intestinal Tract 
Fozzie Bear Wilshaw 
9yo Mn Chow Chow 
Two year history of intermittent bouts of ‘GIT 
disease/pancreatitis’. Recent bout more severe. 
Abdominal ultrasound showed intestinal mass. 
Exploratory laparotomy removed 4cm mass 
attached to caecum; HP = leiomyosarcoma (CD117 
negative) 
None Leiomyosarcoma Monitoring with abdominal ultrasound every 
3 months. First ultrasound normal, then 





Perianal Tumours Rocky Mollica 
10yo Mn Keeshond 
Anal gland mass noted 3 weeks ago. Bloods show 
mild serum hypercalcaemia; marked weight loss; 
incisional biopsy diagnosed anal sac 
adenocarcinoma 






Soft Tissue Sarcomas Toby Gasmier 
2yo Mn crossbreed 
4 week history of mass that developed in the left 
front foot, on both dorsal and palmar surfaces. 
Ultrasound showed mass tracking between 
metacarpals III and IV; marginal excisional biopsy 
haemangiopericytoma, grade 2 
None Haemangiopericytoma, 
Grade 2 
Owner declined further diagnostics and 
monitoring at this time; may consider limb 






Tumours of the 
Skeletal System 
Zeus Josey 
7yo Mn Rottweiler 
Had an injury of left foreleg as pup and 
intermittently lame on this leg. The last month has 
been lame which is non-responsive to analgesics 
and now progressive. Radiographs demonstrated 
aggressive bone lesion proximal humerus 
CBC, Biochemistry, U/A; FNA left 
prescapular node; thoracic and pelvic 
radiographs 
Open – suspect 
osteosarcoma 
Owner declined definitive treatment; 






Lymphosarcoma Scruffy Farrell 
13yo Fn DLH cat 
3-4 weeks of inappetance and weight loss, then 
more recently vomiting and diarrhoea; enlarged 
nodes seen on abdominal ultrasound; generalized 
lymphadenopathy on physical examination; FNA 
suggestive of lymphoma 







Tumours of the 
Skeletal System 
Rocket Thompson 
8yo Mn Beagle 
Left facial swelling for at least 3 months, slowly 
progressing. FNA – possible sarcoma 
None Maxillary fibrosarcoma Marginal excision of mass, followed by 
metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 
daily for life. Recurrence of disease; 







Urethral Tumours Jedda Hutchinson 
13yo Fn terrier cross 
10 month history of screaming when toileting. 
Extensive work up by referring veterinarian 
investigated GIT disease but no final diagnosis. 
More recently showed haematuria and 
investigation diagnosed urethral thickening 
CBC, Biochemistry Open – suspected urethral 
carcinoma 
Mitoxantrone every 3 weeks x 6; piroxicam 
0.3mg/kg daily. Excellent clinical response 
after first dose with few side effects; 
however, owner declined further 





Mast Cell Tumours Nugget Honore 
5yo Mn Ridgeback cross 
Two MCTs recently excised: one grade 2 (low 
grade) and one grade 1 
FNA right axillary and right 
prescapular nodes; thoracic 
radiographs; abdominal ultrasound 
MCT; grade 2 (low grade) 
and grade 1; Stage IIIa 
No further treatment required; monitoring 




Mast Cell Tumours Boss Webster 
7yo Mn Pug 
Mass present on dorsal right front foot for about 12 
months; excisional biopsy – grade 1 mast cell 
tumour, incomplete excision 
CBC, Biochemistry, U/A; FNA right 
prescapular node; thoracic 
radiographs; abdominal ultrasound 






Tumours of the 
Skeletal System 
Daisy Turner 
7yo Fn Great Dane cross 
First became lame 7 months ago and was 
diagnosed with suspected osteosarcoma 5 months 
ago based on radiographic appearance of distal 
radial lesion; since then treated with carprofen and 
tramadol. Minimal disease progression 
CBC, Biochemistry, U/A; FNA left 
prescapular node; thoracic 




Referred for forequarter amputation; 
followed by adjuvant chemotherapy: 





Soft Tissue Sarcoma Mickey Hegedus 
10yo Mn Border Collie 
cross 
Mass over left elbow noted 2 weeks ago. Marginal 
excision diagnosed haemangiopericytoma, grade 1, 
incomplete excision 




None. Recommended referral for marginal 
excision of mass, to be followed by 
metronomic chemotherapy. Owner declined 





Nasal Tumours Satan O’Malley 
12yo Mn Border Collie 
Six week history of gagging and snoring. 2 weeks 
ago had acute epistaxis from left nostril. 
Rhinoscopy and curette diagnosed 
chondrosarcoma, MI 20/10hpf 
None Nasal chondrosarcoma None. Dog had another bilateral epistaxis 





Tumours of the 
Skeletal System 
Could A Bridson 
7yo Mn Rottweiler 
Left CCL repaired 18 months ago. Now 3 week 
history of LHL lameness. L stifle radiographs show 
geographic lysis of distal L femur 
CBC, Biochemistry, U/A; thoracic 
radiographs; radiographs L and R 
stifles, L and R elbows and hips; 
Jamshidi biopsy distal femur 
Osteoblastic to fibroblastic 
osteosarcoma 
Medical therapy only – Doxorubicin x 2, 






Lymphosarcoma Jackson Terry 
8yo Mn Bichon Frise 
2 month history of progressive lameness RHL. 3 
week history of generalized lymphadenopathy. 
Node biopsy diagnosed diffuse intermediate to 
high grade large cell lymphoma 
None Lymphosarcoma, Stage 
IIIa or higher 









Tumours of the 
Mammary Gland 
Bay Monkhouse 
12yo Fn Beagle 
18 months ago had grade 1 STS removed from left 
axilla. Speyed at same time. 
Recent recurrence of that mass - repeat removal 
and other lumps removed: one over mammary 
gland 4 right side (mammary carcinoma), another 
small one MG 3 LHS (not tested), and a firmer 
mass over right rump (intermediate grade sarcoma)  
CBC, Biochemistry, iCa, U/A; FNA 
right inguinal LN; thoracic 
radiographs; abdominal ultrasound; 
ACTH stimulation test 
Mammary carcinoma; soft 
tissue sarcomas x 2 
Referred for further surgery: right side 
mammary chain strip and further surgery of 
soft tissue sarcoma right rump. Complete 
excision with no poor prognostic indicators; 









Nasal Tumours Jessie Jarrett 
12yo Fn Heeler cross 
8 months since first epistaxis. Repeat episode 6 
months ago and investigation elsewhere via CT 
scan and biopsy performed. CT scan showed left 
sided nasal mass with lysis of the orbit and 
extension into the nasopharynx; biopsies only 
demonstrated inflammatory rhinitis. Managed with 
piroxicam only since, but now a mass is protruding 
through left frontal sinus 
CBC, Biochemistry, iCa, U/A; FNA 
mass left frontal sinus 
Nasal carcinoma; 
hypercalcemia 
Owner declined pamidronate to lower iCa. 
Continue piroxicam at 0.2mg/kg daily. 
Commence CTX 10mg sid.. Disease 
progression after one month therefore 
stopped cyclophosphamide and maintained 





Lymphosarcoma Kiara Chilton 
2yo F Birman cat 
Two week history of lethargy and inappetance; 
abdominal mass palpated and seen on ultrasound to 
be associated with the small intestine. 
FNA enlarged nodes – suggestive of 
reactive lymph node. Exploratory 
laparotomy and excision of mass for 
histopathology 





Cancer of the Nasal 
Planum 
Smut Jenkins 
12yo Mn domestic cat 
8 month history of small non healing wound left 
nasal planum. Histofreezed 2 months ago by ref 
vet. Now marked progression with lesion 
measuring 3x10mm 





Mast Cell Tumours Gromet Cooper 
9yo Fn Bull terrier cross 
One month history of waxing and waning mass 
over lateral left hock. Incisional biopsy diagnosis 
of MCT grade 2 (low grade); marked post-biopsy 
swelling and persistent bleeding/ooze 
Abdominal ultrasound; FNA left 
popliteal lymph node 
MCT, Grade 2 (low grade) None. Palliation with omega-3 fish oils; 





Cancer of the Oral 
Cavity 
Bear Varley 
11yo Mn Kelpie 
3cm ulcerated mass noted in right upper buccal 
fold 2 weeks ago. Marginal excisional biopsy 
diagnosed malignant melanoma; MR 40/10 hpf and 
nuclear atypia 5/10hpf 






Tumours of the 
Endocrine System 
Defar Grandidge 
12yo Fn Kelpie cross 
Change in bark noted 2 months ago. One week ago 
collapsed on walk. Ref vet noted mass in left 
jugular groove; FNA suggestive of thyroid 
carcinoma 
CT scan neck and thorax Thyroid carcinoma Referred for surgical excision of mass. Post 
operative complications due to laryngeal 






Lymphosarcoma Jake Parkin 
8yo Mn Boxer 
Sudden onset urinary incontinence. Bloods showed 
mild serum hypercalcaemia and no azotaemia. 
Thoracic and abdominal radiographs taken – 
cranial mediastinal mass; Ultrasound guided FNA 
of mass suggestive of lymphoma 
CBC; iCa Lymphosarcoma, cranial 
mediastinal 
One dose pamidronate, followed by UW-19. 
Early response but then recurrence mid-






Tumours of the 
Mammary Gland 
Chanel Trapuzzano 
11yo Fn Pomeranian 
3-4 week history of rapidly growing mass to 4cm 
in the right mammary gland 5. Wide excisional 
biopsy diagnosed high grade mammary carcinoma, 
incomplete excision with evidence of tumour cells 
in vessels 
CBC, Biochemistry, U/A; thoracic 
radiographs; abdominal ultrasound 
Mammary carcinoma; 
T2NM 







Haemangiosarcoma? Lucy Huxtable 
10yo Fn Labrador 
3 week history of being ‘not right’ and abdominal 
pain noted by referring vet. Abdominal ultrasound 
showed one small hepatic nodule and 2 small 
splenic nodules. FNA of liver nodule suggestive of 
sarcoma.  
CT scan thorax and abdomen – 










Cancer of the Nasal 
Planum 
Timmy Sharp 
18yo Mn DMH cat 
Had pinnae removed years ago for SCC and had 
nose treated with cryosurgery at same time. Has 
had a lesion on nose now for 8-12 months which 
has slowly progressed 
CBC, Biochemistry, U/A; thoracic 
radiographs; biopsy of nasal planum 
lesion 




Soft Tissue Sarcomas Nala Murray 
10yo Fn golden retriever 
5 month history of small mass adjacent left medial 
canthus. Excisional biopsy diagnosed soft tissue 
sarcoma, grade 1, 1mm margins 
CBC, Biochemistry, U/A Soft Tissue Sarcoma, 
Grade 1 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 





Tumours of the 
Skeletal System 
Rosie Smith 
10yo Fn Labrador 
Four week history of acute onset lameness on right 
hindleg after jumping onto bed. Radiographs 
showed mainly lytic lesion of distal right femur. 
Biopsy diagnosed osteoblastic osteosarcoma 
CBC, Biochemistry Osteoblastic osteosarcoma Amputation of limb followed by adjuvant 
chemotherapy: doxorubicin x 2, carboplatin 





Lymphosarcoma Bonny Sabadima 
10yo Fn Staffordshire Bull 
Terrier 
Two week history of enlarged peripheral lymph 
nodes; FNA suggestive of lymphoma 
None Lymphoma; Stage IIIa None. Owner declined further diagnostics 





Soft Tissue Sarcomas Chloe Van Tiel 
12yo Fn Bull Terrier cross 
3-4 month history of mass slowly enlarging over 
left face. Excisional biopsy diagnosed high grade 
soft tissue sarcoma, incomplete. Staging tests 
performed by referring veterinarian. 
None Soft Tissue Sarcoma; high 
grade 
Electrochemotherapy of surgery wound. 
Then commenced metronomic 
chemotherapy: 10mg/m2 cyclophosphamide, 






Lymphosarcoma Max Callaghan 
9yo Mn Kelpie cross 
Dyspnoea for one week; weight loss noted with 
hindsight. Thoracic radiographs and ultrasound 
diagnosed extensive cranial mesenteric mass with 
pleural effusion; FNA of mass showed population 
of small lymphocytes 
CBC, Biochemistry, ionized calcium, 
U/A 






Cancer of the Oral 
Cavity 
Diesel Cruden 
5yo Mn Norwegian 
Elkhound 
3-4 week history of owner noticing the right lower 
lip drooping, then swelling of mandible noted.  
CT scan head and thorax; biopsy of 
soft tissue swelling right mandible 







Soft Tissue Sarcomas Bear Hayles 
11yo Mn Labrador cross 
10 day history of mass noted in right axilla; FNA 
suggestive of high grade soft tissue sarcoma 




Referred for marginal excision of mass; 
followed by metronomic chemotherapy: 
10mg/m2 cyclophosphamide, 0.3mg/kg 
piroxicam daily for life. Developed oral 
melanoma March 2011. Euthanased May 






Soft Tissue Sarcomas Ebony Kelly 
6yo Fn DSH cat 
Two week history of left foreleg lameness then 2 
day history of firm non painful swelling over left 
carpal joint. Radiographs showed radiocarpal 
dislocation. FNA of mass showed anaplastic cells 
suspicious of sarcoma 
Incisional biopsy Undifferentiated anaplastic 
sarcoma 
Referred for left forelimb amputation; 





Soft Tissue Sarcomas Olive Kester 
9yo Fn Labrador 
4cm diameter mass found near right tail base on 
routine check up. Wide excision and 
histopathology diagnosed spindle cell tumour, high 
grade, marginal excision 
CBC, Biochemistry; Abdominal 
ultrasound  
Soft Tissue Sarcoma; high 
grade 
Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 






Lymphosarcoma Calvin Franks 
7yo Mn DSH cat 
2-3 week history of inappetance and weight loss. 
Abdominal ultrasound showed marked 
hepatosplenomegaly and multiple enlarged 
mesenteric/inguinal nodes. FNA suggestive of 
lymphoma. 
CBC, Biochemistry Lymphosarcoma UW-25. Owner stopped treatment after first 








[Hepatic Tumours] Oswald Lawrence-Ward 
11 yo Mn Maltese cross 
 
6 month history of chronic small bowel diarrhoea 
with no weight loss. No vomiting. Six week history 
of PU/PD. Recent bloods showed increased ALP 
and ALT; abdominal U/S - mild hepatomegaly 
with multifocal target shaped nodules throughout 
the liver as well as cystic hyperplasia of prostate 
CBC, Biochemistry, U/A and culture; 
abdominal ultrasound; FNA liver and 




Started 2mg/kg trilostane sid; food 
elimination trial using z/d. Gained control of 
hyperadrenocorticism and IBD with 
treatment. 6 months later developed 
haematemesis and weight loss. Owner 







Tumours of the Male 
Reproductive System 
Mack Jackson 
8yo Mn Labrador 
One month of intermittent haematuria and 
stranguria. Prostatic wash diagnosed carcinoma 
CBC, Biochemistry; thoracic and 
lumbar spinal radiographs 
Prostatic carcinoma Gemcitabine and carboplatin every 3 weeks 
x 6; piroxicam 0.3mg/kg sid. Grade 4 
neutro[enia and sepsis developed after first 
treatment and owner declined further 





Tumours of the 
Skeletal System 
Angus Walker 
4yo Mn Great Dane 
One week history of non weight-bearing lameness 
of right hindleg. Radiographs showed large area of 
moth-eaten lysis distal tibia 
CBC, Biochemistry Open – suspected 
osteosarcoma 
Palliation: pamidronate, carprofen and 
codeine. Received 5 doses of pamidronate at 
3 weekly intervals. Last contact 29/12/09 for 













7yo Fn Husky cross 
Two week history - owner noticed a small amount 
of blood on the fur near the shoulder. Saw vet and 
a small skin lesion seen. Suspected dog bite. A few 
days later developed lots of lesions over the body. 
Initially pruritic but after biopsy and culture was 
given single dexamethasone injection and course of 
doxycycline and within the week the lesions had all 
but completely cleared. 
None Cutaneous (epitheliotropic) 
lymphoma 
Owner declined further diagnostics and 





Lymphosarcoma Rosie Kermode 
12yo Fn German 
Shorthaired Pointer 
One month history of enlarging nodes. Node 
biopsy confirmed lymphoma. Bloods and urine 
tests unremarkable. Thoracic and abdominal 
radiographs normal 
CBC Lymphosarcoma, 







Lymphosarcoma Issy Henderson 
5yo Fn Labrador 
3-4 week history of conjunctivitis, then 
inappetance and panting. Generalized 
lymphadenopathy noted; FNA = lymphoma 
CBC Multicentric lymphoma; 
Stage IIIa or higher 
Lomustine every 3 weeks x 6. Owner 
stopped treatment after first dose due to lack 









7yo Mn DSH cat 
One week prior found lying in puddle of urine, 
then became inappetant and lethargic. Mass in 
trigone region of bladder noted on ultrasound. 
Post-renal azotemia due to urethral spasm post 
catheterization 
Ultrasound-guided FNA of bladder 
mass; CBC, Biochemistry, U/A 








11yo Fn Staffy cross 
Rapid growth of mass between digits 4 and 5 right 
fore foot; excision biopsy = round cell sarcoma, 
intermediate grade 
IHC: toluidine blue, CD3, CD79a, 
Melan A 
Presumed soft tissue 
sarcoma, intermediate 
grade 








9yo Fn Staffordshire Bull 
Terrier 
3 month history of squamous cell carcinoma on 
ventrum, now recurrent 
CBC, Biochemistry, U/A Squamous cell carcinoma x 
3; carcinoma in situ 
Owner declined treatment. Lost to follow up 
29/04/10 
467 
Perianal Tumours Lulu Sloan 
13yo Fn cross breed 
5 days of licking anus; 2x1.5cm raised black mass 
noted; FNA = melanoma 
CBC, biochemistry; U/A; thoracic 
radiographs; abdominal ultrasound 
Melanoma; T? N0M0 Owner declined further diagnostics or 





Tumours of the 
Skeletal System 
Buffy Lloyd 
10yo Fn German 
Shorthaired Pointer 
7 days of limping of left hindleg; radiographs 
showed lysis and periosteal reaction distal left 
femur; thoracic radiographs negative for metastatic 
disease 
Jamshidi biopsy Fibroblastic osteosarcoma Owner elected amputation and 
chemotherapy at referring veterinarian. Lost 








Tumours of the 
Intestinal Tract 
Barney Carey 
11yo Mn Labrador cross 
2 weeks of vomiting and inappetance. Abdominal 
ultrasound demonstrated a 10cm length of 
thickened SI, up to 10mm diameter. Excision and 
anastomosis 
None Open – either T cell 
lymphoma, or 
granulomatous enteritis 
Clinically well so monitoring only via 
abdominal ultrasound and routine bloods and 
U/A; ultrasound one month later showed 
recurrence of disease, therefore presumed 
lymphoma. Completed LOPP protocol but 
one month later developed disease 






Cancer of the Oral 
Cavity 
Simba Wong 
13yo M Lhasa Apso 
3-4 week history of halitosis then raised, flashy 
mass noted over upper left PM1 and 2. Excisional 
biopsy = undifferentiated sarcoma 
IHC (Melan A), CT scan head and 
thorax; CBC, Biochemistry, U/A; 
FNA left submandibular lymph node 
Melanoma Segmental maxillectomy; adjuvant 
carboplatin q3weeks x 6. Recurrence post 
chemotherapy. Commenced Oncept course, 
but further disease progression and 








12yo Fn Blue Heeler cross 
One month history of masses over neck; HP = 
epitheliotrophic lymphoma; lesions ranged from 
epidermal crusts to nodules to ulcerations 
IHC (CD3, CD79a) Epitheliotrophic T-cell 
lymphoma 
Owner declined further treatment due to 






Cancer of the Oral 
Cavity 
Sophie Tan 
12yo Fn Pomeranian 
6 week history of right facial swelling. Dental 8 
days ago vet noted oral mass surrounding upper 
premolars. HP = squamous cell carcinoma; right 
submandibular node moderately enlarged right 
SMLN, left normal 
None Squamous cell carcinoma Owner declined further diagnostics and 




Urethral Tumours Lynk Voitkevich 
13yo Fn Heeler cross 
Concurrent hyperA. Haematuria and stranguria for 
2 weeks. Abdominal US showed bladder trigonal 
and urethral masses 
CBC, Biochemistry, Electrolytes, UA Transitional Cell 
Carcinoma (presumptive) 
Mitoxantrone q3wks x 6. No improvement 










11yo Fn Labrador 
Developed bilateral ocular discharge about 3 weeks 
prior which is when the lump on her left rump 
developed. Ref vet also noted 2 firm masses on R 
and L side of neck. FNA of all 3 masses suggestive 
of lymphoma. 
Biopsy of mass on rump for 
histopathology and 
immunohistochemistry; bone marrow 
aspirate; CBC, Chemistry, UA 
Lymphoma Dog arrested the evening after her diagnostic 




Cancer of the Oral 
Cavity 
Elva Dunne 
11yo Fn Rottweiler cross 
6 week history of bleeding from the mouth. 
Referring vet removed mass but owner declined 
histopathology. Now bleeding has returned. 
None Open – melanoma, SCC, 
FSA, etc 
Owner declined further diagnostics and 






Lymphosarcoma Oscar McDonald 
8yo Mn Beagle 
2-3 week history of preogressive inappetance and 
lethargy. Pyrexic; enlarged prescapular nodes; HP 
= diffuse intermediate grade lymphocytic 
lymphoma. CBC – PCV 0.19, PLT 10, Neuts 0.34, 
Lymphs 33 with atypicals circulating 
None Diffuse intermediate grade 
lymphocytic lymphoma; 
Stage Vb 
Owner declined further diagnostics and 





Haemangiosarcoma Ramses Hay 
9yo Mn Husky cross 
6 week history of inappetance and weight loss. 
Bloods unremarkable. Abdominal ultrasound found 




Owner declined further diagnostics and 




Tumours of the 
Intestinal Tract 
Dax Fowler 
8yo M Boxer 
2-3 month history of inappetance, vomiting and 
small intestinal diarrhoea. Endoscopic biopsies 
diagnosed lymphoma 
None Intestinal Lymphoma Owner declined further diagnostics and 





Mast Cell Tumours Jewels Santich 
11yo Fn crossbreed 
Mass over right antebrachium for 2 months. 
Excisional biopsy = MCT. Abdominal mass noted 
at surgery. Exploratory laparotomy removed mass 
= granulosa cell tumour of ovary. 
CBC, Biochemistry, U/A; Abdominal 
ultrasound 
Mast cell tumour; Grade 2 
(high grade); Stage 0a 
Recurrence March 2011. Minimal response 
to ongoing medical therapy. Amputation 
performed but metastatic disease developed 






Haemangiosarcoma Bodhi Willmore 
12yo Mn German Shepherd 
cross 
Had episode of lethargy 6 weeks prior to 
presentation; but then 10d prior developed acute 
haemabdomen due to splenic mass. Splenectomy 





VAC protocol and concurrent metronomic 
chemotherapy as well: 
CTX 10mg/m2 and piroxicam 0.3mg/kg. 






Tumours of the 
Endocrine System 
Choumi Raynes 
12yo Fn shih Tsu 
Developed haematuria and on examination vet 
suspected hyperadrenocorticism. LDDST 
confirmed this. Abdominal ultrasound found left 
adrenal mass 
CT scan thorax and abdomen Low grade adrenocortical 
adenocarcinoma, with 
direct extension into liver 
Surgical excision of adrenal and hepatic 




Lymphosarcoma Cookie Goodridge 
9yo F Kelpie 
2-3 week history of increased nodes; FNA then 
biopsy confirmed lymphoma 
CBC Diffuse intermediate grade 
large cell lymphoma; Stage 
IIIa or higher 
Lomustine every 3 weeks x 8. Partial 
response achieved but succumbed to her 





Tumours of the 
Intestinal Tract 
Jack Fleming 
12yo Mn DSH cat 
Acute onset of vomiting and weight loss. 
Exploratory laparotomy and multiple intestinal and 
mesenteric lymph node biopsies taken = diffuse 
lymphocytic lymphoma 
IHC on biopsies (CD3, CD79a); CBC, 
Biochemistry; Bone marrow aspirate; 
serum folate and Vitamin B12 
Diffuse lymphocytic T-cell 
lymphoma with mesenteric 
node involvement 
UW-25. Repeat abdominal ultrasound 
January 2011 confirmed clinical remission. 








12yo Fn Kelpie cross 
Owner acquired dog from pound 3 months ago and 
already had very large mass over caudal right 
elbow 
CBC, Biochemistry, U/A; FNA mass Soft tissue sarcoma Metronomic chemotherapy: 10mg/m2 
cyclophosphamide, 0.3mg/kg piroxicam 




Tumours of the 
Skeletal System 
Winston McGlynn 
12yo Mn Ridgeback cross 
2 month history of swelling distal right 
antebrachium. Radiographs show proliferative 
lesion over distal right radius 
None Open – suspected 
osteosarcoma  
Owner declined further diagnostics and 






Mast Cell Tumours Lester Burt 
8yo Mn terrier cross 
8 week history of mass over caudal right thigh, 
slow growth in this time and mildly pruritic. Wide 
excision performed = mast cell tumour, marginal 
excision 
CBC, Biochemistry, U/A; abdominal 
ultrasound 
Mast cell tumour, grade 2 
(high grade) (MI 8/10hpf); 
T1N0M0 
Vinblastine/prednisolone protocol; 
Recurrence Jan 2011; partial responses to 
imitinib and toceranib. Developed metatatic 










14yo Fn Staffordshire Bull 
terrier 
Stranguria and haematuria for a couple of weeks; 
abdominal ultrasound demonstrated bladder mass 
near apex 
Thoracic radiographs (3-view); U/S 
guided FNA of the MILNs; 




Referred for partial cystectomy; followed by 
mitoxantrone and piroxicam. Disease 
recurrence Nov 2010; bone tumour also 
developed lumbar spine at a similar time – 






Lymphosarcoma Molly Powell 
8yo Fn German shorthaired 
pointer 
5 days history of enlarged peripheral nodes, 
otherwise well. FNA = probable lymphoma 
Lymph node biopsy for 
histopathology and IHC (CD3, 
CD79a) 
Diffuse intermediate grade 
large cell lymphoma, B-
cell; Stage IIIa or higher 
UW-19 protocol. Stopped treatment after 8 




Mast Cell Tumours Hugo Reynolds 
11yo Mn Labrador 
3 month history of mass on ventral chest. Wide 
excisional biopsy performed = mast cell tumour, 
complete resection 
CBC, Biochemistry, U/A; FNA 
regional lymph node; thoracic 
radiographs; abdominal ultrasound 
Mast cell tumour, grade 2 






Lymphosarcoma Peter Pyke 
12yo Mn wire-haired Fox 
terrier 
12 month history of chronic large bowel diarrhea, 
responsive to prednisolone. Generalized 
lymphadenopathy noted 3 days ago. 
CBC, Biochemistry, U/A; bone 
marrow aspirate cytology; node 
biopsy for histopathology and IHC 
(CD3, CD79a) 
Diffuse intermediate grade 
lymphocytic lymphoma, B-
cell; Stage V 
Owner declined chemotherapy; palliation 






Haemangiosarcoma Indianna Prentice 
9yo Fn Staffordshire Bull 
terrier 
5 day history of inappetance then abdominal 
enlargement. Abdominal mass palpable and seen 
with ultrasound, presumed splenic. CP2/PT/PTT 
unremarkable 
CBC; 3-view thoracic radiographs; 
echocardiogram 
Open – mass not clearly 
splenic on repeat 
abdominal ultrasound 
Recommended CT scan to more accurately 
characterize mass prior to surgery. Owner 





Mast Cell Tumours Bailey Platt 
2yo Mn Groodle 
2 week history of 1cm mass over right thorax. FNA 
= MCT; wide excision for histopathology: grade 1 
MCT, complete excision 
CBC; FNA right axillary lymph node; 
abdominal ultrasound 
Mast cell tumour, grade 1 
(MI <2/hpf) 






Tumours of the 
Intestinal Tract 
Nero Richmond 
2yo Mn Beagle cross 
2 week history of lethargy and inappetance. 
Abdominal mass detected. Ultrasound-guided FNA 
of mass and enlarged mesenteric nodes suggestive 
of lymphoma. Circulating atypical mononuclear 
cells on peripheral blood smear 




Lymphosarcoma Tahlee Thompson 
10yo Fn Border Collie 
One month history of PU/PD and enlarged 
peripheral lymph nodes. FNA of nodes = 
lymphoma 
CBC, Biochemistry, U/A, iCa Lymphoma; Stage IIIa or 
higher 
Doxorubicin every 3 weeks x 6. Still in 





Cancer of the Nasal 
Planum 
Hammer Appicchato 
10yo Fn DSH cat 
Seen 18 months prior for non healing lesion right 
dorsal nasal planum, presumed SCC, treated with 
cryosurgery. Now similar lesion left side nasal 
planum 
None Squamous Cell Carcinoma 
(presumptive) 
Cryosurgery. Recurrence after 4 months 
therefore nosetomy performed. ‘Dirty’ left 
lateral margins and disease recurrence within 




Lymphosarcoma Miffy Crowley 
11yo Fn Shih Tsu cross 
1-2 week history of enlarged nodes; FNA = 
probable lymphoma 
None Probable multicentric 
lymphoma; Stage IVa or 
higher 
Owner declined further diagnostics and 




Mast Cell Tumours Roly Norton 
13yo Mn Labradoodle 
4-5 day history of enlarged left inguinal node and 
marked associated inflammation; FNA 
inconclusive 
Abdominal ultrasound and fine needle 
aspirate cytology left inguinal node 
Inconclusive None. No further recurrence of inflammation 






Thymoma Dante Lovelock 
17yo Mn Burmese cat 
Routine geriatric check-up and spinal radiographs 
to assess DJD detected cranial mediastinal mass 
3-view thoracic radiographs; 
ultrasound cranial mediastinum and 
abdomen; FNA cranial mediastinal 
mass and spleen 
Thymoma Owner declined further diagnostics and 




Tumours of the 
Endocrine System 
George Mitchell 
5yo Mn Labrador cross 
Mass left ventral neck for 2-3 months; 3cm 
diameter, mobile; incisional biopsy = thyroid 
follicular carcinoma 
CBC, Biochemistry, U/A; TT4/TSH; 
CT scan neck and thorax 
Follicular Thyroid 
Carcinoma 




Lymphosarcoma Rex Perris 
5yo M Golden retriever 
One week history of enlarged nodes. Incisional 
biopsy = Diffuse large cell B-cell lymphoma 
CBC, Biochemistry, U/A; bone 
marrow aspirate 
Diffuse large cell B-cell 
lymphoma; Stage Va 
UW-19 with 5 day cytarabine infusion. 
Euthanased 17/8/11 due to disease 
recurrence and progression 
 
 
Glossary of Abbreviations: 
 
ALL – Acute lymphoblastic leukaemia 
ALT – Alanine aminotransaminase 
ALP – Alkaline phosphatase 
CBC – Complete Blood Count 
CT- Computed tomography 
FNA – Fine needle aspirate 
IHC – Immunohistochemistry 
M/C/S – Microscopy/Culture/Sensitivity 
MCT – Mast cell tumour 
PT/PTT – Prothrombin time/partial thromboblastin time 
PU/PD – Polyuria, polydipsia 
U/A – Urinalysis  
UPCR – Urine protein: creatinine ratio 
HDC-BMT – High Dose Cyclophosphamide, Bone Marrow Transplant chemotherapy protocol 
UW-19 – University of Wisconsin-Madison canine 19 week chemotherapy protocol 
UW-25 - University of Wisconsin-Madison feline 25 week chemotherapy protocol 
VAC – Vincristine, Adriamycin, Cyclophosphamide chemotherapy protocol 
 
 
Cases were classified according to the suspected disease for which they were referred to Perth Veterinary Oncology. Further diagnostics may 
have later confirmed that the suspected disease was incorrect. However, the breakdown of these cases classified according to suspected or 
confirmed tumour type is as follows (from most to least frequent): 
 
1. Lymphosarcoma:     121  (24.2%) 
2. Mast Cell Tumours:    82  (16.4%) 
3. Soft Tissue Sarcomas:    47  (9.4%)   
4. Tumours of the Skeletal System:   43  (8.6%) 
5. Tumours of Skin & Subcutaneous Tissues:  35  (7%) 
6. Haemangiosarcoma:    25  (5%) 
7. Cancer of the Oral Cavity:    24  (4.8%) 
8. Tumours of the Intestinal Tract:   14  (2.8%) 
9. Tumours of the Endocrine System:  13  (2.6%)  
10. Hepatic Tumours:     12  (2.4%)  
11. Perianal Tumours:     11  (2.2%)   
12. Cancer of the Nasal Planum:   11  (2.2%)   
13. Tumours of the Mammary Gland:   9  (1.8%)   
14. Tumours of Male Reproductive System:  7  (1.4%)   
15. Urinary Bladder Cancer:    7  (1.4%)  
16. Nasal Tumours:     7  (1.4%)  
17. Histiocytic sarcoma:    6  (1.2%) 
18. Ocular Tumours:     5  (1%) 
19. Leukaemias & Myeloproliferative Disorders:  4  (0.8%) 
20. Lung Cancer:     4  (0.8%) 
21. Plasma Cell Neoplasms:    3  (0.6%) 
22. Cancer of the Salivary Glands:   3  (0.6%)   
23. Renal Cancer:    3  (0.6%) 
24. Urethral Tumours:     2  (0.4%) 
25. Thymoma:      1  (0.2%) 
26. Mesothelioma:     1  (0.2%) 
27. Neoplasia of the Heart:    0   
28. Oesophageal Cancer:    0   
29. Exocrine Pancreas Cancer:   0   
30. Gastric Cancer:     0   
31. Cancer of the Larynx and Trachea:  0   
32. Cancer of the Ureter:    0  
33. Tumours of Female Reproductive System:  0   
34. Tumours of the Nervous System:   0  
35. Transmissible Venereal Tumour:   0  
 
There were 58 feline cases (11.6%) and 442 canine cases (88.4%). Of the canine cases, there were 150 dogs listed as a crossed breed. The ten 
most common pure breeds seen were as follows: 
1. Labrador:    27  (6.1%) 
2. Golden retriever:   26  (5.9%) 
3. Staffordshire bull terrier:  26  (5.9%) 
4. Rottweiler:    23  (5.2%) 
5. Boxer:    19  (4.3%) 
6. Jack Russell terrier:   14  (3.2%) 
7. German shepherd dog:  13  (2.9%) 
8. Cocker spaniel:   12  (2.7%) 
9. Border Collier:   11  (2.5%) 
10. Beagle:    9  (2%) 
 
Although some of these breeds have been reported in previous studies to be at a higher risk of developing various tumours, without a comparison 
to the general hospital population and the canine population of the wider state of Western Australia, it cannot be confirmed whether the above 






Patient and tumour characteristics for osteosarcoma in dogs in Western Australia 
have not previously been described and we currently extrapolate information 
published by American or European institutions onto our patients. However, we 
know that this doesn’t hold true for some diseases. This first part of this section 
provides a brief description of the cases from Section One classified as ‘Tumours of 
the Skeletal System’, which included all cases with bony lesions suggestive of 
skeletal neoplasia. Dogs with a confirmed diagnosis of osteosarcoma, in addition to 
cases seen at Perth Veterinary Oncology prior to and following the period of case 
log accrual, are then described in more detail. The patient signalment and disease 
presentation are compared and contrasted to previous studies to determine 
whether osteosarcoma in our cohort of dogs is a similar entity.  
 
2.1 All bone lesions 
This section is a description of cases classified as ‘Tumours of the Skeletal System’ 
in the activity log included as Section One of this document, which included all 
cases that were referred to Perth Veterinary Oncology with bony lesions 
suggestive of skeletal neoplasia. 
 
Tumours of the skeletal system comprised 43 of the 500 cases seen during this 
time period. This is a prevalence of 8.6% of cases. Of these, 20 had a 
histopathologically confirmed diagnosis of osteosarcoma. There were two poorly 
differentiated sarcomas, and one each of multilobular osteochondrosarcoma, 
maxillary fibrosarcoma and extramedullary osteosarcoma. There were two non-





The initial diagnosis was confirmed in 26 cases using either a Jamshidi biopsy or 
post amputation of the affected limb. One dog had a sarcoma diagnosed on fine 
needle aspirate cytology of a lesion in the distal radius that then proceeded to limb 
amputation, which confirmed the diagnosis of OSA.  Sixteen dogs did not have 
further diagnostics performed to confirm the underlying disease. 
 
Staging 
Further staging of the disease was performed using the following diagnostic tests: 
complete blood count (n=18), serum biochemistry (n=18), urinalysis (n=13), 3-
view thoracic radiographs (n=16), fine needle aspirate cytology of the regional 
lymph node (n=12), abdominal ultrasound (n=3), computed tomography of the 
head and thorax (n=3), thorax only (n=2) or head thorax and abdomen (n=1). 




2.2 Osteosarcoma cases only 
For dogs with OSA, various patient characteristics are reported to occur more 
commonly. Some of these characteristics may have been reported in early studies 
and with time become ‘dogma’ with no further scientific evidence. The following 
section aims to describe the patient characteristics of the dogs from the case log 
included in Part One of this thesis with a histopathological confirmation of OSA 
(n=20), plus the inclusion of additional patients presented to Perth Veterinary 
Oncology who have also had a definitive diagnosis of OSA (n=30) giving a total of 
50 dogs to analyze. Of these, 45 cases had appendicular OSA and 5 cases were axial 
OSA. This will then be compared and contrasted with collated results of previously 
published studies. In each section, the results from published reports on 
appendicular osteosarcoma will be collated, followed by comparison with any 
information available for axial tumours and extraskeletal osteosarcomas. 
 
Age 
For the cases with appendicular OSA: 
Median = 8 years  
Mean = 8.67 years 
Mode = 7 years  
Range = 4-16 years 
 
Age is variably reported as a mean or median value, often followed by the range. 
Five studies of dogs with appendicular osteosarcoma reported age as a mean 
value.5,18-19,26,32 Taking a further average of these values gives a final mean age of 
8.08 years (range 11 months – 15.9 years). Similarly, 12 studies reported age as a 
median value.1-3,7,9,15-16,20,22-23,28-29  The median value of these patient ages is 8 years 
(range 8 months – 16 years). Our results are comparable with these. 
 
OSA has been reported to develop most commonly in middle-aged and slightly 
older dogs (mean 7.7yrs), with a second earlier age peak in dogs <3 years old.8 This 
early statement is supported by the data above confirming middle aged and 
slightly older dogs to be more commonly affected, but although the stated age 
ranges show young dogs may be affected, no other studies have suggested a 
distinct earlier age peak. More recent studies have confirmed a slightly earlier 
onset of disease when compared with other neoplasia. One study found there was 
a pronounced peak in the 6- to 10-year age group with the mode at 8 to 9 years of 
age, followed by a sharp decline thereafter10. Similarly, another study reported 
that 65% of dogs that developed OSA were aged between 7-10 years25. Whether 
the decrease in incidence in older dogs is due to the shorter lifespan of the more 
commonly affected large breed dogs has not been confirmed. Our results are again 
comparable to these numbers with a peak at 7-8 years of age. 
 
Four studies assessing axial osteosarcoma also reported age as median or mean 
values.11,13-14,30 The median values were both 9 years (range 2-14 years). The mean 
values were 8.7 and 9.5 years (range 3-15 years). Of the 5 dogs included in our 
results, four of the five were 9 years or older. This may indicate that axial 
osteosarcoma affects slightly older dogs, but may also simply be due to a smaller 
total number of dogs to be assessed. OSA of the rib is reported to occur in younger 
dogs with a mean age of 4.5-5.4 years.12,14 The three dogs in our group with rib 
OSA were 8, 11 and 11 years of age, which differs to this hypothesis but it is 
difficult to make comparisons with the small number of dogs in our group. 
Gender 
For the cases with appendicular OSA there were 24 females (1 entire, 23 desexed) 
and 21 males (5 entire, 16 desexed).  
 
Appendicular OSA is reported to occur 1.1-2.0x more frequently in males than in 
females8,20,28 whereas axial OSA is seen twice as often in females than males13. 
Analysis of 22 studies involving dogs with appendicular osteosarcoma1-5,7,9,15-20,22-
24,26-29,31-32 showed that there were 900 male dogs affected and 892 female dogs 
affected, giving a male to female ratio of 1:0.99. This demonstrates that male and 
female dogs appear to be equally at risk for the development of canine 
appendicular osteosarcoma. In our group of dogs, there were 21 males and 24 
females with appendicular OSA, giving a male to female ratio of 1:14, consistent 
with this theory. One study has shown histological tumour grade (which was 
associated with OST) was not associated with gender18. Most studies involving 
dogs with osteosarcoma assess gender as a patient and tumour related variable 
but no studies have found gender to be significantly associated with disease free 
interval or overall survival time. 
 
In three studies involving dogs with non-appendicular osteosarcoma that had 
gender recorded11-12,30, there were 53 male dogs and 65 female dogs affected, 
giving a male to female ratio of 1:1.23. Of the 5 patients with axial OSA in our 
cohort, 4 were female (neutered) and 1 was male. It may appear that for axial OSA, 
females may be over-represented. There is no plausible explanation for this and a 
larger group of dogs should be assessed to confirm this finding. 
 
In comparison, a study of 1702 human patients with osteosarcoma of the 
extremities or trunk recorded 59.2% males and 40.2% females, giving a male to 
female ratio of 1:0.68, which shows a slightly higher male predominance. In that 
study, the female sex was associated with a higher likelihood of a good response to 
treatment but this did not translate into a survival advantage.6 
 
Breed 
Of the 45 cases with appendicular OSA, breeds represented included Rottweiler 
(n=16) or their crosses (n=2), Labrador (n=3) or their crosses (n=2), Rhodesian 
ridgeback (n=1) or their crosses (n=3), Australian Cattle dog (n=2) or their crosses 
(n=1), Golden retriever (n=2) and one each of Border Collie, German Shorthaired 
pointer, Christmas Island terrier, Rough Coated Collie, Bernese Mountain dog, 
Kelpie, Kelpie cross, Bull Mastiff cross, Great Dane cross, Greyhound cross, terrier 
cross, Staffordshire Bull terrier cross and a German Shepherd cross. 
 
From 13 research papers describing canine appendicular OSA1,3,7,9,15,19-20,22-24,26-28 
excluding mixed breeds, Rottweilers were the most common breed affected in 
eight papers, followed by Labrador retrievers in three papers, and golden 
retrievers and Dobermans in one paper each.  Alternatively, if the three most 
common breeds in each paper are counted, the most commonly affected breeds 
were: Rottweiler (n=9), Labrador retriever (n=8), golden retriever (n=8), 
greyhound (n=5), Great Dane (n=3), German shepherd (n=2) and the Doberman, 
Irish setter and Irish wolfhound were listed once each. Our results are similar to 
these with Rottweilers again being listed as the most commonly affected breed. A 
comparison of affected breeds to the general hospital population is rarely 
performed, so it cannot be stated definitively that Rottweilers are commonly 
affected simply due to their popularity. However, given the large number of 
research papers from various parts of the world finding this breed to be most 
affected, it may be that there is a heritable component to the tumour, which is 
carried along this breed’s line. No further research has been performed to 
determine this genetic abnormality. 
 
In studies describing axial OSA11,13-14,30, golden retrievers, Labradors and German 
shepherd dogs were the three most commonly affected breeds, similar to above. 
However, the Rottweiler was listed infrequently. This may suggest that the 
aetiology of OSA affecting Rottweilers may be a different disease to that affecting 
other breeds, or simply reflect the relatively small numbers of axial OSA cases 
reported in the veterinary literature.  Our five cases having axial OSA were a 




For the cases with appendicular OSA: 
Mean = 34.22kg 
Median = 34.5kg 
Range = 14.5 - 62kg 
 
Bodyweight is variably reported as a mean or median value, often followed by the 
range. Six studies of dogs with appendicular OSA reported bodyweight as a mean 
value.5,17,19,22,26,32 Taking a further average of these values gives a final mean 
bodyweight of 40.9kg (range 9-73kg). Similarly, 8 studies reported bodyweight as 
a median value.1-3,15-16,20,23,28 The median value of these patient bodyweights is 
36kg (range 8.2-107kg).  
 
Four studies assessing axial osteosarcoma11,13-14,30 reported mean bodyweights of 
27.8kg and 28.2kg (range 4.3-54.4kg) in two papers and median bodyweights of 
29kg and 30kg (range 4-55kg) in the two others. One of these studies reported that 
axial OSA affects medium to large breed dogs14, differing from appendicular OSA, 
which tends to affect large or giant breed dogs.8,21,29 The average bodyweight of 
40.9kg calculated above for dogs with appendicular OSA is much higher than the 





Of the 45 appendicular OSA lesions, there were 20 affecting the foreleg and 25 
affecting the hind leg. There were 24 affecting the right side and 21 affecting the 
left side. There were 15 lesions in the femur: 12 distal, 2 proximal and one mid-
femur; 10 proximal and 2 distal humeral lesions; 7 distal and 3 proximal tibial 
lesions; 6 distal and one mid radial lesions; and one scapula lesion. 
 
Tumour location is most commonly recorded in research papers as an exact 
anatomical location. Some papers record only the bone involved but not whether 
the lesion is proximal or distal. Some papers list the most frequently affected sites 
but not the locations where only small numbers occurred (grouped together as 
‘others’). Rarely, only the number of lesions involving the forelimb versus the 
hindlimb is noted.  
From 15 research papers where the number of forelimb versus hindlimb lesions 
could be calculated 1-5,9,15,19-20,23,26-29,31, there were 783 OSA lesions affecting the 
forelimb and 420 lesions affecting the hind limb. This provides a forelimb to 
hindlimb ratio of 1.86:1, or that forelimb tumours account for 65% of primary 
appendicular OSA. This is consistent with a previous report stating that forelimb 
lesions occurred in 60% of cases.21 Our results differ from this with 45% of 
tumours affecting the forelimb and 55% affecting the hindlimb.  There is no 
rational explanation as to why this may be and is likely related to the relatively 
small numbers assessed. 
 
From 10 research papers where the exact location of the tumour was recorded1-
4,15,19-20,27,29,31, there were (in descending order of frequency): 
 215 lesions in the distal radius 
 193 lesions in the proximal humerus 
 95 lesions in the distal femur 
 63 lesions in the distal tibia 
 53 lesions in the proximal tibia 
 19 lesions in the proximal femur 
 18 lesions in the distal ulna 
 12 lesions in the distal humerus  
 12 lesions in the scapula 
 3 lesions in the proximal radius 
 1 lesion in the proximal ulna 
 
From this data, distal radial lesions comprise 31% and proximal humeral lesions 
comprise 28% of all canine appendicular OSA lesions. This supports the often-
quoted description that canine OSA occur ‘away from the elbow, and close to the 
knee’. 
Similarly, from our data of 45 appendicular lesions the distal femur and proximal 
humerus were the most common locations for primary OSA tumours to be 
diagnosed.  
 
Tumour locations recorded for axial OSA tumours in three studies11,13-14 were (in 
descending order of frequency): 
 46 lesions in the mandible 
 37 lesions in the maxilla 
 27 lesions in the spine 
 23 lesions in the cranium 
 19 lesions in the rib 
 13 lesions in the nasal cavity/paranasal sinuses 
 11 lesions in the pelvis 
 1 lesion in the sternum 
 
Our patients had a slightly different frequency of occurrence, with rib lesions being 
the most frequent (3/5 cases). It is possible referring veterinarians may feel more 
capable treating tumours of the mandible with surgical excision, thereby causing a 




The population of dogs definitively diagnosed with OSA at Perth Veterinary 
Oncology is similar to that published by institutions elsewhere. The result of 
collaboration of signalment findings in previous research papers allows us to 
conclude that appendicular OSA affects middle-aged to older dogs most commonly, 
and that axial OSA tends to affect slightly older dogs; that males and females are 
affected with appendicular OSA with equal frequency, although axial OSA may tend 
to affect females more commonly; Rottweilers and Labradors are the breeds most 
commonly affected by appendicular OSA suggesting a genetic component to the 
disease, and that Labradors and Golden retrievers are most commonly affected by 
axial OSA, but not Rottweilers; and that appendicular OSA favours the forelimb 
more frequently than the hindlimb, with the distal femur and proximal humerus 
being the most commonly affected locations, and that the mandible, maxilla and 
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This section discusses risk and prognostic factors for the development of osteosarcoma 
that have been reported and includes a literature review demonstrating or refuting the 
evidence for these factors.  
 
Canine osteosarcoma is an aggressive cancer that is ultimately fatal in the majority of 
patients affected. The current treatment recommendations include treatment of the 
primary tumour by surgery (limb amputation, limb-sparing surgery or local excision for 
non-appendicular lesions where possible) or radiation therapy (stereotactic 
radiotherapy), followed by treatment of micrometastases, present in at least 90% of 
patients, with adjuvant chemotherapy. These treatments may lead to patient discomfort 
or morbidity in the short or long term, and at the worst extreme, death. The costs for 
these treatments are also significant and may influence an owner’s decision. Therefore, 
for owners to make the decision to proceed with treatment, being able to provide an 
accurate prognosis for that particular patient is imperative.   
 
Various factors have been identified in studies published in peer-reviewed journals that 
may indicate a more or less favorable prognosis. These factors will be described, and 
the evidence supporting or refuting their benefit will be discussed. Emphasis will be on 
canine osteosarcoma of the appendicular skeleton as 75% of canine osteosarcomas 
develop in long bones, compared to 25% arising in the skull and axial skeleton. (Brodey 
and Riser, 1969). This information will be compared to results published in the human 
literature, particularly from the largest retrospective study and a recent systematic 
review of human patients with osteosarcoma. (Bielack et al, 2002; Pakos et al, 2009) 
 





DFI disease free interval 




Studies have conflicting results when determining whether young or old age carries a 
poorer prognosis, or whether age is prognostic at all.  
 
Advancing age was a predictor of poor survival in the study by Moore et al (2007). 
These authors hypothesized that chemotherapy may be more effective against 
micrometastatic disease in younger animals, or that younger animals had less 
histologically aggressive tumours. Age was significant in all multivariate analyses, 
except when mitotic rate was added into the analysis. There was no explanation as to 
why this variable may affect the significance of age, but it is most likely due to study 
design. Phillips et al (2009) reported that following multivariate analysis, age > 5 years 
maintained negative prognostic significance, with a risk ratio of 2.1. 
 
Spodnick et al (1992) found that prognosis appeared to be most favorable in middle-
aged dogs (7-10yrs), and was poorer among younger and older dogs. The poorer 
prognosis in older dogs was explained by their tendency to be more quickly and 
severely debilitated by the effects of advanced metastatic disease than are younger dogs. 
The poorer prognosis in younger dogs was more difficult to explain, but has been 
documented in humans. (Taylor, 1989; Bentzen, 1988) Sottnik at al (2010) confirmed 
with multivariate modeling that younger dogs (<8 years) had a shorter DFI compared 
with older dogs.  
 
Age was not a significant prognosticator in two studies by Kent et al (2004) and Bailey 
et al (2003), although both these studies may have lacked the power to detect a 
significance due to the small number of dogs included in the analysis (32 and 24 dogs, 
respectively. 
 
In humans, the median age at diagnosis is 15 years (range 2-68 years). Patients over 40 
years of age are more likely to present with axial tumours, secondary osteosarcomas, 
have a prolonged history of symptoms, and have a delayed start of treatment. (Bielack, 
2002) Age was not significant on multivariate analysis of prognostic factors in the 
retrospective study by Bielack at al (2002).  However, in the review by Pakos et al 
(2009), age less than 14 years was a consistent independent negative prognostic factor. 
Bielack et al (2002) suggest that the impression that older patients do worse may be 
attributable to the increased proportion of unfavorable axial lesions with increasing age.  
 
From these results, it is difficult to conclude that age may be useful as a prognostic 
factor in dogs with appendicular OSA. Loukopoulos et al (2007) reported that young 
animals differed from old animals in having OSA of a higher grade, score and mitotic 
index. Dogs aged ≤ 4yrs had a significantly higher tumour grade than >4yrs. Therefore, 
if left untreated may result in a shorter survival time for younger dogs. However, these 
dogs may have a better response and survival time if treated with cytotoxic 







Increasing bodyweight has predicted shorter survival in several studies of dogs with 
appendicular OSA. (Bergman et al, 1996, Lascelles et al, 2005, Moore et al, 2007) 
Similarly, bodyweight >40kg was associated with a shorter DFI and OST. (Ru et al, 
1998)  
 
Bergman et al (1996) hypothesized that chemotherapy dosing by body surface area 
allows for higher dosing to smaller dogs and therefore a higher percentage of tumour 
cell kill. For this reason, Moore et al (2007) argues for increasing chemotherapy dosage 
in patients that do not show toxicity at starting dosages. Another possibility suggested 
by Lascelles et al (2005) was that larger dogs may be more difficult to nurse and 
euthanasia is opted for earlier.  
 
Large breed dogs tend to have an overall shorter life span, irrespective of the presence 
of disease, meaning they are at a higher geriatric level compared to smaller dogs when 
diagnosed with cancer, which may contribute to their earlier demise. (i.e. a 7-year-old 
Great Dane that weighs 80kg is ‘biologically’ older than a 7-year-old Kelpie that weighs 
20kg). 
 
Rosenberger et al (2007) found bodyweight to not be a risk factor for OSA; however, 
these authors were only comparing the 3 breeds with the highest prevalence in their 
study which were all large breed dogs (Greyhound, Rottweiler and Great Dane) and 
therefore all of a heavier bodyweight, with no comparison to smaller breeds of lighter 
bodyweight. Bodyweight was also not a significant prognosticator in the study by 
Bailey et al (2003), but again, this study only included 24 dogs and may have lacked 
statistical power. 
Overall, it appears there is consensus that a higher bodyweight is associated with an 
increased risk of developing appendicular OSA in dogs.
 
Breed 
Most research papers do not compare the frequency of breeds affected by OSA with the 
most frequent breeds within the general hospital population to determine if there is a 
true genetic predisposition. 
 
In 1974, Cohen et al published data from the University of Pennsylvania School of 
Veterinary Medicine, which highlighted the Boxer as having the highest relative risk for 
developing OSA (and other neoplasms) compared to other breeds.  The Boxer has only 
been listed as a commonly affected breed in one other early study (Misdorp and Hart, 
1979). The lack of more recent studies noting the Boxer to be at increased risk may be 
due to geographical differences, or due to the breed becoming less popular, or to 
evolving genetic changes (intentionally or inadvertently not breeding from genetic lines 
which have developed OSA). 
 
Ru et al (1998) postulated that commonly affected breeds may not simply be affected 
due to their large bodyweight, as suggested by Tjalma (1996), but rather a genetic 
susceptibility to OSA for individual breeds might be possible. They found that among 
breeds of similar body size, the risk of OSA showed a wide range. A report of OSA 
affecting first generation Saint Bernards suggests a familial genetic component. (Bech-
Nielsen et al, 1978)  
 
There is currently no evidence that the disease in different breeds has a different 
aetiology or clinical outcome. For three of the most commonly affected breeds 
(Rottweiler, Greyhound and Great Dane) Rosenberger (2007) confirmed that the 
location of the tumours in their cases was similar to other reports, being the proximal 
humerus and distal radius. All studies that have included breed in their statistical 
analysis reported that there is no correlation between breed and DFI or OST, allowing 
the conclusion that while certain breeds may be at increased risk for the development of 
appendicular OSA, their breed does not influence their outcome.  
 
Prolonged duration of clinical signs before surgery 
Two papers have found a significant correlation between the length of time of 
demonstrable clinical signs prior to presentation and outcome, although the results were 
conflicting. 
 
Brodey and Abt (1976) showed that the duration of clinical signs was longer in dogs 
that did not develop metastatic disease, compared with dogs that did develop 
metastases.  
 
In contrast, Bailey et al (2003) reported the median duration of clinical signs for patients 
that developed progressive disease was 30 days (range 9–180 days), and the median 
duration for patients that did not develop progressive disease was 21 days (range 7-30 
days). Patients with a longer duration of clinical signs were more likely to develop 
progressive disease (p = 0.02).  These authors did not propose reasoning for this 
finding.  
 
A lower grade disease could explain a prolonged history of symptoms with a better 
outcome. Alternatively, it is possible that the longer the disease is present prior to 
treatment a larger burden of micrometastases may develop, leading to an overall 
increased tumour burden. 
 
Saam et al (2011) did not find an association between duration of lameness prior to 
surgical removal of the tumour and OST. 
 
Tumour location 
Again, there is a discrepancy between research papers as to whether the location of the 
primary tumour is important prognostically. 
 
The proximal humeral location has been reported to be a negative prognostic indicator 
by several authors. Bergman et al (1996) reported that their nine dogs with proximal 
humeral OSA had an increased hazard ratio (HR 4.72) compared with dogs with OSA in 
other sites, and that proximal humeral OSA was a significant negative survival 
prognostic factor on multivariate analysis. Both Mehl et al (2005) and McMahon et al 
(2011) reported that of all prognostic factors evaluated, only the proximal humeral 
location was associated with a significantly shorter DFI. Phillips et al (2009) also 
confirmed the proximal humeral location as having a negative prognostic significance 
following multivariate analysis (with a risk ratio 1.6). Sottnik et al (2010) reported that 
dogs with primary tumours of the humerus had a significantly reduced DFI compared 
with dogs with primary tumours in other appendicular locations, and multivariate 
modeling of all variables determined that primary tumour location was significantly 
related to DFI. These latter four papers included 105, 50, 155 and 69 dogs, respectively, 
and therefore had sufficient power to detect significance. 
 
Conversely, tumour location as a positive prognostic factor has been suggested for the 
distal radial location. McNeill et al (2007) reported that OST was longest for tumours 
affecting the radius (392 days) and shortest for tumours affecting the humerus (201 
days) but this was not statistically significant (p =0.45). Bacon et al (2008) supported 
this finding with their results showing that of the 50 dogs in their study, those with 
radial tumours had a significantly longer DFI and OST than other locations. Saam et al 
(2011) found dogs with OSA in the distal radius had a numerically superior MST 
relative to dogs with OSA in the proximal humerus, but this was not statistically 
significant in their study of 65 dogs.  
 
In humans, patients with distally located tumours (i.e. below the elbow or knee) have a 
better prognosis than do patients with proximally located tumours (Taylor et al, 1978; 
Taylor et al, 1985). 
 
Bielack et al (2002) reported that in humans, 87.7% of extremity tumours were located 
in the leg and 12.3% in the arm. Tumours involving the knee (distal femur, proximal 
tibia or fibula) made up 75.7% of limb tumours and 71% of all OSA. The prognostic 
preference of the distal location was supported with the tibia being a prognostically 
favourable site and the humerus being an unfavourable site. A previous observation that 
the earlier growth spurt of the humerus was associated with an earlier development of 
OSA at this site was not observed.  
 
The reason for primary appendicular OSA of the proximal humeral location as being a 
negative prognostic factor is unknown. The above authors hypothesized that this site 
may allow for more advanced local growth (contributing to a larger tumour volume) 
before diagnosis which leads to an increased risk for the development of metastases. 
Larger tumour size as an independent risk factor for OSA is discussed below. 
Comparison of the radiographic or scintigraphic volume of radial tumours versus 
tumours of other sites was suggested as being potentially useful to help investigate this 
further. Interestingly, Spodnick et al (1992) could not demonstrate a significant 
association between primary tumour site and DFI or OST in their study of 162 dogs 
treated with amputation alone. It is possible that tumours of the distal radius only gain a 
positive prognostic significance once treated with adjuvant chemotherapy. Loukopoulos 
and Robinson (2007) reported that tumour grade was significantly higher in distal OSA 
compared with proximal OSA, and, as stated above, the higher grade of the tumour with 
more actively dividing cells may be killed more effectively by cytotoxic drugs. 
 
With respect to the prognostic importance of tumour location for axial OSA, Hammer et 
al (1995) reported that tumours arising from the scapula or ribs were associated with the 
highest prevalence of metastatic disease. Loukopoulos and Robinson (2007) described 
rib OSA to have a degree of necrosis significantly higher than that at most other sites, 




Serum ALP concentration 
Ehrhart et al (1998) reported that a preoperative total alkaline phosphatase (TALP) 
concentration above 110U/L was associated with a shorter survival (median OST 177 
days versus 495 days if less than 100U/L). Preoperative bone-specific ALP (BALP) 
concentration less than 23U/L had a significantly longer OST (546 days versus 218 
days). Increased BALP activity after surgery was significantly associated with a shorter 
survival interval. The type of surgery (amputation versus limb-spare) did not influence 
this finding. These authors proposed that dogs with increased TALP and BALP might 
have larger tumour burdens and therefore, have shorter survival times than dogs with 
lower tumour burdens. However, percentage of bone length involved, a rough indicator 
of tumour volume, was not correlated with preoperative concentration of TALP or 
BALP or associated with OST or DFI. The authors also postulated that a tumour in 
which cells are poorly differentiated might be associated with higher preoperative 
activities of TALP and BALP, but this was not the case in their study.  
 
Garzotto et al (2000) reported similar results in their study of 61 dogs with appendicular 
OSA treated with amputation and adjuvant chemotherapy. In this study TALP, as well 
as bone (BALP), liver (LALP) and corticosteroid-induced (CALP) isoenzymes were 
measured. Preoperative TALP and LALP concentrations were significantly associated 
with survival. Median survival times for dogs with normal or increased preoperative 
TALP concentrations were 12.5 and 5.5 months, respectively. The clinical relevance of 
the increased LALP could not be fully explained; however, the authors hypothesized 
that neoplastic osteoblasts may produce LALP or a LALP-like substance. Alternatively, 
if the glycosylation of BALP was abnormal, the assay may have incorrectly recorded 
BALP as LALP due to their structural similarity. In this study, all isoenzymes decreased 
significantly after treatment and there was no significant correlation between post-
treatment concentration of TALP or any isoenzyme and survival.  
 
Kirpensteijn et al (2002) reported that serum ALP concentration was one of only two 
independent prognosticators in their study, although the bone-specific isoenzyme was 
not analysed. Fifteen of 49 dogs (30.6%) had an increased TALP concentration. An 
increased level of ALP was associated with a shorter DFI and ST. Dogs with a normal 
ALP value benefited from chemotherapy, compared with dogs with an increased ALP 
who did not benefit from adjuvant chemotherapy. Increased ALP values were not 
associated with tumours of a higher grade.  
 
Vail et al (2002) reported that 16 of the 38 (42%) dogs included in their study had an 
ALP concentration above the reference range. This was the only variable analysed that 
was of prognostic significance. The DFI for dogs with normal TALP versus increased 
TALP at the time of diagnosis were 485 and 128 days, respectively, and the OST were 
459 and 207 days, respectively. 
 
Hillers et al, (2005) reported that 90 out of 214 dogs (42%) had an ALP concentration 
above the reference range. Median DFI for dogs with an increased preoperative serum 
ALP activity (160 days) was significantly (P  = 0.025) shorter than median DFI for dogs 
with normal preoperative serum ALP activity (238 days). An increased serum ALP 
activity was not significantly associated with evidence of regional lymph node 
metastasis. 
 
Moore et al (2007) found TALP was increased in 92 out of 293 (30%) at presentation. 
BALP was increased in 72 out of 240 (24%) at presentation. 
Increased TALP and BALP significantly affected survival on univariate analysis. These 
authors concluded that increased serum ALP activity at presentation was strongly 
predictive of poor survival. In addition, high serum BALP activity was an even stronger 
predictor of low long-term survival. 
 
Phillips et al (2009) and Selvarajah et al (2009) supported these findings in their 
analyses, with an elevated ALP being associated with a negative prognostic significance 
on multivariate analysis.  
 
Conversely, Kent et al (2004) and Chun et al (2005) reported in their studies of 32 and 
35 dogs, respectively, that ALP activity greater than the reference range was not 
prognostic for overall survival. McMahon et al (2011) also reported in their study that 
the eight out of 50 dogs (16%) that had an elevated preoperative TALP did not have a 
significantly different DFI to dogs that had TALP concentration within the reference 
range at presentation. These results may have been due to the relatively smaller number 
of dogs included these studies and overall it would appear that an increased TALP at 
presentation can be considered as a negative prognostic factor. 
 
Similarly, a high ALP concentration was also considered to be a factor that was 
independently predictive of a poorer outcome in the review of human OSA by Pakos et 
al (2009).
Blood monocyte and lymphocyte count 
Sottnick et al (2010) reported that pretreatment values of blood monocytes and 
lymphocytes might be prognostic for dogs with appendicular OSA. Dogs with a 
monocyte count greater than 0.4 x 10
3
 cells/μL and lymphocyte count greater than 1 x 
10
3
 cells/μL had a significantly shorter DFI. The author’s explanation for the increased 
monocyte count being associated with a poorer prognosis was that the monocytes being 
counted on a routine CBC might actually be myeloid-derived suppressor cells, which 
suppress anti-tumour immune responses. The finding that dogs with lymphopenia had a 
significantly longer DFI could not be definitively explained, but the authors hypothesize 
that lymphocytes may be redistributed from the circulation into tumour tissues in dogs 
with OSA micrometastases. 
 
Metastasis at presentation 
The presence of metastases at presentation is considered a poor prognostic indicator. 
Boston et al (2006) evaluated retrospectively dogs diagnosed with Stage III OSA 
(defined as OSA that had metastasized to any site) who underwent treatment of any 
type. The overall MST was 10.9 weeks, which is shorter than that reported in other 
studies (which included dogs of any disease stage) describing surgery as sole treatment: 
14.5 weeks (Shapiro et al, 1988); 25 weeks (Maudlin et al, 1988); 19.2 weeks (Spodnick 
et al, 1992) or surgery followed by adjuvant chemotherapy: 33.6-59 weeks (Kraegel et 
al, 1991; Straw et al, 1991; Thompson et al, 1992; Berg et al, 1992; Berg et al, 1995; 
Bergman et al, 1996; Berg et al, 1997; Bailey et al, 2003; Kent et al, 2004; Chun et al, 
2005; Bacon et al, 2008; Phillips et al, 2009). In the paper by Boston et al (2006), dogs 
treated with palliative radiation therapy and chemotherapy had a significantly longer 
survival time (130 days) than dogs in all other treatment groups. The proposed reason 
for this was that the primary tumour remained which suppressed the progression of 
metastases. Removal of a primary tumour may lead to an increase in angiogenic activity 
and rapid growth of metastases. (Tsunemi et al, 2003). The alternative theory was that a 
definitive histopathological diagnosis might not have been made for these patients, with 
the diagnosis being based on typical signalment and radiographic findings only. 
 
Boston et al (2006) also found dogs with bone metastases had a longer survival time 
(132 days) than dogs with lung (59 days) or lymph node (57 days) metastases.  The six 
dogs that survived the longest (from 359-1583 days) all had metastasis to long bones 
with no evidence of pulmonary metastases. Proposed theories for this included 
metastatic OSA confined to bone could be a distinct clinical entity that is less 
aggressive than OSA that has metastasized to lung and bone; or dogs with pulmonary 
lesions are predisposed to development of pulmonary tumour emboli and sudden death 
during surgery; or dogs with pulmonary lesions show more systemic signs of illness 
prompting earlier euthanasia by owners. This is in contrast to Meyers et al (1993) who 
reported that humans with bone metastases had shorter survival times than those with 
lung metastases. 
 
Bielack et al (2002) reported that in their human patients clinically detectable 
metastases were an independent adverse prognostic factor in all analyses. The proposed 
reason for the low success rate in primary metastatic disease was not that chemotherapy 
is less effective, but that complete surgery is difficult to accomplish. 
 
Hillers et al, (2005) reported on the prognostic significance of lymph node metastasis in 
dogs with appendicular OSA. Ten out of 228 dogs (4.4%) included in the study had 
histologic evidence of regional lymph node metastasis at the time of amputation. The 
axillary lymph nodes were affected in 3 dogs, the superficial cervical lymph nodes in 1 
dog, and the popliteal lymph nodes in 2 dogs. In the remaining 4 dogs, location of the 
regional lymph nodes in which metastases were found was not recorded. Median DFI 
for dogs without regional lymph node metastasis (238 days) was significantly (P < 
0.001) longer than median DFI for dogs with regional lymph node metastasis (48 days). 
Similarly, median OST for dogs without lymph node metastasis (318 days) was 
significantly (P < 0.001) longer than median OST for dogs with lymph node metastasis 
(59 days). 
Completeness of surgical excision 
The importance of achieving complete resection of the primary OSA tumour is logical. 
The smaller the overall tumour burden, the more likely time to disease recurrence will 
be longer. Bielack et al (2002) stated that ‘the prognostic importance of complete 
surgery cannot be overstressed’. In their series, failure to achieve a complete remission 
was a strong negative prognostic factor. This factor was also considered to be 
significant by Pakos et al (2009). 
 
Similarly in dogs, in their study of dogs with axial OSA, Hammer et al (1995) identified 
surgical margin as prognostic on univariate and multivariate analyses, with incomplete 
resection correlating with a poorer outcome. These authors hypothesized that the higher 
local recurrence rate of axial OSA tumours is associated with the difficulty in achieving 
complete excision due to location (e.g. vertebrae). 
 
Kuntz et al (1998) reported that in dogs with proximal humerus OSA undergoing 
adjuvant chemotherapy after limb-spare surgery, the completeness of surgical margins 
was prognostic for development of metastatic lesions on multivariate analysis. Dogs 
with incomplete surgical margins were 7.7 times more likely to develop metastases than 
dogs with complete surgical margins. Incomplete surgical margins were associated with 
significant increases in the incidence of both local recurrence and distant metastasis. 
The authors hypothesized that this may be due to the persistence of malignant tumour 
cells at the surgical site resulting in a greater opportunity for systemic spread or, more 
likely, because tumours with higher metastatic potential are likely to be more locally 
aggressive and therefore difficult to completely excise.  
 
In 2002, Kirpensteijn et al also found in their study assessing pathological submissions 
that dogs with complete surgical resection had an increased OST compared with dogs 
with incomplete or no resection at all.  
 
This prognostic factor is of less overall importance in dogs as limb amputation is more 
commonly performed to remove primary OSA, as opposed to limb-spare surgery which 
is more commonly employed in humans. However, if more veterinary institutions adopt 
limb-sparing surgery, it will be important to ensure that patients are only recruited if the 
surgeon is confident that complete excision of the tumour will be achieved. Currently, 
the guidelines as to which canine patients are eligible for limb-spare surgery of the 
distal radius dictate the primary neoplasm must involve less than 50% of the bone 
length. (Lascelles et al 2005). 
 
Tumour diameter and volume 
Misdorp and Hart (1979) first proposed the correlation between tumour size or volume 
and outcome. They found that OSA of large diameters and volumes were more likely to 
have pulmonary metastases at necropsy. 
 
Further support for this correlation came from Forrest et al (1992), who identified a 
statistically significant relationship between time to metastasis and the radiographic 
tumour area. 
 
Kuntz et al (1998), in their study describing limb-sparing surgery in dogs with OSA of 
the proximal humerus, found that the overall survival time in their study was shorter 
compared to that previously reported for appendicular OSA treated with adjuvant 
chemotherapy. These authors postulated that the relatively large size of proximal 
humeral OSA might be responsible for this difference. 
 
In a similar study describing limb-sparing surgery in dogs with OSA of the radius, 
Lascelles et al (2005) found there was a significant relationship between the percentage 
length involved and overall survival, although there was a comment that this should be 
interpreted with caution as some data was missing which may have interfered with the 
statistical modeling. 
 
Larger tumor size has also been reported to be a negative prognostic factor in human 
osteosarcoma. (Davis et al, 1994; Spanier et al, 1990; Bieling et al, 1996; Brostrom et 
al, 1982; Taylor et al, 1989) 
 
Bielack et al (2002) confirmed in their large retrospective study the prognostic 
importance of tumour size in the extremities. However, there was no correlation 
between tumour size and response to treatment. These authors proposed that the higher 
risk of relapse in patients with large primary tumours is more likely to be attributable to 
an increased metastatic burden parallel to tumour size. The studies reviewed by Pakos et 
al (2009) consistently reported larger tumours to be of negative prognostic significance, 
although whether it is large size (length) or large volume that is the more important 
measurement could not be determined. 
Histologic grade and mitotic index 
Kirpensteijn et al (2002) used a 3-tier grading scheme incorporating degree of 
pleomorphism, number of mitoses, amount of tumour matrix, number of tumour cells 
and degree of necrosis. Using this scheme to classify 166 primary OSA and 34 
metastatic OSA lesions, there were 4.2% grade I, 20.5% grade II, and 75.3% primary 
grade III OSA. The 34 metastases were all grade III tumours. Grade I and grade II OSA, 
which represents approximately 25% of the OSA reported in this study, had a 
significantly better prognosis than grade III OSA. Grade III tumours were associated 
with a significantly decreased OST and DFI. These authors believe that histologic grade 
provides a better assessment of the biologic aggressiveness of OSA tumours than 
subtype. As tumour grading is a relatively simple procedure without additional costs, it 
should be performed prior to treatment. Interestingly, several specific histologic 
variables, such as pleomorphism, proportion of tumour cells, amount of matrix, degree 
of necrosis and invasiveness, did not show any significant effect on survival data. The 
histologic variables associated with an increased risk were the number of mitoses and 
tumour cell invasion into blood vessels. 
 
Moore et al (2007) found that in 121 biopsy specimens that could be assessed, tumour 
grade itself was not a predictor of survival. The criteria differed from those used by 
Kirpensteijn et al (2002) (e.g. inclusion of vascular invasion). However, similar to 
Kirpensteijn et al (2002), the number of mitoses was a predictor of survival, with 
decreasing survival times seen as the mitotic rate increased. A categorical mitotic index 
which could potentially be prospectively applied was not described.  
 
Loukopoulos and Robinson (2007) found a correlation between tumour histological 
grade and various clinicopathological parameters, such as metastasis, age, tumour 
location and histopathological subtype. A score was assigned to the degree of nuclear 
pleomorphism, mitotic rate and degree of necrosis. This cumulative score was then 
translated into a tumour grade. There were 28% grade I, 37% grade II and 35% grade III 
tumours. Higher-grade tumours were seen in primary tumours that had metastasized; 
appendicular versus axial tumours; and OSA arising from the rib. Cranial OSA was of a 
significantly lower grade.  
 
Using a grading scale incorporating amount of tumour matrix, as well as degree of 
necrosis, degree of nuclear pleomorphism and mitotic index, for 69 tumour biopsy 
samples, Phillips et al (2009) classified 30.4% as low grade, 46.4% as intermediate 
grade, and 23.2% as high grade. Tumour grade had no impact on prognosis for either 
DFI or OST in this study of dogs with appendicular OSA. 
 
Saam et al (2011) used the histologic grading scheme described by Kirpensteijn et al 
(2002), although the presence of lymph node metastasis did not generate an automatic 
grade of III.  Of the 38 biopsy samples analysed, there were 21% grade I, 47% grade II 
and 32% grade III. There was a significant difference in outcome between grade III 
tumours compared with grade I or II tumours, with increasing grade associated with a 
poorer outcome. Of the individual variables, a mitotic index >5 per 3hpf and the 
presence of tumour cells in blood vessels were factors for a poor prognosis.  
 
Straw et al (1996), in their analysis of canine mandibular OSA, classified 7 dogs with 
grade I, 33 dogs with grade II, and 5 dogs with grade III tumours. While dogs with 
grade II tumours tended towards a shorter OST, this was not statistically significant. 
With such small numbers of dogs with grade I and III tumours, the power to detect 
significance in this study was likely to be too low. Hammer et al (1995) also reported 
that histological grade was not of prognostic significance in their analysis of dogs with 
axial OSA. 
 
Tumour grade is not routinely recorded on histopathological reports diagnosing canine 
OSA. A unified classification scheme is required to be prospectively applied to a larger 
number of cases to determine its utility. Of the categories that comprise the tumour 
grade, the mitotic index appears to be the most frequently prognostic as an individual 
marker. Tumours with a MI greater than 5 per 3/hpf may have a poorer prognosis. 
 
Tumour subtype 
The histopathologic subtype has been proposed as being a prognostic factor in patients 
with OSA. Overall, the results below do not support this, although differing 
classification schemes have been used, making comparison and amalgamation of results 
from all studies difficult, if not impossible. 
 
Misdorp and Hart (1979) reported that in 144 dogs with OSA, 47% were classified as 
osteoblastic, 23% were chondroblastic, 14% were fibroblastic, and 15% were 
chondroblastic-fibroblastic. The fibrosarcomatous subtype was found to be associated 
with a relatively favourable prognosis compared to other subtypes. 
 
In the World Health Organisation International Histological Classification of Tumors in 
Animals, Slayter et al (1994) described eight histological subtypes for canine OSA: 
poorly differentiated; osteoblastic productive; osteoblastic non-productive; 
chondroblastic; fibroblastic; telangiectatic; and giant cell type. These authors do not 
attest that the subtypes are indicative of prognosis, but rather present the subtypes to 
allow diagnostic recognition. 
 
Kirpensteijn et al (2002) classified 166 canine OSA tumours as osteoblastic (52.4%), 
chondroblastic (3.0%), fibroblastic (3.0%), mixed fibro- and osteoblastic (15.7%), 
mixed chondro- and osteoblastic (10.2%), mixed telangiectatic and osteoblastic (7.2%), 
mixed fibro-, chondro-, and osteoblastic (5.4%), mixed telangiectatic, fibro-, and 
osteoblastic (2.4%), and mixed telangiectatic, chondro-, and osteoblastic (0.6%). These 
authors argued that the importance of the subtyping is limited because the histologic 
features vary greatly both between tumours and within tumours. No subtypes were 
associated with a significantly better or worse prognosis in their study. 
 
Loukopoulos and Robinson (2007) used the subtypes described by Slayter et al (1994), 
although the term ‘osteoblastic-minimally productive’ was used instead of ‘osteoblastic 
non-productive’. The osteoblastic-productive subtype was the most commonly 
observed. There were no significant differences between subtypes with respect to 
mitotic index, degree of necrosis or degree of pleomorphism. Tumour grade was 
significantly different between the osteoblastic-minimally productive and fibroblastic 
subtypes. For this result alone, these authors argue that subtyping is beneficial and may 
provide prognostic information. 
 
Ehrhart et al (1998) classified tumours into five histologic subtypes. There were 48% 
osteoblastic, 16% fibroblastic, 16% poorly differentiated, 12% telangiectic, and 8% 
chondroblastic. Histologic subtype was not associated with preoperative TALP or 
BALP concentrations.  
 
Moore et al (2007) classified tumours into seven histologic subtypes. This information 
was recorded for 225 of the 303 dogs included in their study. There were 63% 
osteoblastic, 15% undifferentiated, 12% fibroblastic, 7% chondroblastic, and 1% 
telangiectatic, osteoclastic and sclerosing. Histologic subtype did not significantly affect 
survival. 
 
Phillips et al (2009) classified tumours into five subtypes. This information was 
recorded for 71 of the 155 dogs included in their study. There were 70% osteoblastic, 
8.5% fibroblastic, 8.5% telangiectatic, and 13% classified as ‘other’, which included 
chondroblastic and osteoclastic. Histological subtype had no impact on prognosis for 
either DFI or OST. 
 
Subtype classification has also been applied to axial OSA. Hammer et al (1995) 
classified axial OSA tumours into five subtypes. There were 64% osteoblastic, 16% 
compound, 9% fibroblastic, 9% telangiectic and 2% chondroblastic. There did not 
appear to be an association between subtype and anatomic location. Subtype was also 
not of prognostic significance. Straw et al (1996) classified their 51 mandibular OSA 
into osteoblastic 45%, chondroblastic 16%, fibroblastic 10%, sclerotic 8%, poorly 
differentiated 6% and telangiectic 4%. There was no significant difference in OST 
between subtypes. 
 
Overall, it appears that the histological subtype of OSA is not a useful prognostic factor 
in dogs with appendicular or axial OSA. 
Tumour microvessel density 
Coomber et al (1998) evaluated the possible contribution of vascularity to differences in 
disease progression and metastatic behaviour. They found no significant differences in 
mean vessel density when comparing male versus female cases, or appendicular versus 
axial cases. When cases were divided based on metastatic status, significant differences 
in vascular density were seen. Animals presenting with gross metastases had 
significantly higher vessel densities in their primary tumours than animals that later 
developed gross metastases. Animals without gross metastasis at death had intermediate 
vascular densities. These were significantly different from animals presenting with 
gross metastases, but not from animals later developing gross metastases.  
These results support the notion that the higher the number of blood vessels within a 
tumour, the faster the rate of growth of the primary tumour, and the higher the risk of 
metastatic disease developing due to provision of a route for tumour emboli to travel 
through. 
 
Tumour MVD assessment is not currently assessed routinely on histopathological 
assessment of OSA biopsy samples as it requires immunohistochemistry using 
antibodies to von Willebrand Factor to highlight blood vessel endothelium, which are 
not available in all laboratories. It is also not known whether the increase in MVD 
occurs before or after shedding of micrometastatic tumour emboli. If it could be 
confirmed that the increase in MVD only occurs after release of tumour emboli, dogs 
with very low MVD may only require surgery to remove the primary tumour, and not 
adjuvant chemotherapy which is aimed at micrometastatic disease. This scenario is 
unlikely as surgical cure is very rare, as reported by Spodnick et al (1992). 
Tumour necrosis after chemotherapy 
Tumour necrosis after pre-operative chemotherapy is a well-recognized prognostic 
factor in human medicine. Percentage necrosis is used to modify postsurgical 
chemotherapy protocols. Bielack et al (2002) stated that tumour response to 
preoperative chemotherapy was probably the most important prognostic factor in 
primary, localized extremity OSA.  
 
In humans, low rates of local recurrence have been reported for tumours in which the 
amount of necrosis induced by preoperative chemotherapy is high. In addition, the 
responsiveness of the primary tumour to preoperative chemotherapy may predict the 
responsiveness of the micrometastases. (Simon and Nachman, 1986), Among people 
who receive preoperative chemotherapy, death attributable to metastatic disease is less 
common if the resected primary tumour is more than 90% necrotic than if it is less than 
90% necrotic.  (Rosen et al, 1982). 
 
Powers et al (1991) demonstrated with their analysis of biopsy specimens from 200 
dogs, that tumour necrosis was strongly correlated with local tumour control. 
Importantly, however, there was no correlation between tumour necrosis and time to 
metastasis, which most commonly leads to the ultimate demise of the canine patient.  
 
Berg et al (1995) reported that there was a significant direct correlation between 
survival time and percentage of the primary tumour that was necrotic following pre-
operative chemotherapy. This study also demonstrated that there was no difference in 
survival times, or percentage of the primary tumour that was necrotic, between dogs 
undergoing surgery after the second or third dose of doxorubicin. Therefore limb 
amputation could be performed after two doses of chemotherapy if analgesia is not 
controlling pain from the primary bone lesion. 
 
The question of whether neoadjuvant chemotherapy conveys a survival benefit in 
humans has not been definitively answered. If surgery is performed upfront, the chance 
to evaluate response to chemotherapy, and thus one of the most reliable prognostic 
indicators, is lost. Also, it has been documented that the local recurrence rate decreases 
with increasing preoperative tumour cell destruction. (Bielack et al, 2002) This latter 
point is more relevant for humans where limb-spare surgery is more commonly 
performed, compared to dogs where radical surgery (limb amputation) is still more 
common. Local recurrence is of little concern in dogs treated with amputation, and 
while the knowledge of the percentage of tumour killed is an important prognosticator, 
at this point in time, there are few alternative treatment options available for dogs if 
results indicated lack of sensitivity to the preoperative chemotherapy drug. Early limb 
amputation for palliative reasons is still a more prudent option, allowing the patient to 
regain pain-free quality of life as soon as possible. 
Delayed initiation of chemotherapy following surgery 
A study using a murine mammary tumour concluded that to achieve the most effective 
control of metastases, the largest tolerable dose of chemotherapy should be given at the 
time of, or before, primary tumour removal. (Fischer et al, 1983). It was hypothesized 
that the primary tumour may suppress the growth of micrometastases, leading to sudden 
rapid growth of the micrometastases following amputation, which may be more 
susceptible to chemotherapy. (Fischer et al, 1983). A study using dogs with spontaneous 
occurring osteosarcoma of the appendicular skeleton could not confirm this. It found the 
timing of the administration of the first chemotherapy treatment did not influence 
overall survival. (Berg et al, 1997) Similarly, Chun et al (2005) found that the timing of 
the first chemotherapy treatment was not significantly associated with survival. 
 
Post-operative chemotherapy is often delayed for 14 days after surgery due to concerns 
of delayed wound healing and risk of infection secondary to chemotherapy-induced 
myelosuppression. This concern may be unfounded as Berg et al (1995) administered 
doxorubicin one day after surgery to 35 dogs and had no post-operative complications.  
 
In a study by Bacon et al (2008), dogs that began chemotherapy more than 14 days after 
amputation had a significantly longer DFI than those that began 14 days or less after 
amputation. This difference was not significant in multivariate analysis and was most 
likely a result of study design as it is unlikely that delaying chemotherapy for long 
periods after amputation will inhibit growth of micrometastatic disease. 
Molecular prognostic markers 
Assessing molecular markers is an expanding area of research in both human and 
veterinary oncology. At this time, there is very little information published to confirm 
their importance in the diagnosis or prognosis of canine OSA. 
 
The tumour suppressor gene p53 has been assessed by Loukopoulos et al (2003). In this 
study of 167 canine bone tumours, p53 staining was higher in OSA versus other 
tumours. Also, an increase in p53 staining was associated with a higher histologic 
grade, mitotic index and degree of tumour necrosis. However, p53 staining was not 
associated with the presence of metastases. 
 
Cyclooxygenase-2 (COX-2) expression was analysed by Mullins et al (2004). Of 44 
canine OSA biopsy samples that were analysed, 77.3% stained positively for COX-2, 
although the majority (88%) had poor to moderate staining. Dogs with strong COX-2 
expression had significantly decreased OST compared to dogs with negative or poor 
staining. 
 
Ezrin is a membrane-cytoskeleton linker protein associated with metastasis. Khanna et 
al (2004) detected ezrin in 83% of canine OSA. A high level of ezrin staining in the 
tumour was associated with a significantly shorter DFI compared with dogs with low 
levels of staining. 
 
Matrix metalloproteinases (MMPs) are proteases capable of degrading the extracellular 
matrix, but they also have numerous other actions. Lana et al (2000) demonstrated that 
canine OSA cells in biopsy specimens had a greater expression of MMPs than 
unaffected stromal cells, suggesting they may play a role in metastasis by allowing 
tumour cells to degrade the extracellular matrix and invade nearby vasculature. Moore 
et al (2007) demonstrated that higher plasma active concentrations of MMP-2 were 
associated with shorter OST. However, administration of an MMP inhibitor, BAY 12-
9566, did not result in a significantly longer OST compared with doxorubicin 
chemotherapy alone. 
 
Fan et al (2008) demonstrated that 10/15 canine OSA primary tumours and 9/12 
pulmonary metastases expressed tropomyosin-related kinase (Trk-A), a proto-oncogene 
that protects against apoptosis. These authors did not attempt to determine whether this 
has prognostic relevance, but suggest this may be a novel therapeutic target. 
References: 
Bacon NJ, Ehrhart NP, Dernell WS, et al. Use of alternating administration of 
carboplatin and doxorubicin in dogs with microscopic metastases after amputation for 
appendicular osteosarcoma: 50 cases (1999–2006). J Am Vet Med Assoc 
2008;232(10):1504-10. 
 
Bailey D, Erb H, Williams L, et al. Carboplatin and doxorubicin combination 
chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern 
Med 2003;17(2):199-205. 
 
Bech-Nielsen S, Haskins ME, Reif JS, et al. Frequency of osteosarcoma among first-
degree relatives of St. Bernard dogs. J Natl Cancer Inst 1978;60(2):349-353. 
 
Bentzen SM, Poulsen HS, Kaae S, et al. Prognostic factors in osteosarcomas. A 
regression analysis. Cancer 1988;62:194-202. 
 
Berg J, Weinstein MJ, Schelling SH, et al. Treatment of dogs with osteosarcoma by 
administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-
1990). J Am Vet Med Assoc 1992;200(12):2005-8. 
 
Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin 
chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206(10):1555-60. 
 
Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on 
survival of dogs with osteosarcoma. Cancer 1997;79:1343-1350. 
 
Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for 
treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 
1996;10(2):76-81. 
 
Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade 
osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on 
neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 
2002;20(3):776-90.  
 
Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated 
osteosarcoma. J Clin Oncol 1996;14(3):848-58. 
 
Brodey RS and Abt DA. Results of surgical treatment in 65 dogs with osteosarcoma. J 
Am Vet Med Assoc 1974;168:1032-35. 
 
Brodey RS, Riser W. Canine osteosarcoma: A clinicopathological study of 194 cases. 
Clin Orthop Relat Res 1969;62:54-64. 
 
Brostrom LA, Strander H, Nilsonne U. Survival in osteosarcoma in relation to tumor 
size and location. Clin Orthop 1982; 16:250-254. 
 
Chun R, Garrett LD, Henry C, et al. Toxicity and efficacy of cisplatin and doxorubicin 
combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp 
Assoc 2005;41(6):382-7. 
 
Cohen D, Reif JS, Brodey RS, et al. Epidemiological analysis of the most prevalent 
sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res 
1974;34:2859-68.  
 
Coomber BL, Denton J, Sylvestre A and Kruth S: Blood vessel density in canine 
osteosarcoma. Can J Vet Res 62: 199-204, 1998. 
 
Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. 
J Clin Oncol 1994;12:423–31. 
 
Ehrhart N, Dernell WS, Hoffmann WE, Weigel RM, Powers BE, Withrow SJ (1998). 
Prognostic importance of alkaline phosphatase activity in serum from dogs with 
appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc Vol. 213: 1002-
1006. 
 
Fan TM, Barger AM, Sprandel IT, et al. Investigating TrkA expression in canine 
appendicular osteosarcoma. J Vet Intern Med 2008;22(5):1181-8. 
 
Fischer B, Gunduz N, Saffer EA. Influence of the interval between primary tumor 
removal and chemotherapy on kinetics and growth of metastases. Cancer research 
1983;43:1488-1492. 
 
Forrest LJ, Dodge RK, Page RL, et al. Relationship between quantitative tumor 
scintigraphy and time to metastasis in dogs with osteosarcoma. J Nucl Med 
1992;33(8):1542-1547. 
 
Garzotto CK, Berg J, Hoffmann WE, et al. Prognostic significance of serum alkaline 
phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000;14: 
587-592. 
 
Hammer AS, Weeren FR, Weisbrode SE, et al. Prognostic factors in dogs with 
osteosarcomas of the flat or irregular bones. J Am Anim Hosp Assoc 1995;31:321-26 
 
Hillers KR, Dernell WS, Lafferty MH, et al. Incidence and prognostic importance of 
lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986-
2003). J Am Vet Med Assoc 2005;226(8):1364-7. 
 
Kent MS, Strom A, London CA, et al. Alternating carboplatin and doxorubicin as 
adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of 
appendicular osteosarcoma in dogs. J Vet Intern Med 2004;18(4):540-4. 
 
Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary 
for osteosarcoma metastasis. Nat Med 2004;10:182-186. 
 
Kraegel SA, Madewell BR, Simonson E, et al. Osteogenic sarcoma and cisplatin 
chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 1991;199:1057-59. 
 
Kirpensteijn J, Kik M, Rutteman GR, et al. Prognostic significance of a new histologic 
grading system for canine osteosarcoma. Vet Pathol 2002;39:240-246. 
 
Kuntz CA, Asselin TL, Dernell WS, et al. Limb salvage surgery for osteosarcoma of the 
proximal humerus: outcome in 17 dogs. Vet Surg 1998;27(5):417-22. 
 
Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in 
canine neoplastic tissue. Am J Vet Res 2000;61:111-114. 
 
Lascelles BD, Dernell WS, Correa MT, et al. Improved survival associated with 
postoperative wound infection in dogs treated with limb-salvage surgery for 
osteosarcoma. Ann Surg Oncol 2005;12:1073-83. 
 
Loukopoulos P, Thornton JR, Robinson WF. Clinical and pathologic relevance of p53 
index in canine osseous tumours. Vet Pathol 2003;40:237-248. 
 
Loukopoulos P, Robinson WF. Clinicopathological relevance of tumour grading in 
canine osteosarcoma. J Comp Pathol 2007;136(1):65-73.  
 
McMahon M, Mathie T, Stingle N, et al. Adjuvant carboplatin and gemcitabine 
combination chemotherapy postamputation in canine appendicular osteosarcoma. J Vet 
Intern Med 2011;25(3):511-7. 
 
Mehl ML, Seguin B, Dernell WS, et al. Survival analysis of one versus two treatments 
of local delivery cisplatin in a biodegradable polymer for canine osteosarcoma. Vet 
Comp Oncol 2005;3(2):81-6. 
 
Meyers P, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable 
metastasis at initial presentation. J Clin Oncol 1993;11:449-453. 
 
Misdorp W and Hart AAM; Some prognostic and epidemiologic factors in canine 
osteosarcoma. J Nat Cancer Inst 1979;62(3):537-545. 
 
Moore AS, Dernell WS, Ogilvie GK, et al. Doxorubicin and BAY 12-9566 for the 
treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled 
study. J Vet Intern Med 2007;21(4):783-90. 
 
Mullins MN, Lana SE, Dernell WS et al. Cyclooxygenase-2 expression in canine 
osteosarcomas. J Vet Intern Med 2004;18:859-865. 
 
Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for 
osteosarcoma: an international collaboration. Eur J Cancer 2009;45:2367-75. 
 
Phillips B, Powers BE, Dernell WS, et al. Use of single-agent carboplatin as adjuvant or 
neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in 
dogs. J Am Anim Hosp Assoc 2009;45(1):33-8. 
 
Ru G, Terracini B, Glickman LT. Host related risk factors for canine osteosarcoma. Vet 
J 1998;156(1):31-9. 
 
Rosenberger JA, Pablo NV, Crawford PC. Prevalence of and intrinsic risk factors for 
appendicular osteosarcoma in dogs: 179 cases (1996-2005). J Am Vet Med Assoc 
2007;231(7):1076-80. 
 
Saam DE, Liptak JM, Stalker MJ, et al. Predictors of outcome in dogs treated with 
adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006). J Am Vet 
Med Assoc 2011;238(2):195-206. 
 
Selvarajah GT, Kirpensteijn J, van Wolferen ME, et al. Gene expression profiling of 
canine osteosarcoma reveals genes associated with short and long survival times. Mol 
Cancer 2009;8:72. 
 
Shapiro W, Fossum TW, Kitchell BE et al. Use of cisplatin for treatment of 
osteosarcoma in dogs. J Am Vet Med Assoc 1988;192(4):507-11. 
 
Simon MA, Nachman J. The clinical utility of preoperative therapy for sarcomas. J 
Bone Joint Surg Am 1986;68(9):1458-63. 
 
Slayter MV, Boosinger TR, Inskeep W, et al. Histological classification of bone and 
joint tumors of domestic animals. Armed Forces Institute of Pathology (1994), 
Washington DC, USA. 
 
Sottnik JL, Rao S, Lafferty MH, et al. Association of blood monocyte and lymphocyte 
count and disease-free interval in dogs with osteosarcoma. J Vet Intern Med 
2010;24(6):1439-44. 
 
Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on 
prognosis in osteosarcoma. J Bone Joint Surg Am 1990;72:643–53. 
 
Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular 
osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 
1992;200(7):995-9. 
 
Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of 
canine osteosarcoma. J Vet Intern Med 1991;5:205-210. 
 
Straw RC, Powers BE, Klausner RA, et al. Canine mandibular osteosarcoma: 51 cases 
(1980-1992). J Am Anim Hosp Assoc 1996;32:257-62. 
 
Taylor WF, lvins JC, Unni KK, et al. Prognostic variables in osteosarcoma: A multi-
institutional study. J Natl Cancer Inst 1989;81(1):21-30. 
 
Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and 
without subsequent administration of cisplatin, for treatment of appendicular 
osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc 1992;200(4):531-3. 
 
Tjalma RA. Canine bone sarcoma: estimation of relative risk as a function of body size. 
J Natl Cancer Inst 1966;36:1137-50. 
 
Tsunemi T, Nagoya S, Kaya M, et al. Postoperative progression of pulmonary 







Toxicity and efficacy of a novel doxorubicin and carboplatin chemotherapy 
protocol for the treatment of canine appendicular osteosarcoma following 
limb amputation 
AE Lane,a* ML Blackb and KM Wyatta 
*Corresponding author. 
aPerth Veterinary Oncology, 305 Selby Street North, Osborne Park 6017, Western 
Australia, Australia; amy@pvo.com.au 
bCentre for Comparative Genomics, Murdoch University, Murdoch, WA, Australia  
 
Objective To evaluate the safety and efficacy of a novel doxorubicin and 
carboplatin chemotherapy protocol for the treatment of dogs with appendicular 
osteosarcoma following limb amputation. 
Design  Retrospective study 
Procedure Dogs diagnosed with appendicular osteosarcoma, with no evidence 
of metastatic disease, treated with amputation and adjuvant chemotherapy 
consisting of two doses of doxorubicin given 14 days apart, followed by four doses 
of carboplatin at 3-weekly intervals between September 2003 and December 2009 
were identified from the medical records of Perth Veterinary Oncology. 
Haematological and gastrointestinal toxicities were assessed based on information 
in the medical records and recorded complete blood count results. The efficacy of 
the protocol was assessed by determining the median disease-free interval (DFI) 
and overall survival time (OST) using the Kaplan-Meier product-limit method. 
Results In total, 33 dogs met the inclusion criteria. The median DFI was 
231.5 days and the median OST was 247 days. With regard to haematological 
toxicity, 56% of dogs had a grade 1–2 neutropenia recorded as their highest 
marrow toxicity and 9% of dogs experienced a grade 3–4 neutropenia, all 
subsequent to doxorubicin administration. The highest gastrointestinal toxicity 
was grade 1–2 in 15 dogs (47%) and 5 dogs (16%) experienced grade 3–4 
gastrointestinal toxicity. 
Conclusion This chemotherapy protocol did not result in a longer time to 
disease recurrence or OST in this population of dogs. Dual-agent protocols have 
failed to improve survival times and therefore we conclude that a single-agent 
protocol using carboplatin may be equally effective with less toxicity. 
Keywords carboplatin; dogs; doxorubicin; osteosarcoma 
Abbreviations ALP, alkaline phosphatase; AUC, area under the 
(concentration-versus-time) curve; BSA, body surface area; CBC, complete blood 
count; DFI, disease-free interval; OSA, osteosarcoma; OST, overall survival time; 
VCOG-CTCAE, Veterinary Cooperative Oncology Group common terminology for 
adverse events 
 
Osteosarcoma (OSA) of the appendicular skeleton is the most common primary 
bone tumour in dogs. It is behaviorally a very aggressive neoplasm and most dogs 
will eventually develop metastatic disease, frequently in the lungs and/or other 
bones.1 Treatment needs to be directed at controlling the primary tumour and the 
microscopic metastatic disease, and the current standard of care is limb 
amputation or limb-sparing surgery, followed by adjuvant chemotherapy. Two 
studies published in 1988 provided early evidence that adjuvant chemotherapy 
may prolong patient survival times. Shapiro et al. demonstrated a significantly 
longer median survival time of 43 weeks in 11 dogs treated with amputation and 
adjuvant cisplatin, compared with their control group of eight dogs treated with 
amputation alone, which had a median survival time of 14.5 weeks.2 Mauldin et al. 
also demonstrated that the median survival time of 300 days for 19 dogs treated 
with amputation and adjuvant doxorubicin and cisplatin was significantly longer 
than the median survival time of 175 days for 19 dogs treated with amputation 
alone.3 Since then, numerous adjuvant chemotherapy protocols using varying 
combinations and schedules of doxorubicin and/or the platinum agents, cisplatin 
or carboplatin, have been studied.4–16 These protocols have offered median 
survival times ranging from 235 to 413 days. Many of these studies used data 
published by Spodnick et al.17 as a historical control group. In that retrospective 
study, 162 dogs treated with amputation alone had a median survival time of 
19.2 weeks. Direct comparisons of the outcomes of any of these studies is difficult 
given their differing inclusion criteria, study design and, at times, small case 
numbers. What can be concluded is that both doxorubicin and the platinum agents 
prolong survival in dogs with osteosarcoma after amputation or limb-sparing 
procedures. What has not yet been determined is the ideal chemotherapy protocol 
that provides long-term survival with minimal associated toxicity. Combination 
chemotherapy is more likely to provide a longer duration of remission, because 
each drug, with its different mechanism of action, has a different effect on a 
heterogeneous tumour cell population, which may prevent or slow development of 
drug resistance.18 The chemotherapy protocol used in our institution is the first 
combination chemotherapy protocol described that uses doxorubicin sequentially 
at a 14-day interval. This dose intensity was selected because doxorubicin 
monotherapy did not provide a survival benefit when given on a 21-day cycle,19 
but did improve survival times when given at the higher dose intensity of a 14-day 
cycle.8,20  
The aim of this single-centre retrospective case series study was to evaluate the 
safety and efficacy of a chemotherapy protocol consisting of two doses of 
doxorubicin given 14 days apart, followed by four doses of carboplatin at 3-weekly 
intervals, for the treatment of dogs with appendicular osteosarcoma, all of which 
had undergone amputation. A secondary aim of this study was to assess patient-, 
tumour- and treatment-related factors for prognosis. 
 
Materials and methods 
Dogs that were diagnosed with appendicular osteosarcoma and treated with 
amputation and adjuvant chemotherapy between September 2003 and December 
2009 were identified from the medical records of Perth Veterinary Oncology. The 
evaluated protocol was the standard offered at that time. Dogs that received at 
least one chemotherapy treatment were considered to have started the protocol 
and were included in this study. Information was collected from the medical 
records and from contact with the referring veterinarian or the owner. Dogs were 
excluded from the study if there was evidence of metastatic disease detected 
during initial staging or if the patient record was incomplete. 
Dogs were staged using one or all of the following diagnostic tests: complete blood 
count (CBC), serum biochemistry, urinalysis, three-view thoracic radiographs, 
computed tomography of the thorax and abdomen, fine needle aspirate cytology of 
the regional lymph node, and abdominal ultrasound. The diagnosis of 
osteosarcoma was confirmed by histopathology in all cases at the time of 
amputation, regardless of whether a preoperative biopsy had been performed. 
Histopathological subtype or grade was not routinely recorded, so this parameter 
was not assessed in the survival analyses for its prognostic influence. 
The time between surgery and the start of chemotherapy varied between patients 
and was dependent on when the owners assessed the dogs to have recovered from 
amputation sufficiently to commence chemotherapy. 
Chemotherapy consisted of six treatments: two cycles of doxorubicin at a 14-day 
interval, followed by four cycles of carboplatin on a 21-day cycle. Doxorubicin was 
dosed at 30 mg/m2 IV (1 mg/kg in dogs <15 kg) and carboplatin was dosed at 300 
mg/m2 IV. Each dog had a CBC immediately prior to each treatment. A CBC was 
also performed 7 days after the first doxorubicin dose and 7–10 days after the first 
carboplatin dose. Dogs with pretreatment neutropenia <1500 cells/µL (reference 
range, 3.9–8.0 cells/µL) had their treatment delayed and were rechecked 7 days 
later to assess if the neutropenia had resolved. The decision to reduce subsequent 
doses of the drug was at the discretion of the clinician and owner. The protocol 
was discontinued if there was evidence of metastatic disease. At the completion of 
chemotherapy, it was recommended clients have their dogs rechecked every 
3 months for at least 2 years at either Perth Veterinary Oncology or their referring 
veterinarian. During these examinations thoracic radiography was recommended. 
Haematological toxicity, specifically neutropenia, was assessed by evaluating the 
recorded CBC results and was graded according to the Veterinary Cooperative 
Oncology Group’s common terminology for adverse events (VCOG-CTCAE) (Table 
1).21 The highest grade of toxicity experienced by each dog for either doxorubicin 
or carboplatin was recorded. Gastrointestinal toxicity was assessed by evaluating 
the medical records as reported by the owner during treatment and was also 
graded according to the VCOG-CTCAE criteria. The highest grade of toxicity for 
either doxorubicin or carboplatin was recorded. 
The disease-free interval (DFI) in days was defined as the interval between 
amputation and detectable metastasis. Dogs with no evidence of metastasis at the 
time of writing, that were lost to follow-up or had died from confirmed, unrelated 
disease were censored from this analysis. Overall survival time (OST) was defined 
as the interval between amputation and death from neoplasia. Dogs with 
unconfirmed causes of death were considered to have died from neoplasia. Median 
DFI and OST were determined using the Kaplan-Meier product-limit method. Log-
rank analysis was used to compare DFI and OST among dogs for the following 
variables: age, body weight, sex, breed, hindleg versus foreleg, duration of clinical 
signs, serum ALP activity, interval between amputation and chemotherapy, dose 
reduction or treatment delay required, myelosuppression observed, 
gastrointestinal toxicosis observed and whether the intended chemotherapy 
protocol was completed. Any variables identified as significant via univariate 
analysis for either DFI or OST were tested for significance via multiple logistic 
regression (Cox’s proportional hazards model). Continuous variables were 
stratified on the basis of the medians for the analyses: age was classified as <8 or 
≥8 years, weight was <34 kg or ≥34 kg, duration of clinical signs was <30 or ≥ 
30 days, and the interval between amputation and chemotherapy was <10 or 




From September 2003 to December 2009, 33 dogs were treated for appendicular 
osteosarcoma with amputation and the evaluated chemotherapy protocol and so 
were included in the study. The median age was 8.8 years (range, 4–16 years). The 
median weight was 34 kg (range, 14.5–54.8 kg). There were 18 neutered females, 
1 entire female, 12 neutered males and 2 entire males. The breeds represented 
were: Rottweiler (n = 10), Australian Cattle Dog (n = 2), Golden Retriever (n = 2), 
Christmas Island Terrier (n = 1), Rough-coated Collie (n = 1), Border Collie (n = 1), 
Bernese Mountain Dog (n = 1), Rhodesian Ridgeback (n = 1), Great Dane (n = 1), 
Kelpie (n = 1) and cross-breeds (n = 12).  
Tumour characteristics 
Tumours were detected in the distal femur (n = 7), proximal humerus (n = 7), 
distal tibia (n = 6), distal radius (n = 4), proximal tibia (n = 3), distal humerus 
(n = 2), proximal femur (n = 2), scapula (n = 1) and mid-femur (n = 1); 42% were 
in a forelimb and 58% in a hindlimb, with 39% on a left limb and 61% on a right 
limb. 
Median duration of clinical signs prior to initial presentation was 36 days (range, 
1–300 days); 15 dogs had a preoperative biopsy performed and 2 dogs presented 
with a pathological fracture. 
Complete staging was not performed in all dogs because of owner financial 
constraints. All dogs had a CBC performed prior to their first chemotherapy 
treatment and 24 dogs had a serum biochemistry panel performed, including 
alkaline phosphatase (ALP). Of these, 5 had an ALP level above the reference range 
for the laboratory used (20–184 U/L); however, 2 of the 5 dogs had values only 
just outside the reference range (186 and 190 U/L), and the dog with an ALP value 
of 1189 was receiving phenobarbitone concurrently. Urinalysis was performed for 
11 dogs, 24 dogs had thoracic radiographs taken, 1 dog had computed tomography 
of the thorax and abdomen, 4 dogs had an abdominal ultrasound; 8 dogs had fine 
needle aspirate cytology performed on the regional lymph node, and all were 
negative for metastatic disease. 
Treatment protocol 
Limb amputation was performed either by the referring veterinarian prior to 
presentation to the referral institution, or after initial assessment and staging was 
performed. The type of amputation performed was dependent on the surgeon’s 
preference and what was required to remove all visible tumour. There were 10 
forequarter amputations (including scapula), 4 mid-humeral amputations, 12 
coxofemoral disarticulations, and 3 mid-femoral amputations; 4 dogs did not have 
this information in their records. The median time between surgery and 
chemotherapy was 10 days (range, 1–35 days).  
In total, 8 dogs did not complete the intended chemotherapy protocol; 6 of these 
dogs had treatment discontinued because of metastatic disease, 1 dog 
discontinued treatment after the third dose because of marked treatment-related 
toxicosis and1 dog only received four treatments because of owner financial 
constraints. 
Toxicosis 
A total of 66 doses of doxorubicin and 116 doses of carboplatin were administered. 
One dog had no toxicity data recorded and was excluded from this analysis. In 18 
dogs (56%), a grade 1–2 neutropenia was recorded as the highest marrow toxicity, 
and 3 dogs (9%) experienced a grade 3–4 neutropenia, all subsequent to 
doxorubicin administration. Of these 3 dogs, 1 required no treatment, 1 was 
treated as an outpatient with oral antibiotics and 1 dog also experienced grade 4 
gastrointestinal toxicity and required hospitalisation for 5 days for IV fluids, 
antibiotics, antiemetic and gastric protectant medication. That dog was a Rough-
coated Collie and it was postulated she carried an MDR1 gene mutation leading to 
the severe toxicosis following doxorubicin, a P-glycoprotein-substrate drug. 
In 15 dogs (47%), a grade 1–2 gastrointestinal toxicity was recorded as the highest 
toxicity, and 5 dogs (16%) experienced grade 3–4 gastrointestinal toxicity, one of 
which was the dog described above. Another two of the dogs required 
hospitalisation for 1–3 days for supportive care and two dogs required no specific 
therapy. 
Five dogs (16%) required a dose reduction for the second doxorubicin treatment 
because of either haematological (n = 4) or gastrointestinal toxicity (n = 1). No 
dogs required a dose reduction for the carboplatin treatments. Five dogs required 
treatment delays because of slow haematological recovery: 1 dog had a 1-week 
delay before the second doxorubicin dose; 3 dogs required treatment delay after 
the first carboplatin dose, and then received the subsequent three doses at 4-week 
intervals; 1 dog had a 1-week delay before the third carboplatin dose, but returned 
to the 21-day cycle before the fourth dose.  
DFI and survival 
The median DFI was 231.5 days and the median survival time was 247 days 
(Figure 1). The 1-year survival rate was 24.2% and the 2-year survival rate was 
15.2%. 
Of the variables assessed for prognostic significance, only completion of the 
chemotherapy protocol and body weight were significant. Dogs weighing <34 kg 
had an OST of 447 days compared with 151 days for dogs ≥34 kg (P = 0.01) (Figure 
2). Age, sex, breed, hindleg versus foreleg, duration of clinical signs, serum ALP 
activity, interval between amputation and chemotherapy, dose reduction or 
treatment delay required, myelosuppression and gastrointestinal toxicosis did not 
influence DFI or OST. 
At the time of data analysis, 2 dogs were still alive with no evidence of metastatic 
disease and 2 dogs were lost to follow-up and a date and cause of death could not 
be determined. Of the other 29 dogs, 17 died of metastatic osteosarcoma in the 
lungs (n = 9) or bones (n = 6) or both (n = 2), confirmed radiographically; 4 dogs 
were euthanased because of severe or progressive paresis or weakness of 
undetermined cause. Radiographs or myelography were not performed in those 
dogs to determine the underlying problem.  
Another 5 dogs were suspected to have died from neoplasia but it was not 
confirmed. One dog developed lethargy and non-localised pain that progressed 
over a 1-month period. It was treated with analgesics, but euthanased when the 
pain became intractable. One dog developed lethargy and anorexia 7 months after 
completing chemotherapy, but no further diagnostic tests were performed before 
euthanasia. Another dog also developed lethargy and anorexia, leading to marked 
weight loss over a 2-month period. The dog then developed widespread bruising 
over the ventrum and was euthanased with no further diagnostic tests performed. 
The fourth dog developed seizures between chemotherapy treatments five and six. 
Metastasis to the brain was suspected but not confirmed with imaging or necropsy. 
The fifth dog developed gastrointestinal disease 5 months after completion of 
chemotherapy. Abdominal ultrasound showed a large mass medial to the right 
kidney, measuring 4.5  4.3 cm. The owner declined further diagnostics and 
treatment and the dog was euthanased 2 days later after no clinical improvement.  
Three dogs died of unrelated disease. One dog ruptured a cranial cruciate ligament 
and the owner elected euthanasia at this time, despite radiographs of the limb and 
thorax showing no evidence of metastases. Another dog developed spinal pain and 
hindlimb ataxia. Thoracic and vertebral radiographs showed no evidence of 
metastatic disease, but did demonstrate multiple narrowed disc spaces, suggestive 
of intervertebral disc disease. The third dog became lethargic and anorexic 
1 month after finishing chemotherapy. Investigation by the referring veterinarian 
included CBC and serum biochemistry blood tests, and radiographs of the thorax. 
The dog had a packed cell volume of 0.25, platelet count of 49  109 cells/L and 
neutrophil count of 0.65  109 cells/L. The radiographs showed a pattern 
suggestive of pneumonia. The owner declined further treatment and elected 
euthanasia. Necropsy was not performed to rule out neoplasia as the underlying 
cause of disease.  
 
Discussion 
The median DFI and OST of 231.5 and 247 days, respectively, were similar to 
previously published results. Although the DFI or time to disease progression is a 
more accurate assessment of treatment efficacy, because of the retrospective 
nature of this study the follow-up intervals and diagnostic tests varied and 
depended on owner compliance. In some cases, the recorded DFI was the same as 
the OST, because the dog was only presented for assessment when it became 
unwell. Therefore, the OST has been used more consistently in this study. 
Not surprisingly, the dogs that completed the chemotherapy protocol had a 
significantly longer median OST (289 days) compared with the dogs that did not 
complete the treatment (108 days; P = 0.0002). Six of the eight dogs that did not 
complete the protocol had developed early evidence of metastatic disease, leading 
to shorter survival times. 
Of the other variables assessed, dogs weighing <34 kg (n = 16) had statistically 
significant greater OSTs. Bergman et al. had a similar finding in their study 
describing amputation and carboplatin for the treatment of appendicular 
osteosarcoma in dogs; dogs <40 kg had a significantly longer DFI and OST.9 Moore 
et al. also showed that increasing body weight predicted a shorter survival in their 
population of dogs with osteosarcoma treated with amputation and doxorubicin.20 
The dose of doxorubicin is recommended to be given on a milligram per kilogram 
basis for dogs <10 kg, as myelosuppression is significantly greater in small dogs 
when dosed according to their body surface area (BSA). The area under the 
concentration-versus-time curve (AUC) is also greater in small dogs if they are 
dosed according to BSA.22 It is possible that larger dogs are being relatively under-
dosed when dosed according to their BSA, leading to shorter survival times. No 
dogs in our study weighed less than 10 kg and only six dogs weighed less than 
20 kg bodyweight. In humans, the Calvert formula is now commonly used to 
calculate the carboplatin dose: 
AUC (carboplatin) = dose/(creatinine clearance + 25), 
where the usual AUC is 4, 5 or 6 mg/m2 per minute.18 The AUC is the 
pharmacokinetic parameter that most accurately predicts carboplatin-associated 
toxicity in humans and cats. The AUC is directly proportional to the dose and 
inversely proportional to clearance.23 No studies have been performed to 
determine whether the AUC dosing strategy for carboplatin would be more 
appropriate than BSA in dogs. 
No other variable had a statistically significant effect on DFI or OST in this study. 
Variables that have been shown to be prognostic in other studies may have 
become statistically significant if a larger sample size had accrued in this study. 
The current chemotherapy protocol was based on several basic chemotherapy 
principles. Both doxorubicin and carboplatin have demonstrated efficacy against 
osteosarcoma as single agents.8,9 As stated earlier, combination chemotherapy is 
more likely to provide a longer duration of remission because of the different 
mechanism of action of each drug having a different effect on the heterogeneous 
tumour cell population, which may prevent or slow development of drug 
resistance.18 Combination chemotherapy protocols, with doxorubicin being an 
essential component, are currently part of the multimodality approach to the 
treatment of human osteosarcoma.24 
A protocol of alternating carboplatin and doxorubicin every 3 weeks for up to 
three cycles reportedly resulted in DFIs and survival times that were no better 
than those previously reported for single-agent protocols.15 The Norton and Day 
model predicts that the sequential use of drug combinations outperforms 
alternating cycles, based on the fact that no two combinations are likely to have 
equal cytotoxic ability or be completely non-cross-resistant.18 Therefore, the 
protocol in the present study commenced with two doses of doxorubicin at 
30 mg/m2 IV given 14 days apart. Previously, doxorubicin was shown not to 
provide a survival benefit in 14 dogs treated on a 21-day cycle, compared with 
amputation alone, although this may have been related to the low power of the 
study with the small number of dogs included.19 When given on a 14-day cycle, 
adjuvant doxorubicin did provide an improvement in OSTs.8,20 In a recent study of 
dogs with osteosarcoma treated with amputation and adjuvant carboplatin and 
doxorubicin on an alternating 21-day cycle, dogs that received doxorubicin as their 
first drug had a significantly longer DFI than those that received carboplatin first.15 
This finding was not significant in multivariate analysis and may just have been a 
result of study design, but the order of drugs in a treatment schedule may 
influence their therapeutic effect. Only administering two doses of doxorubicin 
also minimises the risk of patients developing cardiomyopathy secondary to 
cumulative drug doses. Although it is recommended not to exceed a cumulative 
dose of 180–240 mg/m2 of doxorubicin,25 breeds at risk of developing dilated 
cardiomyopathy may have a higher risk after lower doses. Three dogs have 
developed presumed doxorubicin-induced cardiomyopathy after a total dose of 
only 150 mg/m2.8 
In our study, carboplatin was administered at 300 mg/m2 IV every 21 days for four 
cycles, which has demonstrated efficacy in the treatment of canine osteosarcoma 
at this dose and frequency.9  
There is currently no consensus on the ideal time to commence chemotherapy 
after limb amputation. In the study by Bacon et al., dogs that began chemotherapy 
more than 14 days after amputation had a significantly longer DFI than those that 
began 14 days or less after amputation.15 This difference was not significant in 
multivariate analysis and was most likely a result of study design, as it is unlikely 
that delaying chemotherapy for long periods after amputation will inhibit growth 
of micrometastatic disease. Postoperative chemotherapy is often delayed for 
14 days after surgery because of concerns about delayed wound healing and the 
risk of infection secondary to chemotherapy-induced myelosuppression. This 
concern may be unfounded, as Berg et al. administered doxorubicin 1 day after 
surgery to 35 dogs and had no postoperative complications.8 A study using a 
murine mammary tumour model concluded that to achieve the most effective 
control of metastases, the largest tolerable dose of chemotherapy should be given 
at the time of, or before, primary tumour removal.26 It was hypothesised that the 
primary tumour may suppress the growth of micrometastases, leading to sudden 
rapid growth of the micrometastases following amputation, which may be more 
susceptible to chemotherapy.26 A study using dogs with spontaneous occurring 
osteosarcoma of the appendicular skeleton could not confirm this. It found the 
timing of the administration of the first chemotherapy treatment did not influence 
overall survival.10 Our study also found no statistically significant difference in the 
DFI and OST between dogs that started chemotherapy less than 10 days following 
amputation compared with those that commenced treatment at 10 days or later.  
The combination chemotherapy protocol in this study was associated with 
frequent toxicity. Of the 25 dogs that received all six doses and had toxicity data 
available, only 3 recorded no toxicity. However, the majority of adverse effects 
recorded were mild and required no specific treatment. Of the 33 dogs that 
commenced the protocol and had toxicity data available, neutropenia was 
identified in 65% of dogs, of which only 9% were grade 3–4. Gastrointestinal 
toxicosis occurred in 63% of dogs, of which 16% were grade 3–4. This is higher 
than in previous studies where doxorubicin or carboplatin was used as a single 
agent. Berg et al., using doxorubicin as a single agent every 14 days, reported that 2 
of 35 dogs (6%) had marked gastrointestinal toxicosis after the first doxorubicin 
dose and were withdrawn from the study, but that  no other dog developed 
clinically important signs of gastrointestinal toxicosis.8 In the same study, 2 dogs 
(6%) developed severe neutropenia and fever 4–5 days after the first doxorubicin 
dose, but then received their subsequent treatments at a reduced dose with no 
further adverse effects.8 Bergman et al., using carboplatin as a single agent every 
3 weeks, reported that 9 of 48 dogs (19%) had mild and transient episodes of 
vomiting.9 One dog required hospitalisation and IV fluid therapy to treat 
dehydration secondary to vomiting after the first treatment and was withdrawn 
from the study. One dog (2%) developed severe neutropenia and sepsis and the 
owner elected euthanasia. Two dogs had unexplained deaths that were attributed 
to carboplatin toxicosis even though this could not be confirmed in either case. 
The difference in the toxicosis rate of the current study and those just described 
may be related to a different grading scheme or more complete records being 
available. It is possible that there is increased toxicity with the combination of 
drugs, although given their sequential, not concurrent, administration, this is 
unlikely. Despite the higher percentage of toxicosis recorded in the current study, 
no dogs died as a result of treatment and only one dog was withdrawn from 
treatment because of owner concerns regarding side effects. Of the 31 dogs that 
received both prescribed doxorubicin treatments, six (19%) required a dose 
reduction for their second dose. Of the 25 dogs that received all four prescribed 
carboplatin treatments, none required a dose reduction, although 4 (16%) 
required a treatment delay. 
Study limitations 
This study had a relatively small sample size and lacked a control group with 
randomisation of patients between groups. Using a historical control may not 
allow accurate comparison, because of differing study designs and case 
management of different institutions. Retrospective studies also rely heavily on 
patients’ records, which may not be complete, leading to potential under-reporting 
of toxicosis. Patient follow-up is also reliant on the owner’s compliance and 
financial position, so there is often marked variability in the frequency and extent 
of patient reassessment.  
 
Conclusion 
The chemotherapy protocol described here, although designed to adhere to basic 
chemotherapy principles, did not result in a longer time to disease recurrence or 
overall survival time in this population of dogs. The rate of toxicosis recorded with 
this combination protocol was also higher than in previous published studies. 
Dual-agent protocols have failed to improve survival times and therefore we 
conclude that a single-agent protocol using carboplatin may be equally effective 
with less toxicity. 
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Figure 1. Kaplan-Meier survival function: overall survival time (OST) in days for all 
patients with appendicular osteosarcoma treated with amputation followed by 
adjuvant chemotherapy 
 
Figure 2. Kaplan-Meier survival function: overall survival time (OST) in days of 
patients <34 kg bodyweight (dashed line) compared with patients 34 kg 
bodyweight (solid line). 
Table 1. Veterinary Cooperative Oncology Group common terminology for 
adverse events21 
Toxicity Grade 
1 2 3 4 





















Gastrointestinal     
Vomiting <3 episodes 
in 24 h 
3–5 episodes 
in 24 h, or <3 
episodes/day 
for 3–4 days 
>5 episodes 
in 24 h, or 
persisting 













or SCF or IVF 
required for 









24 h  
SCF, subcutaneous fluids; IVF, intravenous fluids.  
 
